

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
17 May 2001 (17.05.2001)

PCT

(10) International Publication Number  
**WO 01/34780 A2**

(51) International Patent Classification<sup>7</sup>: C12N 9/00

(21) International Application Number: PCT/US00/31254

(22) International Filing Date:  
13 November 2000 (13.11.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/165,250 12 November 1999 (12.11.1999) US

(71) Applicant (for all designated States except US): WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION [US/US]; NE 1615 Eastgate Boulevard, Pullman, WA 99163 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CROTEAU, Rodney, B. [US/US]; 1835 N.E. Valley Road, Pullman, WA 99163 (US). SCHOENDORF, Anne [FR/FR]; 36 Impasse de l'Epinglier, F-74160 Bossey (FR). JENNEWEIN, Stefan [DE/US]; 1835 N.E. Valley Road, Pullman, WA 99163 (US).

(74) Agent: DEGRANDIS, Paula, A.; Klarquist, Sparkman, Campbell, Leigh & Winston, LLP, One World Trade Center, Suite 1600, 121 SW Salmon Street, Portland, OR 97204 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CYTOCHROME P450 OXYGENASES AND THEIR USES

(57) Abstract: Oxygenase enzymes and the use of such enzymes to produce paclitaxel (Taxol<sup>TM</sup>), related taxoids, as well as intermediates in the Taxol biosynthetic pathway are disclosed. Also disclosed are nucleic acid sequences encoding the oxygenase enzymes.

WO 01/34780 A2

## CYTOCHROME P450 OXYGENASES AND THEIR USES

### FIELD OF THE INVENTION

The invention relates to oxygenase enzymes and methods of using such  
5 enzymes to produce Taxol (paclitaxel) and related taxoids.

### ACKNOWLEDGMENT OF GOVERNMENT SUPPORT

This invention was made with government support under National Cancer  
Institute Grant No. CA-55254. The government has certain rights in this invention.

10

### INTRODUCTION

#### Cytochrome P450

Cytochrome P450 proteins are enzymes that have a unique sulfur atom  
ligated to the heme iron and that, when reduced, form carbon monoxide complexes.  
15 When complexed to carbon monoxide they display a major absorption peak (Soret  
band) near 450 nm. There are numerous members of the cytochrome P450 group  
including enzymes from both plants and animals. Members of the cytochrome P450  
group can catalyse reactions such as unspecific monooxygenation, camphor 5-  
monooxygenation, steroid 11 $\beta$ -monooxygenation, and cholesterol monooxygenation  
20 (Smith et al. (eds.), Oxford Dictionary of Biochemistry and Molecular Biology,  
Oxford University Press, New York, 1997).

#### Paclitaxel

The complex diterpenoid Taxol (® Bristol-Myers Squibb; common name  
25 paclitaxel) (Wani et al., *J. Am. Chem. Soc.* 93:2325-2327, 1971) is a potent  
antimitotic agent with excellent activity against a wide range of cancers, including  
ovarian and breast cancer (Arbuck and Blaylock, *Taxol: Science and Applications*,  
CRC Press, Boca Raton, 397-415, 1995; Holmes et al., *ACS Symposium Series*  
583:31-57, 1995). Taxol was isolated originally from the bark of the Pacific yew  
30 (*Taxus brevifolia*). For a number of years, Taxol was obtained exclusively from yew  
bark, but low yields of this compound from the natural source coupled to the  
destructive nature of the harvest, prompted new methods of Taxol production to be  
developed. Taxol currently is produced primarily by semisynthesis from advanced

taxane metabolites (Holton et al., *Taxol: Science and Applications*, CRC Press, Boca Raton, 97-121, 1995) that are present in the needles (a renewable resource) of various *Taxus* species. However, because of the increasing demand for this drug both for use earlier in the course of cancer intervention and for new therapeutic applications (Goldspiel, *Pharmacotherapy* 17:110S-125S, 1997), availability and cost remain important issues. Total chemical synthesis of Taxol currently is not economically feasible. Hence, biological production of the drug and its immediate precursors will remain the method of choice for the foreseeable future. Such biological production may rely upon either intact *Taxus* plants, *Taxus* cell cultures (Ketchum et al., *Biotechnol. Bioeng.* 62:97-105, 1999), or, potentially, microbial systems (Stierle et al., *J. Nat. Prod.* 58:1315-1324, 1995). In all cases, improving the biological production yields of Taxol depends upon a detailed understanding of the biosynthetic pathway, the enzymes catalyzing the sequence of reactions, especially the rate-limiting steps, and the genes encoding these proteins. Isolation of genes encoding enzymes involved in the pathway is a particularly important goal, since overexpression of these genes in a producing organism can be expected to markedly improve yields of the drug.

The Taxol biosynthetic pathway is considered to involve more than 12 distinct steps (Floss and Mocek, *Taxol: Science and Applications*, CRC Press, Boca Raton, 191-208, 1995; and Croteau et al., *Curr. Top. Plant Physiol.* 15:94-104, 1996). However, very few of the enzymatic reactions and intermediates of this complex pathway have been defined. The first committed enzyme of the Taxol pathway is taxadiene synthase (Koepp et al., *J. Biol. Chem.* 270:8686-8690, 1995) that cyclizes the common precursor geranylgeranyl diphosphate (Hefner et al., *Arch. Biochem. Biophys.* 360:62-74, 1998) to taxadiene (Fig. 1). The cyclized intermediate subsequently undergoes modification involving at least eight oxygenation steps, a formal dehydrogenation, an epoxide rearrangement to an oxetane, and several acylations (Floss and Mocek, *Taxol: Science and Applications*, CRC Press, Boca Raton, 191-208, 1995; and Croteau et al., *Curr. Top. Plant Physiol.* 15:94-104, 1996). Taxadiene synthase has been isolated from *T. brevifolia* and characterized (Hezari et al., *Arch. Biochem. Biophys.* 322:437-444, 1995), the mechanism of action defined (Lin et al., *Biochemistry* 35:2968-2977, 1996), and the

corresponding cDNA clone isolated and expressed (Wildung and Croteau, *J. Biol. Chem.* 271:9201-9204, 1996).

The second specific step of Taxol biosynthesis is an oxygenation (hydroxylation) reaction catalyzed by taxadiene-5 $\alpha$ -hydroxylase. The enzyme has  
5 been demonstrated in *Taxus* microsome preparations (Hefner et al., *Methods Enzymol.* 272:243-250, 1996), shown to catalyze the stereospecific hydroxylation of taxa-4(5),11(12)-diene to taxa-4(20),11(12)-dien-5 $\alpha$ -ol (i.e., with double-bond rearrangement), and characterized as a cytochrome P450 oxygenase (Hefner et al., *Chemistry and Biology* 3:479-489, 1996).

10 Since the first specific oxygenation step of the Taxol pathway was catalyzed by a cytochrome P450 oxygenase, it was logical to assume that subsequent oxygenation (hydroxylation and epoxidation) reactions of the pathway would be carried out by similar cytochrome P450 enzymes. Microsomal preparations (Hefner et al., *Methods Enzymol.* 272:243-250, 1996) were optimized for this purpose, and  
15 shown to catalyze the hydroxylation of taxadiene or taxadien-5 $\alpha$ -ol to the level of a pentaol (see Fig. 2 for tentative biosynthetic sequence and structures based on the evaluation of taxane metabolite abundances (Croteau et al., *Curr. Topics Plant Physiol.* 15:94-104, 1995)), providing evidence for the involvement of at least five distinct cytochrome P450 taxane (taxoid) hydroxylases in this early part of the  
20 pathway (Hezari et al., *Planta Med.* 63:291-295, 1997).

Also, the remaining three oxygenation steps (C1 and C7 hydroxylations and an epoxidation at C4-C20; see Figs. 1 and 3) likely are catalyzed by cytochrome P450 enzymes, but these reactions reside too far down the pathway to observe in microsomes by current experimental methods (Croteau et al., *Curr. Topics Plant  
25 Physiol.* 15:94-104, 1995; and Hezari et al., *Planta Med.* 63:291-295, 1997). Since *Taxus* (yew) plants and cells do not appear to accumulate taxoid metabolites bearing fewer than six oxygen atoms (i.e., hexaol or epoxypentaol) (Kingston et al., *Prog. Chem. Org. Nat. Prod.* 61:1-206, 1993), such intermediates must be rapidly transformed down the pathway, indicating that the oxygenations (hydroxylations)  
30 are relatively slow pathway steps and, thus, important targets for gene cloning.

Isolation of the genes encoding the oxygenases that catalyze the oxygenase steps of Taxol biosynthesis would represent an important advance in efforts to increase Taxol and taxoid yields by genetic engineering and *in vitro* synthesis.

## SUMMARY OF THE INVENTION

5 The invention stems from the discovery of twenty-one amplicons (regions of DNA amplified by a pair of primers using the polymerase chain reaction (PCR)). These amplicons can be used to identify oxygenases, for example, the oxygenases shown in SEQ ID NOS: 56-68 and 87-92 that are encoded by the nucleic acid  
10 sequences shown in SEQ ID NOS: 43-55 and 81-86. These sequences are isolated from the *Taxus* genus, and the respective oxygenases are useful for the synthetic production of Taxol and related taxoids, as well as intermediates within the Taxol biosynthetic pathway, and other taxoid derivatives. The sequences also can be used for the creation of transgenic organisms that either produce the oxygenases for  
15 subsequent *in vitro* use, or produce the oxygenases *in vivo* so as to alter the level of Taxol and taxoid production within the transgenic organism.

Another aspect of the invention provides the nucleic acid sequences shown in SEQ ID NOS: 1-21 and the corresponding amino acid sequences shown in SEQ ID  
20 NOS: 22-42, respectively, as well as fragments of these nucleic acid sequences and amino acid sequences. These sequences are useful for isolating the nucleic acid and amino acid sequences corresponding to full-length oxygenases. These amino acid sequences and nucleic acid sequences are also useful for creating specific binding agents that recognize the corresponding oxygenases.

Accordingly, another aspect of the invention provides for the identification  
25 of oxygenases and fragments of oxygenases that have amino acid and nucleic acid sequences that vary from the disclosed sequences. For example, the invention provides oxygenase amino acid sequences that vary by one or more conservative amino acid substitutions, or that share at least 50% sequence identity with the amino acid sequences provided while maintaining oxygenase activity.

30 The nucleic acid sequences encoding the oxygenases and fragments of the oxygenases that maintain taxoid oxygenase and/or CO binding activity can be cloned, using standard molecular biology techniques, into vectors. These vectors

then can be used to transform host cells. Thus, a host cell can be modified to express either increased levels of oxygenase or decreased levels of oxygenase.

Another aspect of the invention provides methods for isolating nucleic acid sequences encoding full-length oxygenases. The methods involve hybridizing at  
5 least ten contiguous nucleotides of any of the nucleic acid sequences shown in SEQ ID NOS: 1-21, 43-55, and 81-86 to a second nucleic acid sequence, wherein the second nucleic acid sequence encodes a taxoid oxygenase and/or maintains CO binding activity. This method can be practiced in the context of, for example, Northern blots, Southern blots, and the polymerase chain reaction (PCR). Hence,  
10 the invention also provides the oxygenases identified by this method.

Yet another aspect of the invention involves methods of adding at least one oxygen atom to at least one taxoid. These methods can be practiced *in vivo* or *in vitro*, and can be used to add oxygen atoms to various intermediates in the Taxol biosynthetic pathway, as well as to add oxygen atoms to related taxoids that are not  
15 necessarily on a Taxol biosynthetic pathway. These methods include for example, adding oxygen atoms to acylation or glycosylation variants of paclitaxel, baccatin III, or 10-deacetyl-baccatin III. Such variants include, cephalomannine, xylosyl paclitaxel, 10-deactyl paclitaxel, paclitaxel C, 7-xylosyl baccatin III, 2-debenzoyl baccatin III, 7-xylosyl 10-baccatin III and 2-debenzoyl 10-baccatin III.

20 Yet another aspect of the invention involves methods of contacting the reduced form of any one of the disclosed oxygenases with carbon monoxide and detecting the carbon monoxide/oxygenase complex.

### SEQUENCE LISTINGS

25 The nucleic acid and amino acid sequences listed in the accompanying sequence listing are shown using standard letter abbreviations for nucleotide bases, and three-letter code for amino acids. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood to be included by any reference to the displayed strand.

30

SEQ ID NOS: 1-21 are the nucleic acid sequences of the 21 different respective amplicons generated from the mRNA-reverse transcription-PCR.

SEQ ID NOS: 22-42 are the deduced amino acid sequences of the nucleic acid sequences shown in SEQ ID NOS: 1-21, respectively.

5        SEQ ID NOS: 43-55 are the full-length nucleic acid sequences of 13 respective oxygenases.

SEQ ID NOS: 56-68 are the deduced amino acid sequences of the nucleic acid sequences shown in SEQ ID NOS: 43-55, respectively.

10

SEQ ID NOS: 69-72 are the PCR primers used in the RACE protocol.

SEQ ID NOS: 73-80 are PCR primers used to amplify the 21 different amplicons.

15

SEQ ID NOS: 81-86 are the full-length nucleic acid sequences of 6 respective oxygenases.

20        SEQ ID NOS: 87-92 are the full-length amino acid sequences of 6 respective oxygenases corresponding to the nucleic acid sequences shown in SEQ ID NOS: 81-90, respectively.

SEQ ID NOS: 93 and 94 are PCR primers that were used to clone oxygenases into FastBac-1 vector (Life Technologies).

25

## FIGURES

Fig. 1 shows an outline of early steps of the Taxol biosynthetic pathway illustrating cyclization of geranylgeranyl diphosphate to taxadiene by taxadiene synthase (A), hydroxylation and rearrangement of the parent olefin to taxadien-5 $\alpha$ -ol by taxadiene 5 $\alpha$ -hydroxylase (B), acetylation by taxadienol-O-acetyl transferase (C), and hydroxylation to taxadien-5 $\alpha$ -acetoxyl-10 $\beta$ -ol by the taxane 10 $\beta$ -hydroxylase (D). The broken arrow indicates several as yet undefined steps.

Fig. 2 shows the proposed sequence for the hydroxylation of taxa-4(5),11(12)-diene to the level of a pentaol based on the relative abundances of naturally occurring taxoids. The reactions are catalyzed by cytochrome P450 oxygenases.

Fig. 3 shows a possible mechanism for the construction of the oxetane ring of Taxol from the 4(20)-ene-5 $\alpha$ -acetoxy functional grouping. Cytochrome P450-catalyzed epoxidation of the 4(20)-double bond, followed by intramolecular acetate migration and oxirane ring opening, could furnish the oxetane moiety.

Fig. 4 shows P450-specific forward primers that were used for differential display of mRNA-reverse transcription-polymerase chain reaction (DD-RT-PCR). Eight nondegenerate primers were necessary to cover all possible nucleotide sequences coding for the proline, phenylalanine, glycine (PFG) motif. Anchors were designed by Clontech as components of the kit.

Figs. 5A and 5D show the relationship between the full-length amino acid sequences of the isolated oxygenases. Fig. 5A is a dendrogram showing peptide sequence relationships between some published, related plant cytochrome P450s and those cloned from *T. cuspidata*. For the published sequences, the first four letters of each name are genus and species abbreviations, CYP is the abbreviation for cytochrome P450, the following two numbers indicate the P450 family, and any additional letters and numbers refer to the subfamily. Cloned sequences from *T. cuspidata* are denoted by "f" followed by a number. The genus and species abbreviations are as follows: Lius – *Linum usitatissimum*; Paar – *Parthenium argentatum*; Caro – *Catharanthus roseus*; Some – *Solanum melongena*; Arth – *Arabidopsis thaliana*; Hetu – *Helianthus tuberosus*; Ziel – *Zinnia elegans*; Poki – *Populus kitamkensis*; Glma – *Glycine max*; Phau – *Phaseolus aureus*; Glec – *Glycyrrhiza echinata*; Mesa – *Medicago sativa*; Pisa – *Pisum sativum*; Pecr – *Petroselinum crispum*; Zema – *Zea mays*; Nita – *Nicotiana tabacum*; Eugr – *Eustoma grandiflorum*; Getr – *Gentiana triflora*; Peam – *Persea americana*; Mepi –



*Mentha piperita*; Thar – *Thlaspi arvense*; Best – *Berberis stolonifera*; Soly –  
*Solanum lycopersicum*; Sobi – *Sorghum bicolor*; Potr – *Populus tremuloides*; Soch –  
*Solanum chacoense*; Nera – *Nepeta racemosa*; Came – *Campanula medium*; Pehy –  
*Petunia hybrida*. **Fig. 5B** shows a pairwise comparison of certain *Taxus* cytochrome  
5 P450 clones. **Fig. 5C** is a dendrogram showing the relationships between the full-  
length peptide sequences of the disclosed proteins. The dendrogram was created  
using the Clustral Method. The sequence identity data used as the basis of the  
dendrogram was created using the Sequence Distance function of the Megalign  
program of the lasergene (Version 99) package from DNASTar™. **Fig. 5D** is a  
10 similarity/identity table. The sequence identity data was generated using the same  
program as that used for generating the dendrogram shown in **Fig. 5C** and the  
similarity data was generated using the Olddistance function of GCG™ (version  
GCG10).

15 **Figs. 6A-6E** show a reversed-phase HPLC radio-trace illustrating the  
conversion of  $[20\text{-}^3\text{H}_2]\text{taxa-4(20),11(12)-dien-5}\alpha\text{-ol}$  to more polar products by yeast  
transformants expressing *Taxus cuspidata* P450 genes and mass spectrum results.  
**Fig. 6A** shows the HPLC radio-trace of the authentic substrate  $[20\text{-}^3\text{H}_2]\text{taxa-}$   
 $4(20),11(12)\text{-dien-5}\alpha\text{-ol}$ . **Figs. 6B** and **6C** show the HPLC radio-trace of the  
20 substrate  $[20\text{-}^3\text{H}_2]\text{taxa-4(20),11(12)-dien-5}\alpha\text{-ol}$  (26.33 min) and more polar products  
(retention ~15 min) obtained after incubation with yeast transformed with clones  
F12 (SEQ ID NO: 43) and F9 (SEQ ID NO: 48), respectively. **Figs. 6D** and **6E**  
show the mass spectrum of the products (at 15.76 minutes and at 15.32 minutes,  
respectively) formed during the incubation of taxadien-5 $\alpha$ -ol with yeast  
25 transformants expressing clones F12 and F9, respectively. Cytochrome P450 clones  
F14 (SEQ ID NO: 51) and F51 (SEQ. ID NO: 47) behaved similarly in yielding diol  
products.

**Fig. 7** shows a 500 MHz proton NMR spectrum of the taxadien-diol  
30 monoacetate in benzene- $\text{d}_6$ .

Fig. 8 shows a  $^1\text{H}$  detected two-dimensional heteronuclear single quantum coherence (HSQC) NMR spectrum of the unknown taxadien-diol monoacetate.

5 Figs. 9A and 9B show a  $^1\text{H}$ - $^1\text{H}$  two-dimensional homonuclear rotating frame NMR of the diol monoacetate. Fig. 9A is a total correlation spectrum (TOSCY) and Fig. 9B is a rotating frame n.O.e. (ROESY).

10 Figs. 10A-10E show slices from the TOCSY spectrum taken along the F2, directly detected, axis.

Figs. 11A-11E show slices from the ROESY spectrum taken along the F2, directly detected, axis.

## 15 DETAILED DESCRIPTION

### Explanations

**Host cell:** A "host cell" is any cell that is capable of being transformed with a recombinant nucleic acid sequence. For example, bacterial cells, fungal cells, plant cells, insect cells, avian cells, mammalian cells, and amphibian cells.

20 **Taxoid:** A "taxoid" is a chemical based on the Taxane ring structure as described in Kingston et al., *Progress in the Chemistry of Organic Natural Products*, Springer-Verlag, 1993.

25 **Isolated:** An "isolated" biological component (such as a nucleic acid or protein or organelle) is a component that has been substantially separated or purified away from other biological components in the cell of the organism in which the component naturally occurs, i.e., other chromosomal and extra-chromosomal DNA, RNA, proteins, and organelles. Nucleic acids and proteins that have been "isolated"

30 include nucleic acids and proteins purified by standard purification methods. The term also embraces nucleic acids and proteins prepared by recombinant expression in a host cell, as well as chemically synthesized nucleic acids.

**Orthologs:** An "ortholog" is a gene encoding a protein that displays a function similar to a gene derived from a different species.

5       **Homologs:** "Homologs" are multiple nucleotide sequences that share a common ancestral sequence and that diverged when a species carrying that ancestral sequence split into at least two species.

10       **Purified:** The term "purified" does not require absolute purity; rather, it is intended as a relative term. Thus, for example, a purified enzyme or nucleic acid preparation is one in which the subject protein or nucleotide, respectively, is at a higher concentration than the protein or nucleotide would be in its natural environment within an organism. For example, a preparation of an enzyme can be considered as purified if the enzyme content in the preparation represents at least  
15       50% of the total protein content of the preparation.

20       **Vector:** A "vector" is a nucleic acid molecule as introduced into a host cell, thereby producing a transformed host cell. A vector may include nucleic acid sequences, such as an origin of replication, that permit the vector to replicate in a host cell. A vector may also include one or more screenable markers, selectable  
20       markers, or reporter genes and other genetic elements known in the art.

25       **Transformed:** A "transformed" cell is a cell into which a nucleic acid molecule has been introduced by molecular biology techniques. As used herein, the term "transformation" encompasses all techniques by which a nucleic acid molecule might be introduced into such a cell, including transfection with a viral vector, transformation with a plasmid vector, and introduction of naked DNA by electroporation, lipofection, and particle-gun acceleration.

30       **DNA construct:** The term "DNA construct" is intended to indicate any nucleic acid molecule of cDNA, genomic DNA, synthetic DNA, or RNA origin. The term "construct" is intended to indicate a nucleic acid segment that may be

single- or double-stranded, and that may be based on a complete or partial naturally occurring nucleotide sequence encoding one or more of the oxygenase genes of the present invention. It is understood that such nucleotide sequences include intentionally manipulated nucleotide sequences, e.g., subjected to site-directed mutagenesis, and sequences that are degenerate as a result of the genetic code. All degenerate nucleotide sequences are included within the scope of the invention so long as the oxygenase encoded by the nucleotide sequence maintains oxygenase activity as described below.

**Recombinant:** A "recombinant" nucleic acid is one having a sequence that is not naturally occurring in the organism in which it is expressed, or has a sequence made by an artificial combination of two otherwise-separated, shorter sequences. This artificial combination is accomplished often by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques. "Recombinant" also is used to describe nucleic acid molecules that have been artificially manipulated, but contain the same control sequences and coding regions that are found in the organism from which the gene was isolated.

**Specific binding agent:** A "specific binding agent" is an agent that is capable of specifically binding to the oxygenases of the present invention, and may include polyclonal antibodies, monoclonal antibodies (including humanized monoclonal antibodies) and fragments of monoclonal antibodies such as Fab, F(ab')<sub>2</sub>, and Fv fragments, as well as any other agent capable of specifically binding to the epitopes on the proteins.

**cDNA (complementary DNA):** A "cDNA" is a piece of DNA lacking internal, non-coding segments (introns) and regulatory sequences that determine transcription. cDNA is synthesized in the laboratory by reverse transcription from messenger RNA extracted from cells.

**ORF (open reading frame):** An "ORF" is a series of nucleotide triplets (codons) coding for amino acids without any termination codons. These sequences are usually translatable into respective polypeptides.

5       **Operably linked:** A first nucleic acid sequence is "operably linked" with a second nucleic acid sequence whenever the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Generally, operably linked DNA  
10 sequences are contiguous and, where necessary to join two protein-coding regions, in the same reading frame.

**Probes and primers:** Nucleic acid probes and primers may readily be prepared based on the amino acid sequences and nucleic acid sequences provided by  
15 this invention. A "probe" comprises an isolated nucleic acid attached to a detectable label or reporter molecule. Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes. Probes are typically shorter in length than the sequences from which they are derived (i.e., cDNA or gene sequences). For example, the amplicons shown in SEQ ID NOS: 1-21 and fragments thereof can be  
20 used as probes. One of ordinary skill in the art will appreciate that probe specificity increases with the length of the probe. For example, a probe can contain less than 800 bp, 700 bp, 600 bp, 500 bp, 400 bp, 300 bp, 200 bp, 100 bp, or 50 bp of constitutive bases of any of the oxygenase encoding sequences disclosed herein. Methods for labeling and guidance in the choice of labels appropriate for various  
25 purposes are discussed, e.g., in Sambrook et al. (eds.), *Molecular Cloning: A Laboratory Manual* 2nd ed., vols. 1-3, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989, and Ausubel et al. (eds.) *Current Protocols in Molecular Biology*, Greene Publishing and Wiley-Interscience, New York (with periodic updates), 1987.

30       **"Primers"** are short nucleic acids, preferably DNA oligonucleotides 10 nucleotides or more in length. A primer may be annealed to a complementary target DNA strand by nucleic acid hybridization to form a hybrid between the primer and

the target DNA strand, and then extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR), or other nucleic-acid amplification methods known in the art.

5           Methods for preparing and using probes and primers are described, for example, in references such as Sambrook et al. (eds.), *Molecular Cloning: A Laboratory Manual*, 2nd ed., vols. 1-3, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989; Ausubel et al. (eds.), *Current Protocols in Molecular Biology*, Greene Publishing and Wiley-Interscience, New York (with periodic  
10       updates), 1987; and Innis et al., *PCR Protocols: A Guide to Methods and Applications*, Academic Press: San Diego, 1990. PCR primer pairs can be derived from a known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, © 1991, Whitehead Institute for Biomedical Research, Cambridge, MA). One of skill in the art will appreciate that the  
15       specificity of a particular probe or primer increases with the length of the probe or primer. Thus, for example, a primer comprising 20 consecutive nucleotides will anneal to a target with higher specificity than a corresponding primer of only 15 nucleotides in length. Thus, in order to obtain greater specificity, probes and primers may be selected that comprise, for example, 10, 20, 25, 30, 35, 40, 50 or  
20       more consecutive nucleotides.

**Sequence identity:** The similarity between two nucleic acid sequences or between two amino acid sequences is expressed in terms of the level of sequence identity shared between the sequences. Sequence identity is typically expressed in  
25       terms of percentage identity; the higher the percentage, the more similar the two sequences.

Methods for aligning sequences for comparison are well known in the art. Various programs and alignment algorithms are described in: Smith & Waterman, *Adv. Appl. Math.* 2:482, 1981; Needleman & Wunsch, *J. Mol. Biol.* 48:443, 1970;  
30       Pearson & Lipman, *Proc. Natl. Acad. Sci. USA* 85:2444, 1988; Higgins & Sharp, *Gene* 73:237-244, 1988; Higgins & Sharp, *CABIOS* 5:151-153, 1989; Corpet et al., *Nucleic Acids Research* 16:10881-10890, 1988; Huang, et al., *Computer Applications*

in the *Biosciences* 8:155-165, 1992; and Pearson et al., *Methods in Molecular Biology* 24:307-331, 1994. Altschul et al., *J. Mol. Biol.* 215:403-410, 1990, presents a detailed consideration of sequence-alignment methods and homology calculations.

The National Center for Biotechnology Information (NCBI) Basic Local  
5 Alignment Search Tool (BLAST™, Altschul et al., *J. Mol. Biol.* 215:403-410, 1990) is available from several sources, including the National Center for Biotechnology Information (NCBI, Bethesda, MD) and on the Internet, for use in connection with the sequence-analysis programs blastp, blastn, blastx, tblastn and tblastx. A description of how to determine sequence identity using this program is available on  
10 the internet under the help section for BLAST™.

For comparisons of amino acid sequences of greater than about 30 amino acids, the "Blast 2 sequences" function of the BLAST™ program is employed using the default BLOSUM62 matrix set to default parameters, (gap existence cost of 11, and a per residue gap cost of 1). When aligning short peptides (fewer than around  
15 30 amino acids), the alignment should be performed using the Blast 2 sequences function, employing the PAM30 matrix set to default parameters (open gap 9, extension gap 1 penalties). Proteins with even greater similarity to the reference sequences will show increasing percentage identities when assessed by this method, such as at least 45%, at least 50%, at least 60%, at least 80%, at least 85%, at least  
20 90%, or at least 95% sequence identity.

As mentioned above, 'Sequence identity' can be determined by using an alignment algorithm such as Blast™ (available at the National Center for Biotechnology Information [NCBI]). A first nucleic acid is "substantially similar" to a second nucleic acid if, when optimally aligned (using the default parameters  
25 provided at the NCBI website) with the other nucleic acid (or its complementary strand), there is nucleotide sequence identity in at least about, for example, 50%, 75%, 80%, 85%, 90% or 95% of the nucleotide bases. Sequence similarity can be determined by comparing the nucleotide sequences of two nucleic acids using the BLAST™ sequence analysis software (blastn) available from NCBI. Such  
30 comparisons may be made using the software set to default settings (expect = 10, filter = default, descriptions = 500 pairwise, alignments = 500, alignment view = standard, gap existence cost = 11, per residue existence = 1, per residue gap cost =

0.85). Similarly, a first polypeptide is substantially similar to a second polypeptide if they show sequence identity of at least about 75%-90% or greater when optimally aligned and compared using BLAST software (blastp) using default settings.

5

**Oxygenase activity:** Enzymes exhibiting oxygenase activity are capable of directly incorporating oxygen into a substrate molecule. Oxygenases can be either dioxygenases, in which case the oxygenase incorporates two oxygen atoms into the substrate; or, monooxygenases, in which only one oxygen atom is incorporated into  
10 the primary substrate to form a hydroxyl or epoxide group. Thus, monooxygenases are referred to sometimes as "hydroxylases." Taxoid oxygenases are a subset of oxygenases that specifically utilize taxoids as substrates.

**Oxygenases:** Oxygenases are enzymes that display oxygenase activity as  
15 described *supra*. However, all oxygenases do not recognize the same substrates. Therefore, oxygenase enzyme-activity assays may utilize different substrates depending on the specificity of the particular oxygenase enzyme. One of ordinary skill in the art will appreciate that the spectrophotometry-based assay described below is a representative example of a general oxygenase activity assay, and that  
20 direct assays can be used to test oxygenase catalysis directed towards different substrates.

## II. Characterization of Oxygenases

### 25 A. Overview of Experimental Procedures

Biochemical studies have indicated that at least the first five oxygenation steps of the Taxol pathway are catalyzed by cytochrome P450 hydroxylases (the remaining three oxygenations are also likely catalyzed by cytochrome P450 enzymes), and that these are slow steps of the reaction pathway and, thus, important  
30 candidates for cDNA isolation for the purpose of over-expression in relevant producing organisms to increase Taxol yields (Croteau et al., *Curr. Topics Plant Physiol.* 15:94-104, 1995; and Hezari et al., *Planta Med.* 63:291-295, 1997). Protein purification of cytochrome P450 enzymes from *Taxus* microsomes (Hefner



et al., *Methods Enzymol.* 272:243-250, 1996), as a basis for cDNA cloning, was not performed because the number of P450 species present, and their known similarity in physical properties (Mihaliak et al., *Methods Plant Biochem.* 9:261-279, 1993), would almost certainly have prevented bringing the individual proteins to  
5 homogeneity for amino acid microsequencing.

Therefore, a strategy based on the differential display of mRNA-reverse transcription-PCR (DD-RT-PCR) was used for isolating transcriptionally active cytochrome P450s in *Taxus* cells, which previous biochemical studies had shown to undergo substantial up-regulation of the Taxol pathway 16 hours after induction  
10 with methyl jasmonate (Hefner et al., *Arch. Biochem. Biophys.* 360:62-74, 1998). Differential display experimental schemes allow for the identification of mRNA species that are up-regulated in response to certain stimulus. Generally, one set of samples is not treated with the stimulant, and a second set of samples is treated with the stimulant. Subsequently, the mRNA from both groups is isolated and amplified.  
15 The mRNA of interest is identified by comparing the mRNA from the stimulated and unstimulated samples. The mRNA that is present only in the stimulated sample appears to represent genes that are activated upon stimulation.

In the experiments described below, mRNA from an untreated cell culture was compared to the mRNA from a culture that had been induced with methyl  
20 jasmonate for 16 hours. In order to obtain predominantly induced cytochrome P450 sequences, forward primers were designed based on a conserved proline, phenylalanine, glycine (PFG) motif in plant cytochrome P450 genes. The use of primers directed towards the (PFG) motif in conjunction with the DD-RT-PCR-based strategy revealed roughly 100 differentially expressed species, and the  
25 sequences of 100 of these were obtained and analyzed. Of these, 39 represented PCR products containing a cytochrome P450-type sequence. Analysis of these sequences revealed that the C-terminus from 21 different and unique cytochrome P450 genes had been isolated. The 21 nucleic acid sequences amplified (amplicons) and identified as regions encoding oxygenases are shown in SEQ ID NOS: 1-21,  
30 respectively.

Twelve amplicons were labeled and used as hybridization probes to screen the methyl jasmonate-induced *T. cuspidata* cell cDNA library. Screening the *T.*

*cuspidata* library allowed identification of nine full-length clones. Four additional clones, which were truncated at the 5'-terminus, were obtained in full-length form using a 5'-RACE (Rapid analysis of cDNA ends) method to acquire the missing 5'-sequences. Thus, the initial use of the amplicons, described above, has allowed for the identification of thirteen full-length oxygenases (SEQ ID NOS: 43-55, respectively). Subsequently, various molecular techniques were used to identify an additional 10 full-length cDNAs (SEQ ID NOS: 81-86, respectively) and their corresponding amino acid sequences (SEQ ID NOS: 87-92, respectively).

The full-length oxygenase clones identified through the use of the amplicon-based probes can then be cloned into prokaryotic-based and eukaryotic-based expression systems. Once expressed, the functional competence of the resulting oxygenases can be assessed using the spectrophotometric assay described below.

The clones that are found to be active using the spectrophotometric assay are at a minimum useful for detecting carbon monoxide. Additionally, in the examples provided below, several of the full-length oxygenase-encoding sequences are shown to have *in situ* oxygenase activity towards taxoids when expressed in *Saccharomyces cerevisiae* and baculovirus-*Spodoptera* cells.

Oxygenases produced by cloned full-length oxygenase-encoding sequences also can be tested for the ability to oxygenate taxoid substrates *in vivo*. This can be done by feeding taxoid intermediates to transgenic cells expressing the cloned oxygenase-encoding sequences.

## B. Cloning of Oxygenases

As described *supra*, a DD-RT-PCR scheme was used for the isolation of transcriptionally active cytochrome P450s in *Taxus* cells, which previously had been shown to undergo substantial up-regulation of the Taxol pathway 16 hours after induction with methyl jasmonate (Hefner et al., *Arch. Biochem. Biophys.* 360:62-74, 1998). Because an increase in the relevant enzyme activities resulted from induction (indicating *de novo* protein synthesis), mRNA from an untreated cell culture was compared to mRNA from a culture that had been so induced for 16 hours. In order to obtain predominantly induced cytochrome P450 sequences, forward primers were designed based on a conserved motif in plant cytochrome P450 genes. Related

strategies have been used with other plants (Schopfer and Ebel, *Mol. Gen. Genet.* 258:315-322, 1998). The proline, phenylalanine, glycine (PFG) motif is a well-conserved region of the heme-binding domain (Durst and Nelson, "Diversity and evolution of plant P450 and P450 reductase," in Durst and O'Keefe (eds.), *Drug Metabolism and Drug Interactions*, Freund, UK, 1995, pp. 189-206). The  
5 corresponding codons of this region contain only two degenerate positions; thus, a set of only eight non-degenerate primers was necessary to encompass all sequence possibilities (Fig. 4). This PFG motif is located 200-250 bp upstream of the stop codon, and the length of the 3'-untranslated region should range between 100 and  
10 300 bp. Thus, the length of the expected PCR fragments would be in the 300-550 bp range. This DD-RT-PCR-based strategy revealed roughly 100 differentially expressed species, and the sequences of 100 of these were obtained and analyzed. Of these, 39 represented PCR products containing a cytochrome P450-type sequence. Analysis of these sequences revealed that the C-terminus from 21  
15 different and unique cytochrome P450 genes had been isolated. These DNA fragments (12 thus far) are being used as labeled hybridization probes to screen the methyl jasmonate-induced *T. cuspidata* cell cDNA library. By this means, nine clones have been obtained in full-length form by screening. Four additional clones, which were truncated at the 5'-terminus, were obtained in full-length form using a 5'-  
20 RACE (Rapid analysis of cDNA ends) method to acquire the missing 5'-sequences.

### C. Sequence Analysis

The full-length oxygenase sequences initially obtained (using 12 partial sequence probes) were compared pairwise. It was shown that a total of 13 unique  
25 sequences (showing less than 85% similarity), designated clones F12, F21, F42, F31, F51, F9, F56, F19, F14, F55, F34, F72, and F10, respectively (SEQ ID NOS: 43-55, respectively) were present. Two of the isolated clones, clone F51 (SEQ ID NO: 47) and clone F9 (SEQ ID NO: 48) were not identical to any of the 21 C-terminal fragments originally found by the DD-RT-PCR cloning strategy, bringing  
30 the total number of initially identified unique oxygenase genes, and gene fragments, to 23.

The clones obtained also were compared pairwise to all known plant cytochrome P450 oxygenase sequences in the databases (provided at the NCBI website) (Figs. 5A and 5B) provide a dendrogram of these relationships and a table of pairwise similarity and identity comparisons).

5        This analysis revealed that 11 of the *Taxus* clones sorted into one cytochrome P450 family. This large group of related clones seems to resemble most closely the CYP90, CYP85, and CYP88 cytochrome P450 families. Some members of these families are known to be involved in terpenoid metabolism [e.g., gibberellin (diterpene, C20) and brassinosteroid (triterpene C30) biosynthesis], suggesting that  
10       the cytochrome P450 clones obtained from *Taxus* could be involved in the biosynthesis of the diterpenoid Taxol. Table 1 lists accession numbers of relevant sequences and related information. Outlying clones F10 (SEQ ID NO:55) and F34 (SEQ ID NO: 53) are related more closely to CYP family 82 (phenylpropanoid metabolism) and CYP family 92 (unknown function), respectively.

15       After the initial 13 full-length clones were identified, six more were isolated. Thus, the total number of full-length oxygenase clones identified is nineteen. A dendrogram showing the relationship of all of the identified oxygenase clones is provided in Fig. 5C. A table providing both the sequence identity and similarity of the clones is provided in Fig. 5D.

**Table 1**  
**Closest Relatives to *Taxus* Cytochrome P450 Sequences**

Family	Description	Clones That Are Similar
<b>CYP90A1</b>	<i>Arabidopsis thaliana</i> GenEMBL X87367 mRNA (1608bp); GenEMBL X87368 gene (4937 bp). Szekeres et al., "Brassinosteroids rescue the deficiency of CYP90, a cytochrome P450, controlling cell elongation and de-etiolation in <i>Arabidopsis</i> ," <i>Cell</i> 85:171-182 (1996).	F9, F12, F14, F19, F21, F31, F42, F51, F55, F56, and F72 (SEQ ID NOS: 48, 43, 51, 50, 44, 46, 45, 47, 52, 49, and 54, respectively)
<b>CYP85</b>	<i>Solanum lycopersicum</i> (tomato) (also <i>Lycopersicon esculentum</i> ) GenEMBL U54770 (1395 bp). Bishop et al., "The tomato dwarf gene isolated by heterologous transposon tagging encodes the first member of a new family of cytochrome P450," <i>Plant Cell</i> 8:959-969 (1996).	F9, F12, F14, F19, F21, F31, F42, F51, F55, F56, and F72 (SEQ ID NOS: 48, 43, 51, 50, 44, 46, 45, 47, 52, 49, and 54, respectively)
<b>CYP88A1</b>	<i>Zea mays</i> GenEMBL U32579 (1724 bp). Winkler and Helentjaris, "The maize dwarf3 gene encodes a cytochrome P450-mediated early step in gibberellin biosynthesis," <i>Plant Cell</i> 7:1307-1317 (1995).	F9, F12, F14, F19, F21, F31, F42, F51, F55, F56, and F72 (SEQ ID NOS: 48, 43, 51, 50, 44, 46, 45, 47, 52, 49, and 54, respectively)
<b>CYP82A1</b>	<i>Pisum sativum</i> (pea) GenEMBL U29333 (1763 bp). Frank et al., "Cloning of phenylpropanoid pathway P450 monooxygenases expressed in <i>Pisum sativum</i> ," unpublished.	Outlying Clone F10 (SEQ ID NO: 55)
<b>CYP82A2</b>	<i>Glycine max</i> (soybean) GenEMBL Y10491 (1757 bp). Schopfer and Ebel, "Identification of elicitor-induced cytochrome P450s of soybean ( <i>Glycine max</i> L.) using differential display of mRNA," <i>Mol. Gen. Genet.</i> 258:315-322 (1998).	Outlying Clone F34 (SEQ ID NO: 53)
<b>CYP92A2</b>	<i>Nicotiana tabacum</i> (tobacco) GenEMBL X95342 (1628bp). Czernic et al., "Characterization of hsr201 and hsr215, two tobacco genes preferentially expressed during the hypersensitive reaction provoked by phytopathogenic bacteria," unpublished.	Outlying Clone F34 (SEQ ID NO: 53)

#### D. Functional Expression

Functional cytochrome P450 expression can be obtained by using the pYeDP60 plasmid in yeast (*Saccharomyces cerevisiae*) engineered to co-express one or the other of a cytochrome P450 reductase from *Arabidopsis thaliana*; the plant-  
5 derived reductase is important for efficient electron transfer to the cytochrome (Pompon et al., *Methods Enzymol.* 272:51-64, 1999).

Since a functional P450 cytochrome, in the appropriately reduced form, will bind competently to carbon monoxide and give a characteristic CO-difference spectrum (Omura and Sato, *J. Biol. Chem.* 239:2370-2378, 1964), a  
10 spectrophotometric means for assessing, and quantitatively estimating, the presence of functional recombinant cytochrome P450 in transformed yeast cells by *in situ* (*in vivo*) measurement was developed. CO-sensor of the 19 full-length cytochrome P450 clones from *Taxus*, thus far obtained, ten have yielded detectable CO-difference spectra (Table 2). It is expected that cytochrome P450 clones that do not  
15 yield reliable expression in *S. cerevisiae* can be transferred to, expressed in, and confirmed by CO-difference spectrum utilizing alternative prokaryotic and eukaryotic systems. These alternative expression systems for cytochrome P450 genes include the yeast *Pichia pastoris*, for which expression vectors and hosts are commercially available (Invitrogen, Carlsbad, CA), as well as established *E. coli* and  
20 baculovirus-insect cell systems for which general expression procedures have been described (Barnes, *Methods Enzymol.* 272:1-14, 1996; Gonzalez et al., *Methods Enzymol.* 206:93-99, 1991; Lee et al., *Methods Enzymol.* 272:86-98, 1996; and Lupien et al., *Arch. Biochem. Biophys.* 368:181-192, 1999).

Clones that prove to be capable of binding to CO are useful at least for  
25 detecting CO in various samples. Further testing of the recombinantly expressed clones may prove that they are additionally useful for adding one or more oxygen atoms to taxoid substrates.

**E. *In vivo* Assays of Yeast Cells Expressing Recombinant Oxygenases**

5                   **1. Use of substrates [20-<sup>3</sup>H<sub>3</sub>]taxa-4(5),11(12)-diene or [20-<sup>3</sup>H<sub>2</sub>]taxa-4(20,11(12)-dien-5 $\alpha$ -ol**

Transformed yeast cells that functionally express a recombinant cytochrome P450 gene from *Taxus* (by CO-difference spectrum) can be tested *in vivo* for their ability to oxygenate (hydroxylate or epoxidize) taxoid substrates fed exogenously to  
10 the cells, thereby eliminating the need for microsome isolation for preliminary *in vitro* assays.

Accordingly, several clones of the available full-length clones were expressed in induced yeast host cells. These cells were fed [20-<sup>3</sup>H<sub>3</sub>]taxa-4(5),11(12)-diene or [20-<sup>3</sup>H<sub>2</sub>]taxa-4(20,11(12)-dien-5 $\alpha$ -ol in separate incubations  
15 and compared to untransformed controls similarly fed (and that were shown to be inactive with taxoid substrates). The extracts resulting from these incubations were analyzed by radio-HPLC, and the clones that yielded a product are shown below in Table 2.

Representative HPLC traces are shown in Figures 6A-6C. Representative  
20 GC-MS (gas chromatography-mass spectrometry) analyses of the products from an incubation are shown in Figs. 6D and 6E. The results shown in Figs. 6A-6E confirm that two distinctly different taxadien-diols derived from taxadien-5 $\alpha$ -ol were formed, one yielding the expected parent ion at  $P^+ = m/z$  304, and the other less stable to the conditions of the analysis in losing water readily to yield the highest mass ion at  $m/z$   
25 286 ( $P^+ - H_2O$ ).

**2. Use of substrate [20-<sup>3</sup>H<sub>2</sub>] taxa-4(20), 11(12)-dien-5 $\alpha$ -yl acetate**

Transformed yeast cells that functionally express a recombinant cytochrome P450 gene from *Taxus* (by CO-difference spectrum) were tested *in vivo* for their  
30 ability to oxygenate (hydroxylate or epoxidize) taxoid substrates fed exogenously, thereby eliminating the need for microsome isolation for such a preliminary *in vitro* assay. The clones indicated in Table 2, below, were induced in yeast host cells that

were fed [20-<sup>3</sup>H<sub>2</sub>]taxa-4(20),11(12)-dien-5 $\alpha$ -yl acetate in separate incubations and compared to untransformed controls similarly fed (and that were shown to be inactive with taxoid substrates). The ether extracts resulting from these incubations were analyzed by radio-HPLC. Several clones converted the taxadienyl-5 $\alpha$ -yl  
5 acetate substrate to a more polar product.



Table 2

Full-length name (SEQ ID NO: nt/aa)	Probe name (SEQ ID NO: nt/aa)	CO diff. spec.	assayed with	product identified HPLC peak
F12 * 43/56	aa1 11/32	+	Taxadiene Taxadien5aol Taxadienyl Ac	No ++ ++
F21 * 44/57	cb1 10/31	+	Taxadiene Taxadien5aol Taxadienyl Ac	No + No
F31 * 46/59	ab2 1/22	+	Taxadiene Taxadien5aol Taxadienyl Ac	No No No
F42 * 45/58	ai2 5/26	-	Taxadiene Taxadien5aol	No No
F51 * 47/60	Lib. Screen	+	Taxadiene Taxadien5aol Taxadienyl Ac	No ++ ++
F72 * 54/67	cm2 19/40	+	Taxadiene Taxadien5aol Taxadienyl Ac	No + +
F82 81/87	dl1 20/41	-	Taxadiene Taxadien5aol Taxadienyl Ac	No + ++
F9 * 48/61	Lib. Screen	+	Taxadiene Taxadien5aol Taxadienyl Ac	No + +/-
F56 * 49/62	el2 8/29	-	Taxadiene Taxadien5aol	No No
F14 * 51/64	ea1 13/34	+++	Taxadiene Taxadien5aol Taxadienyl Ac	No ++ ++
F19 * 50/63	ds1 14/35	-	Taxadiene Taxadien5aol	No No
F55 * 52/65	cf2 6/27	-	Taxadiene Taxadien5aol	No No
F16 82/88	ae1 2/23	+++	Taxadiene Taxadien5aol Taxadienyl Ac	No ++ ++
F7 83/89	cj1 7/28	-	Taxadiene Taxadien5aol Taxadienyl Ac	No ++ ++
F23 84/90	di1 15/36	-	Taxadiene Taxadien5aol	No No
F10 * 55/68	ba1 17/38	+	Taxadiene Taxadien5aol	No No

F34 * 53/66	du1	++	Taxadiene Taxadien5 $\alpha$ ol	No No
F15 85/91	df 12/33			
F38 86/92	ad6 16/37			

Additional testing of the clone F14 (SEQ ID NO: 64) metabolite was conducted. The metabolite isolated by HPLC was subjected to GC-MS analysis and shown to possess a retention time (compared to the starting material) and mass spectrum that were consistent with respective data obtained from a taxadien-diol monoacetate [the parent ion ( $P^+$ ) was observed at  $m/z$  346 (taxadienyl acetate (MW = 330) plus O) with diagnostic ions at  $m/z$  328 ( $P^+ - H_2O$ ), 313 ( $P^+ - H_2O - CH_3$ ), 286 ( $P^+ - CH_3COOH$ ), 271 ( $P^+ - CH_3COOH - CH_3$ ), 268 ( $P^+ - CH_3COOH - H_2O$ ) and 253 ( $P^+ - CH_3COOH - CH_3 - H_2O$ )].

Preparative-scale incubations of the transformed yeast harboring clone F14 (SEQ ID NO: 51), with the taxadien-5 $\alpha$ -yl acetate substrate, yielded the HPLC-based isolation of about 100  $\mu$ g of the unknown diol monoacetate (>97% purity by GC) for NMR analysis. Since all of the  $^1H$  resonances of taxadien-4(20),11(12)-dien-5 $\alpha$ -ol (and of the acetate ester) had been assigned previously (Hefner et al., *Chem. and Biol.* 3:479-489, 1996), elucidation of the structure of the unknown diol monoacetate was accomplished by  $^1H$  detection experiments (sample-size-limited direct  $^{13}C$  measurements).

The  $^1H$ -NMR spectrum is illustrated in Fig. 7, and Table 3, below, lists the complete  $^1H$  assignments along with their respective one-carbon correlated  $^{13}C$  assignments as determined indirectly from heteronuclear single quantum coherence (HSQC; Fig. 8). The assignments are consistent with those of other known taxadien monool and diol derivatives. For example, chemical shifts for C5 ( $\delta$  75.9, C5;  $\delta$  5.47, H5) and C10 ( $\delta$  67.2, C10;  $\delta$  4.9 H10) are assigned as oxy-methines. The shifts for C20 ( $\delta$  111.6, C20;  $\delta$  5.07, H20, exo;  $\delta$  4.67, H20, endo) are consistent with the exocyclic methylene observed in other taxa-4(20),11(12)-dienes. Other characteristic shifts are observed for H7 $\alpha$  ( $\delta$  1.84), H19 methyl ( $\delta$  0.56), H3 ( $\delta$  2.84), and the gem-dimethyls H16 ( $\delta$  1.14, exo) and H17 ( $\delta$  1.59, endo).

**Table 3**

Complete  $^1\text{H}$ -NMR assignments and one-bond correlated  $^{13}\text{C}$  assignments (as measured indirectly from HSQC) for the biosynthetic product derived from taxadien-5 $\alpha$ -yl acetate by the cytochrome P450 expressed from clone F14. For position numbering, see Fig. 1.

5

Position number	Carbon ( $\delta$ )	$\alpha$ -proton ( $\delta$ )	$\beta$ -proton ( $\delta$ )
1	43.9		1.59
2	28	1.47	1.53
3	35.9	2.84	
4			
5	75.9		5.47
6	27.9	1.66	1.55
7	33.6	1.94	0.9
8			
9	47.6	1.42	2.21
10	67.2	4.9	
11			
12			
13	30.3	1.8	2.26
14	22.7	1.26	1.96
15			
16	31.8	1.14 ( <u>exo</u> )	
17	25.3	1.59 ( <u>endo</u> )	
18	20.7	1.71	
19	21.4		0.66
20	111.6	5.07 ( <u>exo</u> )	
		4.67 ( <u>endo</u> )	
21 (acetate)	21	1.66	

The 2D-TOCSY spectra (Figs. 9A and 10) complemented the HSQC data and permitted additional regiochemical assignments. The H5 proton ( $\delta$  5.47) (Figs. 10A and 10E) was correlated strongly with H6 ( $\delta$  1.66,  $\delta$  1.55) and H7 ( $\delta$  1.94,  $\delta$  0.9) protons but had no appreciable coupling to either of the H20 signals ( $\delta$  5.07,  $\delta$

10

4.67) or to H3 ( $\delta$  2.84), which is a common feature observed with taxadiene derivatives. The spin system defined in part by H3 ( $\delta$  2.84), H2 ( $\delta$  1.47 and  $\delta$  1.53), H1 ( $\delta$  1.59), H13 ( $\delta$  1.80,  $\delta$  2.26), and H14 ( $\delta$  1.26,  $\delta$  1.96) was apparent in Figs. 10C and 10E. The H18 allylic methyl ( $\delta$  1.71) also displayed a weak correlation with H13. In contrast to the extended spin correlations noted in Fig. 10D, the H9 ( $\delta$  1.42,  $\delta$  2.21) and H10 ( $\delta$  4.9) signals formed an isolated spin system (see Fig. 10B), which included the H10 hydroxyl ( $\delta$  0.85). A correlation also was observed between the two gem-dimethyl signals ( $\delta$  1.14 and  $\delta$  1.59), which was consistent with the spectra of other taxadiene derivatives.

<sup>1</sup>H-<sup>1</sup>H ROESY (Rotational nuclear Overhauser Effect Spectroscopy) is useful for determining which signals arise from protons which are close in space but not closely connected by chemical bonds. Therefore, 2D-ROESY spectra (Figs. 9B and 11) were used to confirm the regiochemical assignments and to assess relative stereochemistry (Several of these n.O.e correlations are listed in Table 4). <sup>1</sup>H-<sup>1</sup>H TOCSY (TOtal Correlated Spectroscopy) is useful for determining which signals arise from protons within a spin system, especially when the multiplets overlap or there is extensive second order coupling. The 2D-TOCSY (total correlation spectrum) described herein, showed that a second heteroatom was introduced into the C9-C10 fragment, but the regiochemistry was ambiguous based on this single measurement. The 2D-ROESY confirmed that oxidation had occurred at C10 and placed the C10 hydroxyl in the  $\beta$ -orientation. This assignment also was supported by an observed n.O.e between the H10 proton ( $\delta$  4.90) (Fig. 11B) and the allylic methyl, H18 ( $\delta$  1.71), which is consistent with an  $\alpha$ -configuration for H10.

Additional stereochemical assignments were made by noting correlations between H9 $\beta$  ( $\delta$  2.21) and the H17 methyl which must be endo ( $\delta$  1.59) (Fig. 11E), the H19 methyl ( $\delta$  0.56) which is  $\beta$ -oriented, and the H2 $\beta$ -proton ( $\delta$  1.53). The other H9 signal ( $\delta$  1.42) correlated with H19 and the H7 $\beta$ -proton ( $\delta$  0.90), as well as H10 ( $\delta$  4.90) (Figs. 11D and 11B). It also was noted that <sup>3</sup>J<sub>HH</sub> was large (11.7 Hz) between the H9 $\beta$ - and H10 $\alpha$ -protons, consistent with a nearly axial arrangement for this pair; a smaller coupling (5.3 Hz) between H9 $\alpha$  and H10 was consistent with an equatorial configuration between these two protons.

ROESY spectroscopy also was used to confirm the stereochemistry at H5. Moderately strong correlations were seen between H5 ( $\delta$  5.47) (see Table 4 and Fig. 11A) and both C6 signals ( $\delta$  1.66,  $\delta$  1.55), consistent with an equatorial orientation for H5. The  $^3J_{HH}$  coupling was quite small ( $< 3$  Hz) between H5 and all other scalar-coupled partners, providing further evidence for the adopted equatorial orientation of H5. A moderately strong n.O.e between H5 and H20<sub>exo</sub> was noted, but there were no n.O.e correlations observed between H5 and other protons on the  $\alpha$ -face of the molecule. These results confirmed that H5 was  $\beta$ -configured and that the acetate group was  $\alpha$ -oriented as in the substrate. One other significant structural motif in taxadiene derivatives was the near occlusion of the H3 proton on the  $\alpha$ -face due to the unusual folding of the molecule, thereby making the H3 proton ( $\delta$  2.84) a useful probe for this face. Indeed, n.O.e correlations were observed between H3, H10, H13 $\alpha$ , and the allylic methyl H18 (Table 4 below, and Fig. 11C).

**Table 4**  
**n.O.e. Correlations**

Proton		n.O.e.	correlations				
H3	alpha	10 (w)	13-a (m)	18 (w)			
H5	beta	20-exo (m)	6-ab (m)				
H7	beta	19 (w)	9-a (m)	6-ab (m)	7-a (s)		
H7	alpha	7-b (s)	3 (m)	10 (m)	21(w) ?		
H9	alpha	9-b (s)	7-b (m-w)	19 (w)	9-a (m)	OH (w)	
H9	beta	17 (m)	9-a (s)	2-b (w)	19 (w)		
H10	alpha	7-a (m)	18 (m)	9-a (m)	19-b (w)	OH (w)	
H13	beta	14-b (m)	13-a (s)	18 (vw)	16-exo (m)		
H14	alpha	3 (w)	14-b (s)	13-a (m)			
H14	beta	14-a (s)	16-exo (m)	1 (m)	13-b (m)		
H16	exo	17-endo (m)	3-b (m)	14-b (m-w)	1 (w)		
H19	beta	20-endo (w)	20-exo (w)	7-b (m)	9-ab (m)	2-b (s)	6-b (m)
H20	endo	20-exo (s)	3 (w)	2-a (s)	19 (w)		
H20	exo	20-endo (m)	5 (m)				

This full assignment of the structure confirms the identity of the biosynthetic product as taxa-4(5),11(12)-dien-5 $\alpha$ -acetoxy-10 $\beta$ -ol, and indicates that a cDNA encoding the cytochrome P450 taxane 10 $\beta$ -hydroxylase has been isolated. This 1494-bp cDNA (SEQ ID NO:51) translates a 497 residue deduced protein of

molecular weight 56,690 that bears a typical N-terminal membrane anchor (Brown et al., *J. Biol. Chem.* 264:4442-4449, 1989), with a hydrophobic insertion segment (Nelson et al., *J. Biol. Chem.* 263:6038-6050, 1988) and a stop-transfer signal (Sakaguchi et al., *EMBO J.* 6:2425-2431, 1987). The protein possesses all of the  
5 conserved motifs anticipated for cytochrome P450 oxygenases, including the oxygen-binding domain (Shimada et al., in Bunabiki (ed.) *Oxygenases and Model Systems*, Kluwer, Boston, MA, pp. 195-221, 1997) and the highly conserved heme-binding motif (Durst et al., *Drug Metab. Drug Interact.* 12:189-206, 1995; and von Wachenfeldt et al., in Ortiz de Montellano (ed.), *Cytochrome P450: Structure,*  
10 *Mechanism, and Biochemistry*, Plenum, New York, NY, pp. 183-223, 1995) with PFG element (aa 435-437).

#### **F. In Vitro Assays of Isolated Enzymes for Taxoid Oxygenase Activity**

15 The standard enzyme assay for assessing oxygenase activity of the recombinant cytochrome P450 employed the following conditions: 25 mM HEPES buffer, pH 7.5, 400  $\mu$ M NADPH, 300  $\mu$ g protein and 30  $\mu$ M substrate (taxadiene, taxadienol, or taxadienyl acetate) in a total volume of 1 mL. Samples were incubated at 32°C for 12 hours, after which 1 mL of saturated NaCl solution was  
20 added to the reaction mixture, followed by extraction of the product with 2 mL of hexane/ethyl acetate (4:1, v/v). The extracts were dried and dissolved in acetonitrile for product analysis by radio-HPLC [column: Alltech Econosil C18 5  $\mu$ m particle size (250 mm X 4.6 mm): solvent system A: 0.01% (v/v) H<sub>3</sub>PO<sub>4</sub>, 2% acetonitrile, 97.99% H<sub>2</sub>O; solvent system B: 0.01% H<sub>3</sub>PO<sub>4</sub>, 99.99 acetonitrile; gradient: 0-5  
25 minutes, 100% A; 5-15 minutes, 0-50% B; 15-55 minutes, 50-100% B; 55-65 minutes, 100% B; 65-70 minutes, 0-100% A; 70-75 minutes, 100% A; flow rate 1 mL/minute; for detection, a radio-chromatography detector (Flow-One®-Beta Series A-100, Radiomatic) was used].

Of the three test substrates (A, B, C), taxadiene was not converted detectably  
30 to an oxygenated product by recombinant cytochrome P450 clone F16 (SEQ ID NO: 93). Of the 5 $\alpha$ -ol derivatives, taxa-4(20),11(12)-dien-5 $\alpha$ -ol was converted most efficiently to a diol product as determined by GC-MS analysis (parent ion indicating

a MW of 304). Preparative incubations with taxadienol allowed the generation of ~100 µg of the diol product that was purified by a combination of reversed phase HPLC, as described above, and normal phase TLC (silica gel with toluene/acetone (3:1, v/v)) in preparation for structural determination by <sup>1</sup>H- and <sup>13</sup>C-NMR analysis (500 MHz). Comparison of spectra to those of authentic taxa-4(20),11(12)-dien-5α-ol (Hefner et al., *Chem. Biol.* 3:479-489, 1996) indicated that the product of the clone F16 (SEQ ID NO: 93) cytochrome P450 oxygenase reaction is taxa-4(20),11(12)-dien-5α,9α-diol. These results indicated that clone F16 (SEQ ID NO: 16) encodes a cytochrome P450 taxane 9α-hydroxylase, likely representing the third regiospecific hydroxylation step of the Taxol biosynthetic pathway.

Additionally, biochemical studies can be done to determine which diol resides on the Taxol pathway (i.e., the gene encoding the next pathway step suspected to be responsible for C10 hydroxylation), and to determine which activities (and genes) reside further down the pathway (catalyzing formation of triol, tetraol, pentaol, etc.) but that yield a cytochrome P450 oxygenase capable of catalyzing the hydroxylation of taxadien-5α-ol as an adventitious substrate. Other expression systems also can be tested to obtain functional expression of the remaining clones, and all functional clones are being tested with other taxoid substrates.

It is notable that some of the clones that are capable of transforming taxoid intermediates are from the same, closely related family (see placement of clones F9, F12, F14, and F51 (SEQ ID NOS: 61, 56, 64, and 60) in the dendrogram of Fig. 5(A)). Outlying clone 34, although it yielded a reliable CO-difference spectrum (confirming a functional cytochrome P450 and its utility for detecting CO), does not transform the taxoid substrates to oxygenated products. However, this clone when expressed in a different expression system may prove to be active against other taxoid substrates.

### III. Other Oxygenases of the Taxol Pathway

The protocol described above yielded 21 related amplicons. Initial use of twelve amplicons as probes for screening the cDNA library allowed for the isolation and characterization of thirteen oxygenase-encoding DNA sequences.

Subsequently, additional full-length enzymes were isolated. Several of these full-length sequences were expressed recombinantly and tested *in situ*, and ten were shown to be capable of binding CO, and, therefore, to be useful for detecting CO (Table 2). Additionally, nine clones were shown to be capable of hydroxylating taxoid substrates *in vivo* (Table 2).

There are at least five distinct oxygenases in the Taxol biosynthetic pathway (Hezari et al., *Planta Med.* 63:291-295, 1997), and the close relationship between the nucleic acid sequences of the 21 amplicons indicates that the remaining amplicon sequences represent partial nucleic acid sequences of the other oxygenases in the Taxol biosynthetic pathway. Hence, the above-described protocol enables the identification and recombinant production of oxygenases corresponding to the full-length versions of the 21 amplicon sequences provided. Therefore, the following discussion relating to Taxol oxygenases refers to the full-length oxygenases shown in the respective sequence listings, as well as the remaining oxygenases of the Taxol biosynthetic pathway that are identifiable through the use of the amplicon sequences. Furthermore, one of skill in the art will appreciate that the remaining oxygenases can be tested easily for enzymatic activity using "functional assays" such as the spectrophotometric assay described below, and direct assays for catalysis with the appropriate taxoid substrates.

#### IV. Isolating Oxygenases of the Taxol Biosynthetic Pathway

##### A. Cell Culture

Initiation, propagation, and induction of *Taxus* sp. cell cultures have been previously described (Hefner et al., *Arch. Biochem. Biophys.* 360:62-75, 1998). Enzymes and reagents were obtained from United States Biochemical Corp. (Cleveland, OH), Gibco BRL (Grand Island, NY), Promega (Madison, WI) and New England BioLabs, Inc. (Beverly, MS), and were used according to the manufacturers' instructions. Chemicals were purchased from Sigma Chemical Co. (St. Louis, MO).



## B. Vectors and DNA Manipulation

Unless otherwise stated, all routine DNA manipulations and cloning were performed by standard methods (Sambrook et al. (eds.), *Molecular Cloning: A Laboratory Manual* 2nd ed., vols. 1-3, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989). PCR amplifications were performed by established procedures (Innis et al., *PCR Protocols: A Guide to Methods and Applications*, Academic Press, New York, 1990). DNA was sequenced using Amplitaq™ DNA polymerase (Roche, Somerville, New Jersey) and fluorescence cycle sequencing on an Applied Biosystems Inc. Prism™ 373 DNA Sequencer (Perkin-Elmer, Norwalk, CT). The *Saccharomyces cerevisiae* expression vector pYeDP60 was as described previously (Pompon et al., *Methods Enzymol.* 272:51-64, 1996).

## C. *E. coli* and Yeast Strains

The *E. coli* strains XLI-Blue MRF' (Stratagene, La Jolla, CA) and TOP10F' (Invitrogen, Carlsbad, CA), were used for routine cloning and for cloning PCR products, respectively. The yeast strains used for expression each expressed one of two different *Arabidopsis thaliana* cytochrome P450 reductases, and were designated WAT11 and WAT21, respectively (Pompon et al., *Methods Enzymol.* 272:51-64, 1996).

## D. cDNA Library Construction

A cDNA library was prepared from mRNA isolated from *T. cuspidata* suspension cell cultures, which had been induced to maximal Taxol production with methyl jasmonate for 16 hours. Isolation of total RNA from 1.5 g *T. cuspidata* cells was developed empirically using a buffer containing 4 M guanidine thiocyanate, 25 mM EDTA, 14 mM 2-mercaptoethanol, and 100 mM Tris-HCl, pH 7.5. Cells were homogenized on ice using a polytron (VWR Scientific, Salt Lake City, UT) (4 X 15 second bursts at setting 7). The homogenate was adjusted to 2 % (v/v) Triton X-100 and allowed to stand 15 minutes on ice, after which an equal volume of 3 M sodium acetate, pH 6.0 was added. After mixing, the solution was incubated on ice for an additional 15 minutes, followed by centrifugation at 15,000 g for 30 minutes at 4°C.

The supernatant was mixed with 0.8 volume of isopropanol and left to stand on ice for 5 minutes. After centrifugation at 15,000 g for 30 minutes at 4°C, the resulting pellet was redissolved in 8 mL 20 mM Tris-HCl, pH 8.0, containing 1 mM EDTA, then adjusted to pH 7.0 by addition of 2 mL 2 M NaCl in 250 mM MOPS buffer at pH 7.0. Total RNA was recovered by passing this solution over a nucleic-acid-isolation column (Qiagen, Valencia, CA) following the manufacturer's instructions. Poly(A)<sup>+</sup> RNA was purified by using the Oligotex<sup>™</sup> mRNA kit following the manufacturer's instructions (Qiagen, Valencia, CA). Messenger RNA prepared in this fashion was used to construct a library using a λZAPII<sup>™</sup>-cDNA synthesis kit and ZAP-cDNA gigapack III<sup>™</sup> gold packaging kit (Stratagene, La Jolla, CA) following the manufacturer's instructions. The isolated mRNA also was used to construct a RACE (Rapid Amplification of cDNA Ends) library using a Marathon cDNA amplification kit (Clontech, Palo Alto, CA).

#### 15           E.       Differential Display of mRNA

Differential display of mRNA was performed using the Delta Differential Display Kit (Clontech, Palo Alto, CA) by following the manufacturer's instructions except were noted. Total RNA was isolated as described above from two different *Taxus cuspidata* suspension cell cultures, one that had been induced with methyl jasmonate 16 hours before RNA isolation and the other that had not been treated (i.e., uninduced). Cytochrome P450-specific forward primers (Fig. 4), instead of random primers, were used in combination with reverse-anchor-(dT)9N-1N-1 primers (where N-1 = A, G, or C) provided in the kit. The anchor designed by Clontech was added to each P450-specific primer to increase the annealing temperature after the fourth low-stringency PCR cycle; this led to a significant reduction of the background signal. Each cytochrome P450-specific primer was used with the three anchored oligo(dT) primers terminated by each nucleotide. PCR reactions were performed with a RoboCycler<sup>™</sup> 96 Temperature Cycler (Stratagene, La Jolla, CA), using one cycle at 94°C for 5 minutes, 40°C for 5 minutes, 68°C for 5 minutes, followed by three cycles at 94°C for 30 seconds, 40°C for 30 seconds, 68°C for 5 minutes, and 32 cycles at 94°C for 20 seconds, 60°C for 30 seconds, and 68°C for 2 minutes. Finally, the reactions were heated at 68°C for 7 minutes. The

resulting amplicons were separated on a 6% denaturing polyacrylamide gel (HR-100, Genomix Corporation, Foster City, CA) using the LR DNA Sequencer Electrophoresis System (Genomix Corporation).

Differential display bands of interest were cut from the dried gel, eluted with  
5 100 mL of 10 mM Tris-HCl buffer, pH 8.0, containing 1 mM EDTA, by incubation overnight at 4°C. A 5-mL aliquot of the extract was used to re-amplify the cDNA fragment by PCR using the same primers as in the original amplification. The reactions initially were heated to 94°C for 2 minutes, then subjected to 30 cycles at 94°C for 1 minute, 60°C for 1 minute, and 68°C for 2 minutes. Finally, to facilitate  
10 cloning of the PCR product, the reactions were heated at 68°C for 7 minutes. Amplicons were analyzed by agarose gel electrophoresis as before. Bands were excised from the gel and the DNA was extracted from the agarose. This gel-purified cDNA was then transferred into the T/A cloning vector pCR2.1-TOPO (Invitrogen, Carlsbad, CA).

15 The DD-RT-PCR-based screening revealed about 100 clearly differentially expressed bands, all of which were sequenced and analyzed. Of these, 39 represented PCR products containing cytochrome P450-like sequences. The nucleotide and deduced peptide sequences of these 39 amplicons were compiled using the GCG fragment assembly programs and the sequence-alignment program  
20 "Pileup" (Genetics Computer Group, Program Manual for the Wisconsin Package, Version 9, Genetics Computer Group, 575 Science Drive, Madison, WI, 1994). This comparison of cloned sequences revealed that C-terminal fragments from 21 different cytochrome P450 genes had been isolated. These cytochrome P450 sequences were used to prepare hybridization probes in order to isolate the  
25 corresponding full-length clones by screening the cDNA library.

#### F. cDNA Library Screening

Initially, 12 probes (SEQ ID NOS: 11, 10, 1, 5, 4, 19, 8, 17, 13, 14, 21, and  
6, respectively) were labeled randomly using the Ready-To-Go™ kit (Amersham  
30 Pharmacia Biotech, Piscataway, NJ) following the manufacturer's instructions. Plaque lifts of the *T. cuspidata* phage library were made on nylon membranes and were screened using a mixture of two radiolabeled probes. Phage DNA was cross-

linked to the nylon membranes by autoclaving on fast cycle for 3 minutes at 120°C. After cooling, the membranes were washed for 5 minutes in 2 X SSC (sodium citrate buffer). Prehybridization was performed for 1 to 2 hours at 65°C in 6 X SSC, containing 0.5% SDS, and 5 X Denhardt's reagent. Hybridization was performed in the same buffer for 20 hours at 65°C. The nylon membranes were washed twice for 5 minutes each in 2 X SSC with 0.1% SDS at room temperature, and twice for 1 hour each in 1 X SSC with 0.1% SDS at 65°C. After washing, the membranes were exposed for 17 hours onto Kodak (Rochester, NY) XAR™ film at -70°C. Positive plaques were purified through one additional round of hybridization. Purified λZAPII clones were excised *in vivo* as pBluescript II SK(+) phagemids (Stratagene, La Jolla, CA) and transformed into *E. coli* SOLR cells. The size of each cDNA insert was determined by PCR using T3 and T7 promoter primers. Inserts (>1.6 kb; of a size necessary to encode a typical cytochrome P450 of 50-60 kDa) were sequenced and sorted into groups based on sequence similarity/identity using the GCG fragment assembly programs (Genetics Computer Group, Program Manual for the Wisconsin Package, Version 9, Genetics Computer Group, 575 Science Drive, Madison, WI, 1994). Each unique sequence was used as a query in database searching using either BLAST or FASTA programs (Genetics Computer Group, Program Manual for the Wisconsin Package, Version 9, Genetics Computer Group, 575 Science Drive, Madison, WI, 1994), to define sequences with significant homology to plant cytochrome P450 sequences. These clones also were compared pairwise at both the nucleic acid and amino acid levels using the "Pileup" and "Gap" programs (Genetics Computer Group, Program Manual for the Wisconsin Package, Version 9, Genetics Computer Group, 575 Science Drive, Madison, WI, 1994).

#### G. Generation of Full-Length Clones by 5'-RACE

Of the 13 clones initially examined, full-length sequences of nine were obtained by screening of the *T. cuspidata* λ-phage library with the corresponding probes (clones F12, F21, F31, F42, F51, F72, F9, F56, and F10, respectively (SEQ ID NOS: 43, 44, 46, 45, 47, 54, 48, 49, and 55, respectively)). To obtain the 5'-sequence portions of the other four truncated clones F14, F19, F34, and F55 (SEQ ID NOS: 51, 50, 53 and 52, respectively), 5'-RACE was performed using the

Marathon cDNA amplification kit (Clontech, Palo Alto, CA) according to the manufacturer's instructions. The reverse primers used were: for F14, 5'-TCGGTGATTGTAACGGAAGAGC-3' (SEQ ID NO: 69); for F19, 5'-CTGGCTTTTCCAACGGAGCAT-GAG-3' (SEQ ID NO: 70); for F34, 5'-ATTGTTTCTCAGCCCGCGCAGTATG-3' (SEQ ID NO: 71); for F55, 5'-TCGGT-TTCTATGACGGAAGAGATG-3' (SEQ ID NO: 72). Using the defined 5'-sequences thus acquired, and the previously obtained 3'-sequence information, primers corresponding to these terminal regions were designed and the full-length versions of each clone were obtained by amplification with *Pfu* polymerase (Stratagene, La Jolla, CA) using library cDNA as target. These primers also were designed to contain nucleotide sequences encoding restriction sites that were used to facilitate cloning into the yeast expression vector.

#### H. cDNA Expression of Cytochrome P450 Enzymes in Yeast

Appropriate restriction sites were introduced by standard PCR methods (Innis et al., *PCR Protocols: A Guide to Methods and Applications*, Academic Press, San Diego, CA, 1990) immediately upstream of the ATG start codon and downstream of the stop codon of all full-length cytochrome P450 clones. These modified amplicons were gel-purified, digested with the corresponding restriction enzymes, and then ligated into the expression vector pYeDP60. The vector/insert junctions were sequenced to ensure that no errors had been introduced by the PCR construction. Verified clones were transformed into yeast using the lithium acetate method (Ito et al., *J. Bacteriol.* **153**:163-168, 1983). Isolated transformants were grown to stationary phase in SGI medium (Pompon et al., *Methods Enzymol.* **272**:51-64, 1996), and used as inocula for a large-scale expression culture grown in YPL medium (Pompon et al., *Methods Enzymol.* **272**:51-64, 1996). Approximately 24 hours after induction of cytochrome P450 expression with galactose (to 10% final concentration), a portion of the yeast cell culture was harvested by centrifugation. One-half of the culture was treated with carbon monoxide, and the cytochrome P450 CO-difference spectrum was recorded directly (using untreated cells as a control) by spectrophotometry (Omura and Sato, *J. Biol. Chem.* **239**:2370-2378, 1964).

This direct, *in situ* method for demonstrating the presence of functional, recombinant cytochrome P450, and for estimating the quantity of the competent enzyme, also can be applied to other expression systems, including *E. coli*, *Pichia pastoris*, insect cells (as described below), and *Spodoptera fugiperda* cells. Of the  
5 13 full-length clones obtained so far, eight exhibit a detectable CO-difference spectrum when the recombinant cytochrome P450 gene product is expressed in this yeast system and assayed by this *in situ* method.

#### I. cDNA Expression of Cytochrome P450 Enzymes in Insect Cells

10 As mentioned above, insect cell expression systems, such as the baculovirus-*Spodoptera* system described below, can be used to express the oxygenases described herein.

For example, the functional identification of the *Taxus cuspidata* cytochrome P450 clone F16 was accomplished using the baculovirus-*Spodoptera* expression  
15 system. (The use of this system for the heterologous expression of cytochrome P450 genes has been described previously (Asseffa et al., *Arch. Biochem. Biophys.* 274:481-490, 1989; Gonzalez et al., *Methods Enzymol.* 206:93-99, 1991; and Kraus et al., *Proc. Natl. Acad. Sci. USA* 92:2071-2075, 1995)). For the heterologous expression of clone F16 in *Spodoptera fugiperda* Sf9 cells with the *Autographa californica* baculovirus expression system, the F16 cytochrome P450 open reading  
20 frame (orf) was amplified by PCR using the F16-pYEDP60 construct as a template. For PCR, two gene-specific primers were designed that contained, for the purpose of subcloning the F16 orf into the FastBac-1 vector (Life Technologies), a *Bam*HI and a *Not*I restriction site (forward primer  
25 5'-gggatccATGGCCCTTAAGCAATTGGAAGTTTC-3' (SEQ ID NO:93); reverse primer 5'-ggcggccgcTTAAGATCTGGAATAGAGTTTAATGG-3' (SEQ ID NO:94)). The gel-purified PCR product so obtained was subcloned into the pCR-Blunt vector (Invitrogen, Carlsbad, CA). From the derived recombinant pCR-Blunt vector, the subcloned cytochrome P450 orf was excised using the added restriction  
30 sites, and the obtained DNA fragment was ligated into the *Bam*HI/*Not*I-digested pFastBac1 vector (Life Technologies, Grand Island, NY). The sequence and the correct insertion of clone F16 into the pFastBac1 vector were confirmed by

sequencing of the insert. The pFastBac/F16orf construct was then used for the preparation of the recombinant Bacmid DNA by transformation of the *Escherichia coli* strain DH10Bac (Life Technologies). Construction of the recombinant Bacmid DNA and the transfection of *Spodoptera frugiperda* Sf9 cells were done according to the manufacturer's protocol.

The *Spodoptera frugiperda* Sf9 cell cultures were propagated either as adherent monolayer cultures in Grace insect cell culture medium (Life Technologies) supplemented with 10% FCS (Life Technologies) or as suspension cultures in Grace medium containing 10% FCS and 0.1% Pluronic F-68 (Sigman, St. Louis, MO). The adherent cell cultures were maintained in a chamber at 28°C. The suspension cultures were incubated in a shaker at 28°C at 140 rpm. The adherent cell cultures were grown in T25 tissue culture flasks (Nalgene Nuc, Rochester, NY) with passage of one-third to one-half of the culture every 2 to 3 days. For heterologous protein production, the cultures were grown as suspensions. The cells from two tissue culture flasks (80-90% confluent) were added to 50 mL of standard suspension insect culture medium in a 100 mL conical flask, and were incubated as above until a cell density of  $\sim 2 \times 10^6$  cells/mL was reached. The cells were collected by centrifugation at room temperature at 140 g for 10 minutes. The resulting cell pellet was resuspended in 1/10 of the original volume with fresh medium.

For the functional characterization of clone F16, the recombinant baculovirus carrying the cytochrome P450 clone F16 ORF was coexpressed with a recombinant baculovirus carrying the *Taxus* NADPH:cytochrome P450 reductase gene. To the insect cell suspension, the two recombinant baculoviruses were added at a multiplicity of infection of 1-5. The viral titers were determined according to the End-Point Dilution method (O'Reilly et al., *Baculovirus Expression Vectors, A Laboratory Manual*, New York, NY, Freeman and Company, 1992). For infection, the cells were incubated for 1 hour at 28°C and 80 rpm. The cell culture volume was brought to 50 mL with standard cell culture medium, and hemin (Sigma) was added to a final concentration of 2 µg/mL. The infected cells were incubated for 48 hours in a gyratory shaker at 28°C and 140 rpm. The infected insect cells were harvested from the cell culture medium by centrifugation as described above, and

washed twice with PBS (50 mM  $\text{KH}_2\text{PO}_4$ , pH 7.5, 0.9% NaCl). The cell pellet so obtained was resuspended in 5 mL of HEPES/DTT Buffer (25 mM HEPES, pH 7.5, 1 mM DTT). The cells were lysed by mild sonication (VirSonic, Virtis Company, Gardiner, NY), the cell debris was removed by centrifugation at 5,000 g for 10 minutes at 4°C, and the resulting supernatant was collected for use in enzyme assays.

#### J. Assay of Recombinant Cytochrome P450 Activity Toward Taxoid Substrates

Isolated transformants for each full-length cytochrome P450 clone shown to express a functional enzyme by CO-difference spectrum (ten clones) were grown to stationary phase in 2 mL SGI medium at 30°C and used to inoculate a 10-mL expression culture (in YPL medium). Approximately 8 hours after induction, cells were harvested by centrifugation (10 minutes at 1500 rpm), and the pellet was resuspended in 2 mL of fresh YPL medium.

To eliminate additional complication and uncertainty associated with microsome isolations for *in vitro* assays,  $10^6$  dpm of  $[20\text{-}^3\text{H}_3]\text{taxa-4(5),11(12)-diene}$  (16 Ci/mol) or  $[20\text{-}^3\text{H}_2]\text{taxa-4(20),11(12)-dien-5-}\alpha\text{-ol}$  (4.0 Ci/mol), or other taxoid substrate were added directly to the cell suspension to assay conversion *in vivo*. After 12 hours of incubation at 30°C with agitation (250 rpm), the mixture was treated for 15 minutes in a sonication bath and extracted 3 times with 2 mL diethyl ether to insure isolation of the biosynthetic products. These ether extracts, containing residual substrate and derived product(s), were concentrated to dryness, resuspended in 200  $\mu\text{L}$  of  $\text{CH}_3\text{CN}$ , and filtered. These samples were analyzed by radio-HPLC (Hefner et al., *Chemistry and Biology* 3:479-489, 1996) using a 4.6 mm i.d. X 250 mm column of Econosil C18, 5  $\mu$  (Alltech, Deerfield, IL) with a gradient of  $\text{CH}_3\text{CN}$  in  $\text{H}_2\text{O}$  from 0% to 85% (10 minutes at 1 mL/minute), then to 100%  $\text{CH}_3\text{CN}$  over 40 minutes.

The foregoing method is capable of separating taxoids ranging in polarity from taxadiene to approximately that of taxadien-hexaol. For confirmation of product type, gas chromatography-mass spectrometry (GC-MS) or liquid



chromatography-mass spectrometry (LC-MS) is employed, depending on the volatility of the product.

In the present example, of the eight clones confirmed to be functional by CO difference spectra, four exhibited a hydroxylated product *in situ* when incubated  
5 with taxadien-5 $\alpha$ -ol.

#### K. Substrate Preparation

The syntheses of [20-<sup>3</sup>H<sub>3</sub>]taxa-4(5),11(12)-diene (16 Ci/mol) and [20-<sup>3</sup>H<sub>2</sub>]taxa-4(20),11(12)-dien-5 $\alpha$ -ol (4.0 Ci/mol) have been described elsewhere  
10 (Hefner et al., *Chemistry and Biology* 3:479-489, 1996; and Rubenstein et al., *J. Org. Chem.* 60:7215-7223, 1995, respectively). Other taxane substrates (diols, triols, and tetraols of taxadiene) needed to monitor more advanced cytochrome P450-mediated bioconversions are generated by incubating radiolabeled taxa-4(20),11(12)-dien-5 $\alpha$ -ol with isolated *T. canadensis* microsomes, or appropriate  
15 recombinant cytochrome P450 enzymes, and separating the products by preparative (radio)HPLC. Taxusin (5 $\alpha$ ,9 $\alpha$ ,10 $\beta$ ,13 $\alpha$ -tetraacetoxy-taxa-4(20),11(12)-diene) is isolated from *Taxus* heartwood and purified by standard chromatographic procedures (De Case De Marciano et al., *Chem. Commun.* 1282-1294, 1969). Following deacetylation and reacetylation with [<sup>14</sup>C] acetic anhydride, this labeled  
20 substrate is used to monitor enzymatic hydroxylation at C1, C2, and C7 and epoxidation at C4-C20. 2 $\alpha$ -Isobutyryloxy-5 $\alpha$ , 7 $\alpha$ , 10 $\beta$ -triaacetoxy-taxa-4(20),11(12)-diene, isolated from the same source (De Case De Marciano et al., *Chem. Commun.* 1282-1294, 1969), can be modified similarly to provide a substrate for monitoring hydroxylation at C9 and C13. If taxa-4(20),11(12)-dien-5 $\alpha$ -ol is  
25 hydroxylated at C10 as an early step, then the surrogate substrates for examining enzymatic oxygenation at all relevant positions of the taxane ring can be procured.

#### L. NMR Spectrometry

All NMR spectra were recorded on a Varian Inova-500 NMR spectrometer  
30 operating at 18°C using a very sensitive 5 mm pulsed-field-gradient <sup>1</sup>H indirect-detection probe. The taxadien-diol monoacetate was dissolved in C<sub>6</sub>D<sub>6</sub> to a final concentration of about 300  $\mu$ M. A 2D-TOCSY spectrum was acquired using a z-

filtered DIPSI mixing sequence, a 60 msec mixing time, 10 kHz spin-lock field, 16 repetitions, 256 ( $t_1$ ) x 2048 ( $t_2$ ) complex points, and 6500 Hz sweep in each dimension. The 2D-ROESY spectrum was acquired using a z-filtered mixing sequence with a 409 msec mixing time, 4 kHz spin-lock field, 128 repetitions, 256 ( $t_1$ ) x 2048 ( $t_2$ ) complex points, and 6500 Hz sweep in each dimension. A 2D-HSQC spectrum was acquired using 256 repetitions, 128 ( $t_1$ ) x 1024 ( $t_2$ ) complex points, and 6500 Hz in F2 and 15000 Hz in F1. The time between repetitions was 1.5 seconds for these experiments. Data were processed using the Varian, Inc. VNMR software, version 6.1C. The final data size, after linear-prediction in ( $t_1$ ) and zero-filling in both dimensions, was 1024(F1) x 2048(F2) complex points for all experiments.

## EXAMPLES

### 1. Oxygenase Protein and Nucleic acid Sequences

As described above, the invention provides oxygenases and oxygenase-specific nucleic acid sequences. With the provision herein of these oxygenase sequences, the polymerase chain reaction (PCR) may be utilized as a preferred method for identifying and producing nucleic acid sequences encoding the oxygenases. For example, PCR amplification of the oxygenase sequences may be accomplished either by direct PCR from a plant cDNA library or by Reverse-Transcription PCR (RT-PCR) using RNA extracted from plant cells as a template. Oxygenase sequences may be amplified from plant genomic libraries, or plant genomic DNA. Methods and conditions for both direct PCR and RT-PCR are known in the art and are described in Innis et al., *PCR Protocols: A Guide to Methods and Applications*, Academic Press: San Diego, 1990.

The selection of PCR primers is made according to the portions of the cDNA (or gene) that are to be amplified. Primers may be chosen to amplify small segments of the cDNA, the open reading frame, the entire cDNA molecule or the entire gene sequence. Variations in amplification conditions may be required to accommodate primers of differing lengths; such considerations are well known in the art and are discussed in Innis et al., *PCR Protocols: A Guide to Methods and Applications*, Academic Press: San Diego, 1990; Sambrook et al. (eds.), *Molecular Cloning: A*

*Laboratory Manual* 2nd ed., vols. 1-3, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989; and Ausubel et al. (eds.) *Current Protocols in Molecular Biology*, Greene Publishing and Wiley-Interscience, New York (with periodic updates), 1987. By way of example, the cDNA molecules corresponding to additional oxygenases may be amplified using primers directed toward regions of homology between the 5' and 3' ends of the full-length clone such as the one shown in SEQ ID NO: 43 sequences. Example primers for such a reaction are:

primer 1: 5'-CCI CCI GGI AAI ITI- 3' (SEQ ID NO. 81)

primer 2: 5'-ICC I(G/C)C ICC (G/A)AA IGG-3' (SEQ ID NO. 82)

These primers are illustrative only; it will be appreciated by one skilled in the art that many different primers may be derived from the provided nucleic acid sequences. Re-sequencing of PCR products obtained by these amplification procedures is recommended to facilitate confirmation of the amplified sequence and to provide information on natural variation between oxygenase sequences.

Oligonucleotides derived from the oxygenase sequence may be used in such sequencing methods.

Oligonucleotides that are derived from the oxygenase sequences are encompassed within the scope of the present invention. Preferably, such oligonucleotide primers comprise a sequence of at least 10-20 consecutive nucleotides of the oxygenase sequences. To enhance amplification specificity, oligonucleotide primers comprising at least 15, 20, 25, 30, 35, 40, 45 or 50 consecutive nucleotides of these sequences also may be used.

#### A. Oxygenases in Other Plant Species

Orthologs of the oxygenase genes are present in a number of other members of the *Taxus* genus. With the provision herein of the oxygenase nucleic acid sequences, the cloning by standard methods of cDNAs and genes that encode oxygenase orthologs in these other species is now enabled. As described above, orthologs of the disclosed oxygenase genes have oxygenase biological activity and are typically characterized by possession of at least 50% sequence identity counted over the full-length alignment with the amino acid sequence of the disclosed oxygenase sequences using the NCBI Blast 2.0 (gapped blastp set to default

parameters). Proteins with even greater sequence identity to the reference sequences will show increasing percentage identities when assessed by this method, such as at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 90%, or at least 95% sequence identity.

5 Both conventional hybridization and PCR amplification procedures may be utilized to clone sequences encoding oxygenase orthologs. Common to both of these techniques is the hybridization of probes or primers that are derived from the oxygenase nucleic acid sequences. Furthermore, the hybridization may occur in the context of Northern blots, Southern blots, or PCR.

10 Direct PCR amplification may be performed on cDNA or genomic libraries prepared from the plant species in question, or RT-PCR may be performed using mRNA extracted from the plant cells using standard methods. PCR primers will comprise at least 10 consecutive nucleotides of the oxygenase sequences. One of skill in the art will appreciate that sequence differences between the oxygenase  
15 nucleic acid sequence and the target nucleic acid to be amplified may result in lower amplification efficiencies. To compensate for this, longer PCR primers or lower annealing temperatures may be used during the amplification cycle. Whenever lower annealing temperatures are used, sequential rounds of amplification using nested primer pairs may be necessary to enhance specificity.

20 For conventional hybridization techniques the hybridization probe is preferably conjugated with a detectable label such as a radioactive label, and the probe is preferably at least 10 nucleotides in length. As is well known in the art, increasing the length of hybridization probes tends to give enhanced specificity. The labeled probe derived from the oxygenase nucleic acid sequence may be hybridized  
25 to a plant cDNA or genomic library and the hybridization signal detected using methods known in the art. The hybridizing colony or plaque (depending on the type of library used) is purified and the cloned sequence contained in that colony or plaque isolated and characterized.

Orthologs of the oxygenases alternatively may be obtained by  
30 immunoscreening of an expression library. With the provision herein of the disclosed oxygenase nucleic acid sequences, the enzymes may be expressed and purified in a heterologous expression system (e.g., *E. coli*) and used to raise

antibodies (monoclonal or polyclonal) specific for oxygenases. Antibodies also may be raised against synthetic peptides derived from the oxygenase amino acid sequence presented herein. Methods of raising antibodies are well known in the art and are described generally in Harlow and Lane, *Antibodies, A Laboratory Manual*, Cold Springs Harbor, 1988. Such antibodies can be used to screen an expression cDNA library produced from a plant. This screening will identify the oxygenase ortholog. The selected cDNAs can be confirmed by sequencing and enzyme activity assays.

#### 10            **B.     Taxol Oxygenase Variants**

With the provision of the oxygenase amino acid sequences (SEQ ID NOS: 56-68) and the corresponding cDNA (SEQ ID NOS: 43-55 and 81-86), variants of these sequences now can be created.

Variant oxygenases include proteins that differ in amino acid sequence from the oxygenase sequences disclosed, but that retain oxygenase biological activity. Such proteins may be produced by manipulating the nucleotide sequence encoding the oxygenase using standard procedures such as site-directed mutagenesis or the polymerase chain reaction. The simplest modifications involve the substitution of one or more amino acids for amino acids having similar biochemical properties.

20     These so-called "conservative substitutions" are likely to have minimal impact on the activity of the resultant protein. Table 4 shows amino acids that may be substituted for an original amino acid in a protein and that are regarded as conservative substitutions.

**Table 4**

<b>Original Residue</b>	<b>Conservative Substitutions</b>
ala	Ser
arg	Lys
asn	Gln; his
asp	Glu
cys	Ser
gln	Asn
glu	Asp
gly	Pro
his	Asn; gln
ile	Leu; val
leu	ile; val
lys	Arg; gln; glu
met	Leu; ile
phe	Met; leu; tyr
ser	Thr
thr	Ser
trp	Tyr
tyr	Trp; phe
val	ile; leu

More substantial changes in enzymatic function or other features may be obtained by selecting substitutions that are less conservative than those in Table 4, i.e., by selecting residues that differ more significantly in their effect on maintaining:

(a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation; (b) the charge or hydrophobicity of the molecule at the target site; or (c) the bulk of the side chain. The substitutions that in general are expected to produce the greatest changes in protein properties will be those in which: (a) a hydrophilic residue, e.g., seryl or threonyl, is substituted for (or by) a hydrophobic residue, e.g., leucyl, isoleucyl, phenylalanyl, valyl or alanyl; (b) a cysteine or proline is substituted for (or by) any other residue; (c) a residue having an electropositive side chain, e.g., lysyl, arginyl, or histadyl, is substituted for (or by) an electronegative residue, e.g., glutamyl or aspartyl; or (d) a residue having a bulky side chain, e.g., phenylalanine, is substituted for (or by) one not having a side chain; e.g., glycine. The effects of these amino acid substitutions or deletions or additions may be assessed for oxygenase derivatives by analyzing the ability of the derivative

proteins to catalyse the conversion of one Taxol precursor to another Taxol precursor.

Variant oxygenase cDNA or genes may be produced by standard DNA-mutagenesis techniques, for example, M13 primer mutagenesis. Details of these techniques are provided in Sambrook et al. (eds.), *Molecular Cloning: A Laboratory Manual* 2nd ed., vols. 1-3, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989, Ch. 15. By the use of such techniques, variants may be created that differ in minor ways from the oxygenase cDNA or gene sequences, yet that still encode a protein having oxygenase biological activity. DNA molecules and nucleotide sequences that are derivatives of those specifically disclosed herein and that differ from those disclosed by the deletion, addition, or substitution of nucleotides while still encoding a protein having oxygenase biological activity are comprehended by this invention. In their simplest form, such variants may differ from the disclosed sequences by alteration of the coding region to fit the codon usage bias of the particular organism into which the molecule is to be introduced.

Alternatively, the coding region may be altered by taking advantage of the degeneracy of the genetic code to alter the coding sequence in such a way that, while the nucleotide sequence is substantially altered, it nevertheless encodes a protein having an amino acid sequence identical or substantially similar to the disclosed oxygenase amino acid sequences. For example, the nineteenth amino acid residue of the oxygenase (Clone F12, SEQ ID NO:43) is alanine. This is encoded in the open reading frame (ORF) by the nucleotide codon triplet GCT. Because of the degeneracy of the genetic code, three other nucleotide codon triplets -- GCA, GCC, and GCG -- also code for alanine. Thus, the nucleotide sequence of the ORF can be changed at this position to any of these three codons without affecting the amino acid composition of the encoded protein or the characteristics of the protein. Based upon the degeneracy of the genetic code, variant DNA molecules may be derived from the cDNA and gene sequences disclosed herein using standard DNA mutagenesis techniques as described above, or by synthesis of DNA sequences. Thus, this invention also encompasses nucleic acid sequences that encode the oxygenase protein but that vary from the disclosed nucleic acid sequences by virtue of the degeneracy of the genetic code.

Variants of the oxygenase also may be defined in terms of their sequence identity with the oxygenase amino acid (SEQ ID NOS: 56-68 and 87-92) and nucleic acid sequences (SEQ ID NOS: 43-55 and 81-86). As described above, oxygenases have oxygenase biological activity and share at least 60% sequence identity with the disclosed oxygenase sequences. Nucleic acid sequences that encode such proteins may be readily determined simply by applying the genetic code to the amino acid sequence of the oxygenase, and such nucleic acid molecules may readily be produced by assembling oligonucleotides corresponding to portions of the sequence.

As previously mentioned, another method of identifying variants of the oxygenases is nucleic acid hybridization. Nucleic acid molecules derived from the oxygenase cDNA and gene sequences include molecules that hybridize under various conditions to the disclosed Taxol oxygenase nucleic acid molecules, or fragments thereof.

Nucleic acid duplex or hybrid stability is expressed as the melting temperature at which a probe dissociates from a target DNA. This melting temperature is used to define the required stringency conditions. If sequences are to be identified that are related and substantially identical to the probe, rather than identical, then it is useful to first establish the lowest temperature at which only homologous hybridization occurs with a particular concentration of salt (e.g., SSC or SSPE). Then, assuming that 1% mismatching results in a 1°C decrease in the  $T_m$ , the temperature of the final wash in the hybridization reaction is reduced accordingly (for example, if sequences having > 95% identity with the probe are sought, the final wash temperature is decreased by 5°C). In practice, the change in  $T_m$  can be between 0.5°C and 1.5°C per 1% mismatch.

Generally, hybridization conditions are classified into categories, for example very high stringency, high stringency, and low stringency. The conditions for probes that are about 600 base pairs or more in length are provided below in three corresponding categories.



Very High Stringency (sequences greater than 90% sequence identity)

Hybridization in	5x	SSC	at	65°C	16 hours
Wash twice in	2x	SSC	at	room temp.	15 minutes each
Wash twice in	2x	SSC	at	55°C	20 minutes each

5

High Stringency (detects sequences that share approximately 80% sequence identity)

Hybridization in	5x	SSC	at	42°C	16 hours
Wash twice in	2x	SSC	at	room temp.	20 minutes each
Wash once in	2x	SSC	at	42°C	30 minutes each

10

Low Stringency (detects sequences that share 70% sequence identity or greater)

Hybridization in	6x	SSC	at	room temp.	16 hours
Wash twice in	2x	SSC	at	room temp.	20 minutes each

15

The sequences encoding the oxygenases identified through hybridization may be incorporated into transformation vectors and introduced into host cells to produce the respective oxygenase.

## 20           **2.     Introduction of Oxygenases into Plants**

After a cDNA (or gene) encoding a protein involved in the determination of a particular plant characteristic has been isolated, standard techniques may be used to express the cDNA in transgenic plants in order to modify the particular plant characteristic. The basic approach is to clone the cDNA into a transformation  
 25   vector, such that the cDNA is operably linked to control sequences (e.g., a promoter) directing expression of the cDNA in plant cells. The transformation vector is introduced into plant cells by any of various techniques (e.g., electroporation), and progeny plants containing the introduced cDNA are selected. Preferably all or part of the transformation vector stably integrates into the genome of the plant cell. That  
 30   part of the transformation vector that integrates into the plant cell and that contains the introduced cDNA and associated sequences for controlling expression (the introduced "transgene") may be referred to as the recombinant expression cassette.

Selection of progeny plants containing the introduced transgene may be made based upon the detection of an altered phenotype. Such a phenotype may result directly from the cDNA cloned into the transformation vector or may be manifest as enhanced resistance to a chemical agent (such as an antibiotic) as a result of the inclusion of a dominant selectable marker gene incorporated into the transformation vector.

Successful examples of the modification of plant characteristics by transformation with cloned cDNA sequences are replete in the technical and scientific literature. Selected examples, which serve to illustrate the knowledge in this field of technology include:

U.S. Patent No. 5,571,706 ("Plant Virus Resistance Gene and Methods")

U.S. Patent No. 5,677,175 ("Plant Pathogen Induced Proteins")

U.S. Patent No. 5,510,471 ("Chimeric Gene for the Transformation of Plants")

U.S. Patent No. 5,750,386 ("Pathogen-Resistant Transgenic Plants")

U.S. Patent No. 5,597,945 ("Plants Genetically Enhanced for Disease Resistance")

U.S. Patent No. 5,589,615 ("Process for the Production of Transgenic Plants with Increased Nutritional Value Via the Expression of Modified 2S Storage Albumins")

U.S. Patent No. 5,750,871 ("Transformation and Foreign Gene Expression in Brassica Species")

U.S. Patent No. 5,268,526 ("Overexpression of Phytochrome in Transgenic Plants")

U.S. Patent No. 5,262,316 ("Genetically Transformed Pepper Plants and Methods for their Production")

U.S. Patent No. 5,569,831 ("Transgenic Tomato Plants with Altered Polygalacturonase Isoforms")

These examples include descriptions of transformation vector selection, transformation techniques, and the construction of constructs designed to over-

express the introduced cDNA. In light of the foregoing and the provision herein of the oxygenase amino acid sequences and nucleic acid sequences, it is thus apparent that one of skill in the art will be able to introduce the cDNAs, or homologous or derivative forms of these molecules, into plants in order to produce plants having enhanced oxygenase activity. Furthermore, the expression of one or more oxygenases in plants may give rise to plants having increased production of Taxol and related compounds.

#### A. Vector Construction, Choice of Promoters

A number of recombinant vectors suitable for stable transfection of plant cells or for the establishment of transgenic plants have been described, including those described in Weissbach and Weissbach, *Methods for Plant Molecular Biology*, Academic Press, 1989; and Gelvin et al., *Plant and Molecular Biology Manual*, Kluwer Academic Publishers, 1990. Typically, plant-transformation vectors include one or more cloned plant genes (or cDNAs) under the transcriptional control of 5'- and 3'-regulatory sequences and a dominant selectable marker. Such plant transformation vectors typically also contain a promoter regulatory region (e.g., a regulatory region controlling inducible or constitutive, environmentally or developmentally regulated, or cell- or tissue-specific expression), a transcription-initiation start site, a ribosome-binding site, an RNA processing signal, a transcription-termination site, and/or a polyadenylation signal.

Examples of constitutive plant promoters that may be useful for expressing the cDNA include: the cauliflower mosaic virus (CaMV) 35S promoter, which confers constitutive, high-level expression in most plant tissues (see, e.g., Odel et al., *Nature* 313:810, 1985; Dekeyser et al., *Plant Cell* 2:591, 1990; Terada and Shimamoto, *Mol. Gen. Genet.* 220:389, 1990; and Benfey and Chua, *Science* 250:959-966, 1990); the nopaline synthase promoter (An et al., *Plant Physiol.* 88:547, 1988); and the octopine synthase promoter (Fromm et al., *Plant Cell* 1:977, 1989). *Agrobacterium*-mediated transformation of *Taxus* species has been accomplished, and the resulting callus cultures have been shown to produce Taxol (Han et al., *Plant Science* 95: 187-196, 1994). Therefore, it is likely that incorporation of one or more of the described oxygenases under the influence of a

strong promoter (like CaMV promoter) would increase production yields of Taxol and related taxoids in such transformed cells.

A variety of plant gene promoters that are regulated in response to environmental, hormonal, chemical, and/or developmental signals also can be used for expression of the cDNA in plant cells, including promoters regulated by: (a) heat (Callis et al., *Plant Physiol.* **88**:965, 1988; Ainley, et al., *Plant Mol. Biol.* **22**:13-23, 1993; and Gilmartin et al., *The Plant Cell* **4**:839-949, 1992); (b) light (e.g., the pea *rbcS-3A* promoter, Kuhlemeier et al., *Plant Cell* **1**:471, 1989, and the maize *rbcS* promoter, Schaffner and Sheen, *Plant Cell* **3**:997, 1991); (c) hormones, such as abscisic acid (Marcotte et al., *Plant Cell* **1**:969, 1989); (d) wounding (e.g., wunI, Siebertz et al., *Plant Cell* **1**:961, 1989); and (e) chemicals such as methyl jasmonate or salicylic acid (see also Gatz et al., *Ann. Rev. Plant Physiol. Plant Mol. Biol.* **48**:9-108, 1997).

Alternatively, tissue-specific (root, leaf, flower, and seed, for example) promoters (Carpenter et al., *The Plant Cell* **4**:557-571, 1992; Denis et al., *Plant Physiol.* **101**:1295-1304, 1993; Opperman et al., *Science* **263**:221-223, 1993; Stockhause et al., *The Plant Cell* **9**:479-489, 1997; Roshal et al., *Embo. J.* **6**:1155, 1987; Schernthaner et al., *Embo J.* **7**:1249, 1988; and Bustos et al., *Plant Cell* **1**:839, 1989) can be fused to the coding sequence to obtain a particular expression in respective organs.

Alternatively, the native oxygenase gene promoters may be utilized. With the provision herein of the oxygenase nucleic acid sequences, one of skill in the art will appreciate that standard molecular biology techniques can be used to determine the corresponding promoter sequences. One of skill in the art also will appreciate that less than the entire promoter sequence may be used in order to obtain effective promoter activity. The determination of whether a particular region of this sequence confers effective promoter activity may be ascertained readily by operably linking the selected sequence region to an oxygenase cDNA (in conjunction with suitable 3' regulatory region, such as the NOS 3' regulatory region as discussed below) and determining whether the oxygenase is expressed.

Plant-transformation vectors also may include RNA processing signals, for example, introns, that may be positioned upstream or downstream of the ORF

sequence in the transgene. In addition, the expression vectors also may include additional regulatory sequences from the 3'-untranslated region of plant genes, e.g., a 3'-terminator region, to increase mRNA stability of the mRNA, such as the PI-II terminator region of potato or the octopine or nopaline synthase (NOS) 3'-terminator regions. The native oxygenase gene 3'-regulatory sequence also may be employed.

Finally, as noted above, plant-transformation vectors also may include dominant selectable marker genes to allow for the ready selection of transformants. Such genes include those encoding antibiotic-resistance genes (e.g., resistance to hygromycin, kanamycin, bleomycin, G418, streptomycin, or spectinomycin) and herbicide-resistance genes (e.g., phosphinothricin acetyltransferase).

#### **B. Arrangement of Taxol oxygenase Sequence in a Vector**

The particular arrangement of the oxygenase sequence in the transformation vector is selected according to the type of expression of the sequence that is desired.

In most instances, enhanced oxygenase activity is desired, and the oxygenase ORF is operably linked to a constitutive high-level promoter such as the CaMV 35S promoter. As noted above, enhanced oxygenase activity also may be achieved by introducing into a plant a transformation vector containing a variant form of the oxygenase cDNA or gene, for example a form that varies from the exact nucleotide sequence of the oxygenase ORF, but that encodes a protein retaining an oxygenase biological activity.

#### **C. Transformation and Regeneration Techniques**

Transformation and regeneration of both monocotyledonous and dicotyledonous plant cells are now routine, and the appropriate transformation technique can be determined by the practitioner. The choice of method varies with the type of plant to be transformed; those skilled in the art will recognize the suitability of particular methods for given plant types. Suitable methods may include, but are not limited to: electroporation of plant protoplasts; liposome-mediated transformation; polyethylene glycol (PEG)-mediated transformation; transformation using viruses; micro-injection of plant cells; micro-projectile

bombardment of plant cells; vacuum infiltration; and *Agrobacterium tumefaciens* (AT)-mediated transformation. Typical procedures for transforming and regenerating plants are described in the patent documents listed at the beginning of this section.

5

#### **D. Selection of Transformed Plants**

Following transformation and regeneration of plants with the transformation vector, transformed plants can be selected using a dominant selectable marker incorporated into the transformation vector. Typically, such a marker confers  
10 antibiotic resistance on the seedlings of transformed plants, and selection of transformants can be accomplished by exposing the seedlings to appropriate concentrations of the antibiotic.

After transformed plants are selected and grown to maturity, they can be assayed using the methods described herein to assess production levels of Taxol and  
15 related compounds.

#### **3. Production of Recombinant Taxol oxygenase in Heterologous Expression Systems**

Various yeast strains and yeast-derived vectors are used commonly for the  
20 expression of heterologous proteins. For instance, *Pichia pastoris* expression systems, obtained from Invitrogen (Carlsbad, California), may be used to practice the present invention. Such systems include suitable *Pichia pastoris* strains, vectors, reagents, transformants, sequencing primers, and media. Available strains include KM71H (a prototrophic strain), SMD1168H (a prototrophic strain), and SMD1168  
25 (a pep4 mutant strain) (Invitrogen Product Catalogue, 1998, Invitrogen, Carlsbad CA).

Non-yeast eukaryotic vectors may be used with equal facility for expression of proteins encoded by modified nucleotides according to the invention. Mammalian vector/host cell systems containing genetic and cellular control  
30 elements capable of carrying out transcription, translation, and post-translational modification are well known in the art. Examples of such systems are the well-known baculovirus system, the ecdysone-inducible expression system that uses

regulatory elements from *Drosophila melanogaster* to allow control of gene expression, and the sindbis viral-expression system that allows high-level expression in a variety of mammalian cell lines, all of which are available from Invitrogen, Carlsbad, California.

5       The cloned expression vector encoding one or more oxygenases may be transformed into any of various cell types for expression of the cloned nucleotide. Many different types of cells may be used to express modified nucleic acid molecules. Examples include cells of yeasts, fungi, insects, mammals, and plants, including transformed and non-transformed cells. For instance, common  
10       mammalian cells that could be used include HeLa cells, SW-527 cells (ATCC deposit #7940), WISH cells (ATCC deposit #CCL-25), Daudi cells (ATCC deposit #CCL-213), Mandin-Darby bovine kidney cells (ATCC deposit #CCL-22) and Chinese hamster ovary (CHO) cells (ATCC deposit #CRL-2092). Common yeast cells include *Pichia pastoris* (ATCC deposit #201178) and *Saccharomyces*  
15       *cerevisiae* (ATCC deposit #46024). Insect cells include cells from *Drosophila melanogaster* (ATCC deposit #CRL-10191), the cotton bollworm (ATCC deposit #CRL-9281), and *Trichoplusia ni* egg cell homoflagellates. Fish cells that may be used include those from rainbow trout (ATCC deposit #CLL-55), salmon (ATCC deposit #CRL-1681), and zebrafish (ATCC deposit #CRL-2147). Amphibian cells  
20       that may be used include those of the bullfrog, *Rana catesbelana* (ATCC deposit #CLL-41). Reptile cells that may be used include those from Russell's viper (ATCC deposit #CCL-140). Plant cells that could be used include *Chlamydomonas* cells (ATCC deposit #30485), *Arabidopsis* cells (ATCC deposit #54069) and tomato plant cells (ATCC deposit #54003). Many of these cell types are commonly used  
25       and are available from the ATCC as well as from commercial suppliers such as Pharmacia (Uppsala, Sweden), and Invitrogen.

Expressed protein may be accumulated within a cell or may be secreted from the cell. Such expressed protein may then be collected and purified. This protein may be characterized for activity and stability and may be used to practice any of the  
30       various methods according to the invention.

#### 4. Creation of Oxygenase Specific Binding Agents

Antibodies to the oxygenase enzymes, and fragments thereof, of the present invention may be useful for purification of the enzymes. The provision of the oxygenase sequences allows for the production of specific antibody-based binding agents to these enzymes.

Monoclonal or polyclonal antibodies may be produced to an oxygenase, portions of the oxygenase, or variants thereof. Optimally, antibodies raised against epitopes on these antigens will detect the enzyme specifically. That is, antibodies raised against an oxygenase would recognize and bind the oxygenase, and would not substantially recognize or bind to other proteins. The determination that an antibody specifically binds to an antigen is made by any one of a number of standard immunoassay methods; for instance, Western blotting, Sambrook et al. (eds.), *Molecular Cloning: A Laboratory Manual*, 2nd ed., vols. 1-3, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.

To determine that a given antibody preparation (such as a preparation produced in a mouse against SEQ ID NO: 56) specifically detects the oxygenase by Western blotting, total cellular protein is extracted from cells and electrophoresed on an SDS-polyacrylamide gel. The proteins are transferred to a membrane (for example, nitrocellulose) by Western blotting, and the antibody preparation is incubated with the membrane. After washing the membrane to remove non-specifically bound antibodies, the presence of specifically bound antibodies is detected by the use of an anti-mouse antibody conjugated to an enzyme such as alkaline phosphatase; application of 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium results in the production of a densely blue-colored compound by immuno-localized alkaline phosphatase.

Antibodies that specifically detect an oxygenase will be shown, by this technique, to bind substantially only the oxygenase band (having a position on the gel determined by the molecular weight of the oxygenase). Non-specific binding of the antibody to other proteins may occur and may be detectable as a weaker signal on the Western blot (which can be quantified by automated radiography). The non-specific nature of this binding will be recognized by one skilled in the art by the



weak signal obtained on the Western blot relative to the strong primary signal arising from the specific anti-oxygenase binding.

Antibodies that specifically bind to an oxygenase according to the invention belong to a class of molecules that are referred to herein as "specific binding agents." Specific binding agents capable of specifically binding to the oxygenase of the present invention may include polyclonal antibodies, monoclonal antibodies and fragments of monoclonal antibodies such as Fab, F(ab')<sub>2</sub> and Fv fragments, as well as any other agent capable of specifically binding to one or more epitopes on the proteins.

Substantially pure oxygenase suitable for use as an immunogen can be isolated from transfected cells, transformed cells, or from wild-type cells. Concentration of protein in the final preparation is adjusted, for example, by concentration on an Amicon filter device, to the level of a few micrograms per milliliter. Alternatively, peptide fragments of an oxygenase may be utilized as immunogens. Such fragments may be synthesized chemically using standard methods, or may be obtained by cleavage of the whole oxygenase enzyme followed by purification of the desired peptide fragments. Peptides as short as three or four amino acids in length are immunogenic when presented to an immune system in the context of a Major Histocompatibility Complex (MHC) molecule, such as MHC class I or MHC class II. Accordingly, peptides comprising at least 3 and preferably at least 4, 5, 6 or more consecutive amino acids of the disclosed oxygenase amino acid sequences may be employed as immunogens for producing antibodies.

Because naturally occurring epitopes on proteins frequently comprise amino acid residues that are not adjacently arranged in the peptide when the peptide sequence is viewed as a linear molecule, it may be advantageous to utilize longer peptide fragments from the oxygenase amino acid sequences for producing antibodies. Thus, for example, peptides that comprise at least 10, 15, 20, 25, or 30 consecutive amino acid residues of the amino acid sequence may be employed. Monoclonal or polyclonal antibodies to the intact oxygenase, or peptide fragments thereof may be prepared as described below.

#### A. Monoclonal Antibody Production by Hybridoma Fusion

Monoclonal antibody to any of various epitopes of the oxygenase enzymes that are identified and isolated as described herein can be prepared from murine hybridomas according to the classic method of Kohler & Milstein, *Nature* 256:495, 1975, or a derivative method thereof. Briefly, a mouse is repetitively inoculated with a few micrograms of the selected protein over a period of a few weeks. The mouse is sacrificed, and the antibody-producing cells of the spleen isolated. The spleen cells are fused by means of polyethylene glycol with mouse myeloma cells, and the excess unfused cells destroyed by growth of the system on selective media comprising aminopterin (HAT media). The successfully fused cells are diluted and aliquots of the dilution placed in wells of a microtiter plate where growth of the culture is continued. Antibody-producing clones are identified by detection of antibody in the supernatant fluid of the wells by immunoassay procedures, such as ELISA (enzyme-linked immunosorbent assay), as originally described by Engvall, *Enzymol.* 70:419, 1980, or a derivative method thereof. Selected positive clones can be expanded and their monoclonal antibody product harvested for use. Detailed procedures for monoclonal antibody production are described in Harlow & Lane, *Antibodies, A Laboratory Manual*, Cold Spring Harbor Laboratory, New York, 1988.

#### B. Polyclonal Antibody Production by Immunization

Polyclonal antiserum containing antibodies to heterogenous epitopes of a single protein can be prepared by immunizing suitable animals with the expressed protein, which can be unmodified or modified, to enhance immunogenicity. Effective polyclonal antibody production is affected by many factors related both to the antigen and the host species. For example, small molecules tend to be less immunogenic than other molecules and may require the use of carriers and an adjuvant. Also, host animals vary in response to site of inoculations and dose, with both inadequate or excessive doses of antigen resulting in low-titer antisera. Small doses (ng level) of antigen administered at multiple intradermal sites appear to be most reliable. An effective immunization protocol for rabbits can be found in Vaitukaitis et al., *J. Clin. Endocrinol. Metab.* 33:988-991, 1971.

Booster injections can be given at regular intervals, and antiserum harvested when the antibody titer thereof, as determined semi-quantitatively, for example, by double immunodiffusion in agar against known concentrations of the antigen, begins to fall. See, for example, Ouchterlony et al., in Wier (ed.), *Handbook of Experimental Immunology*, Chapter 19, Blackwell, 1973. A plateau concentration of antibody is usually in the range of 0.1 to 0.2 mg/mL of serum (about 12  $\mu$ M). Affinity of the antisera for the antigen is determined by preparing competitive binding curves using conventional methods.

#### **C. Antibodies Raised by Injection of cDNA**

Antibodies may be raised against an oxygenase of the present invention by subcutaneous injection of a DNA vector that expresses the enzymes in laboratory animals, such as mice. Delivery of the recombinant vector into the animals may be achieved using a hand-held form of the "Biolistic" system (Sanford et al., *Particulate Sci. Technol.* 5:27-37, 1987, as described by Tang et al., *Nature* (London) 356:153-154, 1992). Expression vectors suitable for this purpose may include those that express the cDNA of the enzyme under the transcriptional control of either the human  $\beta$ -actin promoter or the cytomegalovirus (CMV) promoter. Methods of administering naked DNA to animals in a manner resulting in expression of the DNA in the body of the animal are well known and are described, for example, in U.S. Patent Nos. 5,620,896 ("DNA Vaccines Against Rotavirus Infections"); 5,643,578 ("Immunization by Inoculation of DNA Transcription Unit"); and 5,593,972 ("Genetic Immunization"), and references cited therein.

#### **D. Antibody Fragments**

Antibody fragments may be used in place of whole antibodies and may be readily expressed in prokaryotic host cells. Methods of making and using immunologically effective portions of monoclonal antibodies, also referred to as "antibody fragments," are well known and include those described in Better & Horowitz, *Methods Enzymol.* 178:476-496, 1989; Glockshuber et al. *Biochemistry* 29:1362-1367, 1990; and U.S. Patent Nos. 5,648,237 ("Expression of Functional Antibody Fragments"); 4,946,778 ("Single Polypeptide Chain Binding Molecules");

and 5,455,030 ("Immunotherapy Using Single Chain Polypeptide Binding Molecules"), and references cited therein.

#### 5. Taxol Production *in vivo*

5       The creation of recombinant vectors and transgenic organisms expressing the vectors are important for controlling the production of oxygenases. These vectors can be used to decrease oxygenase production, or to increase oxygenase production. A decrease in oxygenase production likely will result from the inclusion of an antisense sequence or a catalytic nucleic acid sequence that targets the oxygenase  
10       encoding nucleic acid sequence. Conversely, increased production of oxygenase can be achieved by including at least one additional oxygenase encoding sequence in the vector. These vectors can be introduced into a host cell, thereby altering oxygenase production. In the case of increased production, the resulting oxygenase may be used in *in vitro* systems, as well as *in vivo* for increased production of Taxol, other  
15       taxoids, intermediates of the Taxol biosynthetic pathway, and other products.

      Increased production of Taxol and related taxoids *in vivo* can be accomplished by transforming a host cell, such as one derived from the *Taxus* genus, with a vector containing one or more nucleic acid sequences encoding one or more oxygenases. Furthermore, the heterologous or homologous oxygenase sequences  
20       can be placed under the control of a constitutive promoter, or an inducible promoter. This will lead to the increased production of oxygenase, thus eliminating any rate-limiting effect on Taxol production caused by the expression and/or activity level of the oxygenase.

#### 25       6. Taxol Production *in vitro*

      Currently, Taxol is produced by a semisynthetic method described in Hezari and Croteau, *Planta Medica* 63:291-295, 1997. This method involves extracting 10-deacetyl-baccatin III, or baccatin III, intermediates in the Taxol biosynthetic pathway, and then finishing the production of Taxol using *in vitro* techniques. As  
30       more enzymes are identified in the Taxol biosynthetic pathway, it may become possible to completely synthesize Taxol *in vitro*, or at least increase the number of steps that can be performed *in vitro*. Hence, the oxygenases of the present invention

may be used to facilitate the production of Taxol and related taxoids in synthetic or semi-synthetic methods. Accordingly, the present invention enables the production of transgenic organisms that not only produce increased levels of Taxol, but also transgenic organisms that produce increased levels of important intermediates, such as 10-deacetyl-baccatin III and baccatin III.

#### 7. Alternative Substrates for Use in Assessing Taxoid Oxygenases Activity

The order of oxygenation reactions on the taxane (taxadiene) nucleus en route to Taxol is not precisely known. However, based on comparison of the structures of the several hundred naturally-occurring taxanes (Kingston et al., *The Taxane Diterpenoids*, in Herz et al. (eds.), *Progress in the Chemistry of Organic Natural Products*, Springer-Verlag, New York, Vol. 61, p. 206, 1993; and Baloglu et al., *J. Nat. Prod.* **62**:1448-1472, 1999), it can be deduced from relative abundances of taxoids with oxygen substitution at each position (Floss et al., *Biosynthesis of Taxol*, in Suffness (ed.), *Taxol: Science and Applications*, CRC Press, Boca Raton, FL, pp. 191-208, 1995) that oxygens at C5 (carbon numbers shown in Fig.) and C10 are introduced first, followed by oxygenation at C2 and C9 (could be either order), than at C13. Oxygenations at C7 and C1 of the taxane nucleus are considered to be very late introductions, possibly occurring after oxetane ring formation; however, epoxidation (at C4/C20) and oxetane formation seemingly must precede oxidation of the C9 hydroxyl to a carbonyl (Floss et al., *Biosynthesis of Taxol*, in Suffness (ed.), *Taxol: Science and Applications*, CRC Press, Boca Raton, FL, pp. 191-208, 1995). Evidence from cell-free enzyme studies with *Taxus* microsomes (Hezari et al., *Planta Medica* **63**:291-295, 1997) and *in vivo* feeding studies with *Taxus* cells (Eisenreich et al., *J. Am. Chem. Soc.* **120**:9694-9695, 1998) have indicated that the oxygenation reactions of the taxane core are accomplished by cytochrome P450 oxygenases. Thus, for example, the cytochrome P450-mediated hydroxylation (with double-bond migration) of taxadiene to taxadien-5 $\alpha$ -ol has been demonstrated with *Taxus* microsomes (Hefner et al., *Chem. Biol.* **3**:479-489, 1996). Most recently, the taxadien-5 $\alpha$ -ol (and acetate ester) have been shown to undergo

microsomal P450-catalyzed oxygenation to the level of a pentaol (i.e., taxadien-2 $\alpha$ ,5 $\alpha$ ,9 $\alpha$ ,10 $\beta$ ,13 $\alpha$  -pentaol) (Hezari et al., *Planta Medica* 63:291-295, 1997).

Because downstream steps are not yet defined, the above-referenced research summarized in Table 2 involved the pursuit of reactions (the timing and regiochemistry (position) of subsequent taxoid hydroxylations) through the use of surrogate substrates. Thus, labeled (+)-taxusin (the tetraacetate of taxadien-5,9,10,13-tetraol) was utilized to evaluate hydroxylations at C1, C2 and C7, and the epoxidation at C4/C20 en route to formation of the oxetane D-ring of Taxol.

Microsome preparations from *Taxus cuspidata* cells, optimized for cytochrome P450-mediated reactions, convert taxusin to the level of an epoxy triol (i.e., hydroxylation at C1, C2 and C7 and epoxidation of the C4/C20 double bond of the tetraacetate of taxadien-5,9,10,13-tetraol). Therefore, microsomal P450 reactions have been tentatively demonstrated for all of the relevant positions on the taxane core structure on route to Taxol (C1, C2, C5, C7, C9, C10 and C13, and the C4/C20 epoxidation), although the exact order for the various positions has not been established firmly.

The screening of the functionally expressed (by CO-difference spectra) clones in yeast (using taxadienol and taxadienyl acetate as test substrates) demonstrated that clone F14 encodes the cytochrome P450 taxane-10 $\beta$ -hydroxylase. Similar screening of functionally expressed clones using baculovirus-*Spodoptera* (especially for clones that do not express well in yeast) also revealed clone F16 as encoding the cytochrome P450 taxane-9 $\alpha$ -hydroxylase.

The remaining regiospecific (positionally specific) oxygenases that functionalize the taxane core en route to Taxol can be obtained by identifying additional full-length clones by library screening with the appropriate hybridization probes or by RACE methods as necessary. Each clone can be functionally expressed (i.e., exhibiting a CO-difference spectrum which indicates proper folding and heme incorporation) in yeast or *Spodoptera*, as necessary. Each expressed cytochrome P450 clone can be tested for catalytic capability by *in vivo* (*in situ*) and *in vitro* (isolated microsomes) assay with the various taxoid substrates as described below, using GC-MS and NMR methods to identify products and thereby establish

the regiochemistry of hydroxylation of the taxane core. Suitable substrates for use in additional assays are provided in Table 5, below.

Table 5

Substrate	Use
Taxa-4(20),11(12)-dien (taxadiene)	A radiolabeled synthetic substrate employed to search for 5 $\alpha$ -hydroxylase.
Taxa-4(20),11(12)-dien-5 $\alpha$ -ol and the corresponding 5 $\alpha$ -acetate (taxadienol and taxadienyl acetate)	Radiolabeled synthetic substrates employed to search for early hydroxylation steps and to assist in sequencing the various regiospecific hydroxylations of the Taxol pathway. These substrates were employed to confirm the taxane 10 $\beta$ -hydroxylase (clone F14) and the taxane 9 $\alpha$ -hydroxylase (clone F16), and to indicate the early hydroxylation order as C5, C10 then C9. Preliminary evidence using these substrates suggests that clones F7, F9, F12 and F51 encode the C1, C2, C7 and C13 hydroxylases, but the corresponding products (four different diols (and diol monoacetates)) have not been identified and the sequence of oxygenation following 9 $\alpha$ -hydroxylation is not yet known.
Taxa-4(20),11(12)-dien-2 $\alpha$ ,5 $\alpha$ -diol (and diacetate ester)	Synthetic substrates used to search for the C1, C7 and C13 hydroxylases and to assist in ordering the C2, C9 and C10 hydroxylation reactions of the pathway.
Taxa-4(20),11(12)-dien-5 $\alpha$ ,9 $\alpha$ ,10 $\beta$ ,13 $\alpha$ -tetraol and corresponding tetraacetate (taxusin tetraol and taxusin, respectively)	Radiolabeled, semisynthetic substrates used to search for the C4/C20 epoxidase and late-stage oxygenations, including C1 and C7 hydroxylases and the C2 hydroxylase. Also used to assist in ordering the late-stage oxygenation steps of the pathway. Although taxusin (and tetraol) do not reside on the Taxol pathway (Floss et al., <i>Biosynthesis of Taxol</i> , in Suffness (ed.), <i>Taxol: Science and Applications</i> , CRC Press, Boca Raton, FL, pp. 191-208, 1995), this surrogate substrate is metabolized to the level of a presumptive taxadien-4,20-epoxy-1,2,5,7,9,10,13-heptaol (and tetraacetate) by microsomal preparations, but structures of the reaction products have not yet been confirmed by NMR.



*Taxa-4(20),11(12)-dien-5 $\alpha$ ,9 $\alpha$ -diol (and monoacetate and diacetate)	Labeled biosynthetic substrates prepared from taxadienol (and acetate) using the above-described clones (clone 16). Used in searching for and ordering downstream oxygenation reactions.
*Taxa-4(20),11(12)-dien-5 $\alpha$ ,10 $\beta$ -diol (and monoacetate and diacetate)	Labeled biosynthetic substrates prepared from taxadienol (and acetate) using the above-described clones (clone 14). Used in searching for and ordering downstream oxygenation reactions.
Taxa-4(20),11(12)-dien-5 $\alpha$ ,9 $\alpha$ ,10 $\beta$ -triol (an acetate esters)	Semisynthetic substrate prepared from taxusin, and used as in * above.

Using these natural and surrogate substrates, along with the established expression methods and bioanalytical protocols, it is anticipated that all of the regiospecific cytochrome P450 taxoid oxygenases of the Taxol pathway will be acquired from the extant set of related cytochrome P450s.

Having illustrated and described the principles of the invention in multiple embodiments and examples, it should be apparent to those skilled in the art that the invention can be modified in arrangement and detail without departing from such principles. We claim all modifications coming within the spirit and scope of the following claims.

We Claim:

1. A purified protein, comprising an amino acid sequence selected from  
5 the group consisting of: SEQ ID NOS: 22-42, 56-86, and 87-92.
2. A specific binding agent that binds a protein according to claim 1.
3. An isolated nucleic acid molecule encoding a protein according to  
10 claim 1.
4. An isolated nucleic acid molecule according to claim 3, further  
comprising a sequence selected from the group consisting of: SEQ ID NOS: 1-21,  
81-86, and 43-55.  
15
5. A recombinant nucleic acid molecule, comprising a promoter  
sequence operably linked to a nucleic acid sequence according to claim 3.
6. A cell transformed with a recombinant nucleic acid molecule according  
20 to claim 5.
7. A transgenic organism, comprising a recombinant nucleic acid  
molecule according to claim 5, wherein the transgenic organism is selected from the  
group consisting of plants, bacteria, insects, fungi, and mammals.  
25
8. An isolated nucleic acid molecule that:  
(a) hybridizes under low-stringency conditions with a nucleic acid  
probe, the probe comprising a sequence selected from the group consisting of SEQ  
ID NOS: 1-21, 43-55, and 81-86 and fragments thereof; and  
30 (b) encodes a protein having oxygenase activity.

9. An oxygenase encoded by a nucleic acid molecule according to claim 8.
10. A recombinant nucleic acid molecule, comprising a promoter sequence operably linked to a nucleic acid sequence according to claim 8.
11. A cell transformed with a recombinant nucleic acid molecule according to claim 10.
12. A transgenic organism, comprising a recombinant nucleic acid molecule according to claim 10, wherein the transgenic organism is selected from the group consisting of plants, bacteria, insects, fungi, and mammals.
13. A specific binding agent that binds to a oxygenase according to claim 8.
14. An isolated nucleic acid molecule that:  
(a) has at least 60% sequence identity with a nucleic acid sequence selected from the group consisting of SEQ ID NOS: 1-21, 56-68, and 81-86; and  
(b) encodes a protein having oxygenase activity.
15. A method for isolating a nucleic acid sequence, comprising:  
(a) hybridizing the nucleic acid sequence to at least 10 contiguous nucleotides of a sequence selected from the group consisting of SEQ ID NOS: 1-21, 56-68, and 81-86; and  
(b) identifying the nucleic acid sequence as one that encodes an oxygenase.
16. The method of claim 15, wherein hybridizing the nucleic acid sequence is performed under low-stringency conditions.
17. A nucleic acid sequence identified by the method of claim 15.

18. A purified oxygenase encoded by a nucleic acid sequence according to claim 17.
- 5 19. A specific binding agent that binds an oxygenase according to claim 18.
20. The method of claim 15, wherein step (a) occurs in a PCR reaction.
- 10 21. The method of claim 15, wherein step (a) occurs during library screening.
22. The method of claim 15, wherein the isolated nucleic acid sequence is isolated from the genus *Taxus*.
- 15 23. A purified protein having oxygenase activity, comprising an amino acid sequence selected from the group consisting of:
- (a) an amino acid sequence selected from the group consisting of SEQ ID NOS: 56-68 and 87-92;
- 20 (b) an amino acid sequence that differs from the amino acid sequence specified in (a) by one or more conservative amino acid substitutions; and
- (c) an amino acid sequence having at least 70% sequence identity to the sequences specified in (a) or (b).
- 25 24. An isolated nucleic acid molecule encoding a protein according to claim 23.
25. An isolated nucleic acid molecule according to claim 24, further comprising a sequence selected from the group consisting of SEQ ID NOS: 43-55
- 30 and 81-86.

26. A recombinant nucleic acid molecule, comprising a promoter sequence operably linked to the nucleic acid sequence of claim 24.

27. A cell transformed with a recombinant nucleic acid molecule according to claim 26.

28. A method for synthesizing a second intermediate in the Taxol biosynthetic pathway, comprising:

(a) contacting a first intermediate with at least one oxygenase as recited in claim 18; and

(b) allowing the oxygenase to transfer at least one oxygen atom group to the first intermediate, wherein transfer of the at least one oxygen atom group yields the second intermediate in the Taxol biosynthetic pathway.

29. The method of claim 28, wherein the oxygenase is produced by an introduced oxygenase gene in a transgenic organism, and step (b) occurs *in vivo*.

30. A method for transferring an oxygen atom to a taxoid, comprising:

(a) contacting a taxoid with at least one oxygenase of claim 18; and  
(b) allowing the oxygenase to transfer an oxygen atom to the taxoid.

31. The method of claim 30, wherein the oxygenase is produced by an introduced oxygenase gene in a transgenic organism, and synthesis of the taxoid occurs *in vivo*.

32. The method of claim 30, wherein at least one paclitaxel molecule is produced.

33. The method of claim 30, wherein the taxoid is an acylation or a glycosylation variant of paclitaxel.

34. The method of claim 33, wherein the variant of paclitaxel is selected from the group consisting of cephalomannine, xylosyl paclitaxel, 10-deactyl paclitaxel, or paclitaxel C.

5 35. The method of claim 30, wherein the taxoid is baccatin III.

36. The method of claim 30, wherein the taxoid is an acylation or a glycosylation variant of baccatin III.

10 37. The method of claim 36, wherein the variant of baccatin III is selected from the group consisting of 7-xylosyl baccatin III or 2-debenzoyl baccatin III.

38. The method of claim 30, wherein the taxoid is 10-deacetyl-baccatin III.

15 39. The method of claim 30, wherein the taxoid is an acylation or a glycosylation variant of 10-deacetyl-baccatin III.

40. The method of claim 39, wherein the variant of baccatin III is selected from the group consisting of 7-xylosyl 10-baccatin III or 2-debenzoyl 10-baccatin III.

1/15





Fig. 1



**Fig. 2**



3/15






Fig. 3

Conserved motif in the heme binding domain

$\text{NH}_2^-$	P	F	G	-COOH	SEQ ID NO:
5'	cca	ttc	gg	3'	
	t	t			
	c				
	g				


5'	attaaccctcactaaa	cct	ttt	gg	3'	73
5'	attaaccctcactaaa	cct	ttc	gg	3'	74
5'	attaaccctcactaaa	cca	ttt	gg	3'	75
5'	attaaccctcactaaa	cca	ttc	gg	3'	76
5'	attaaccctcactaaa	ccg	ttt	gg	3'	77
5'	attaaccctcactaaa	ccg	ttc	gg	3'	78
5'	attaaccctcactaaa	ccc	ttt	gg	3'	79
5'	attaaccctcactaaa	ccc	ttc	gg	3'	80

anchor

**Fig. 4**

5/15

Fig. 5A



6/15

% of identity

	F12	F21	F42	F51	F72	F9	F31	F14	F19	F56	F55	F10	F34
F12		83	61	57	57	67	53	69	62	75	66	21	20
F21	85		62	58	55	67	52	67	60	74	66	20	20
F42	67	68		59	57	66	52	64	57	61	63	13	20
F51	65	65	66		53	62	53	61	55	59	60	0	16
F72	67	65	64	61		59	57	60	59	58	58	16	19
F9	74	75	69	67	67		53	69	61	67	70	20	20
F31	63	63	60	61	66	62		56	55	53	55	20	18
F14	79	77	72	68	69	76	65		64	66	71	23	22
F19	71	68	65	63	67	68	64	72		61	63	14	23
F56	80	80	66	65	67	74	62	76	69		66	21	20
F55	71	72	69	68	67	76	64	79	70	72		13	20
F10	32	31	26	14	26	26	30	31	28	31	26		37
F34	31	31	26	16	28	31	29	34	31	30	31	51	

% of similarity

Fig. 5B

7/15

SEQ. ID. NO.:




Fig. 5C

8/15

Percent Sequence Identity

Clone/ SEQ ID NO:	F 10/ 68	F 12/ 56	F 14/ 64	F 15/ 91	F 16/ 88	F 19/ 63	F 21/ 57	F 23/ 90	F 31/ 59	F 34/ 66	F 38/ 92	F 42/ 58	F 51/ 60	F 55/ 65	F 56/ 62	F 7/ 89	F 72/ 67	F 82/ 87	F 9/ 61
F10		15	16	14	16	15	16	14	15	32	15	14	14	14	14	14	14	15	14
F12	28		68	56	60	60	82	29	51	15	22	59	55	65	74	64	56	62	65
F14	27	79		58	63	62	66	28	55	17	26	62	60	70	66	69	60	65	68
F15	25	66	67		57	55	54	27	59	13	23	55	53	57	55	60	66	60	55
F16	27	71	72	67		58	60	30	56	17	25	57	55	60	61	61	60	62	60
F19	25	70	71	65	68		58	27	54	17	24	55	53	60	60	63	57	75	60
F21	28	85	77	65	71	68		29	51	15	23	59	54	65	74	66	55	62	65
F23	25	41	42	41	42	40	42		25	13	24	28	25	28	28	28	29	30	29
F31	26	63	64	70	65	63	63	42		14	24	51	52	53	53	55	56	55	52
F34	51	29	30	25	29	27	28	26	27		15	15	16	15	16	16	15	14	15
F38	28	37	40	38	38	37	38	38	40	29		25	22	25	23	25	25	25	25
F42	27	66	70	64	67	64	67	42	60	29	38		58	61	60	62	56	58	65
F51	25	64	68	62	65	63	64	39	62	26	35	66		59	57	58	51	56	61
F55	28	72	79	66	71	69	73	42	63	29	40	67	68		65	75	57	63	67
F56	26	80	77	66	71	68	81	42	63	29	38	66	65	73		66	57	63	66
F7	26	72	76	68	70	69	73	43	63	27	39	69	66	83	74		60	66	67
F72	27	67	69	75	68	66	66	40	65	27	38	63	61	67	66	67		59	57
F82	26	72	72	67	71	83	71	43	66	26	39	66	65	71	72	72	66		64
F9	27	73	74	62	67	67	73	42	60	28	39	66	64	75	72	73	65	71	

Fig. 5D

9/15




Fig. 6A-6C

10/15




Fig. 6D-6E



11/15




Fig. 7

12/15




Fig. 8

13/15




Fig. 9A-9B




Fig. 10A-10E




Fig. 11A-11E

## SEQUENCE LISTING

<110> Croteau, Rodney et al.

<120> CYTOCHROME P450 OXYGENASES AND THEIR USES

<130> 56458

<140>

<141>

<150> 60/165,250

<151> 1999-11-12

<160> 94

<170> PatentIn Ver. 2.1

<210> 1

<211> 192

<212> DNA

<213> Taxus cuspidata

<400> 1

```
ccatttgag gagagcggcg gacatgtcca ggatgggaat acgcaaaagt ggaaatatta 60
ctgttctctc atcattttgt gaaagcattc agtgggttaca cccaactga ccctcatgaa 120
aggatttggt ggtatccagt ccctcttgct cctgtcaagg gatttccaat aaaacttatt 180
gccagatcct ga 192
```

<210> 2

<211> 192

<212> DNA

<213> Taxus cuspidata

<400> 2

```
cctttcggag gaggcattgc tgtttgtcca gggatgggaat tcgccaagat ggagacatta 60
ctgtttctcc atcattttgt taaagccttc tctgggttga aggcaattga tccaatgaa 120
aaactttcag ggaaaccact tcctcctctc cctgtcaatg ggcttcccat taaactctat 180
tccagatcct aa 192
```

<210> 3

<211> 192

<212> DNA

<213> Taxus cuspidata

<400> 3

```
ccattcggag caggagtgcg catatgtgca ggatgggaat ttgcgaagac agaactatta 60
ctgtttgtcc atcactttgt taaaaacttc agaggttgca ttgtaattga tcctaatgaa 120
aaaatttcag gggatccatt ccctccactc cctaccagtg gacaactcat gaaacttatt 180
ccgagatcat aa 192
```

<210> 4

<211> 192

<212> DNA

<213> Taxus cuspidata

<400> 4

```
ccattcggag caggcgtacg catatgtgca ggatgggaat ttgcaaagac agaactatta 60
ctctttgtcc atcactttgt taaaaacttc agcgggttgca ttgtaattga tcctagttaa 120
aaaatttcag gggatccatt ccctcctctc cctaccagtg gacaacgcac gaaacttatt 180
ccgagatcct aa 192
```

<210> 5  
 <211> 192  
 <212> DNA  
 <213> *Taxus cuspidata*

<400> 5  
 cctttcgggg caggcaaacg catatgccca ggatgggagt tgcgtaagtt ggagatgtta 60  
 ctgttcaccc atcattttgt caaaaatttc agcggatacc tcccacttga caccaaggaa 120  
 aagatctccg gagatccatt ccctcctctc cccaaaaatg gatttcccat taaactatatt 180  
 ccgagaacct aa 192

<210> 6  
 <211> 201  
 <212> DNA  
 <213> *Taxus cuspidata*

<400> 6  
 ccattcggag gaggcgcgcg cacatgccca ggatgggaat tttcaaagac ggagatatta 60  
 ctgttcaccc atcattttgt tagaactttc agcagctacc tcccagttga ctccaacgaa 120  
 aaaatttcag cagatccatt ccctcccctc cctgccaatg gggttcccat aaaacttttt 180  
 cccagatctc aatccaattg a 201

<210> 7  
 <211> 192  
 <212> DNA  
 <213> *Taxus cuspidata*

<400> 7  
 ccattcggag gaggcctgcg cacatgtcca ggatgggaat tttcaaagac ggagatatta 60  
 ctgtttatcc atcattttgt taaaactttc ggcagctacc tcccagttga cccaacgaa 120  
 aaaatttcag cagatccatt ccctcctctc cctgccaatg gcttttctat aaaacttttt 180  
 cccagatctt aa 192

<210> 8  
 <211> 192  
 <212> DNA  
 <213> *Taxus cuspidata*

<400> 8  
 ccgttcggag gcggcctgcg catatgtcca ggatgggaat ttgcaaagac agagatgtta 60  
 ctgtttatcc attattttgt taaaactttc agcagctacc tcccagttga cccaacgaa 120  
 aagatttcag cagatccgct cgcttctttc cctgttaatg gatttccgt aaaacttttt 180  
 ccaagtcct aa 192

<210> 9  
 <211> 192  
 <212> DNA  
 <213> *Taxus cuspidata*

<400> 9  
 ccatttggag caggcctgcg cgtatgtcca ggatgggaat tggctaagac ggagatatta 60  
 ctgtttgtgc atcattttgt taaaacgttc agtagctaca tacctgttga ccctaaagaa 120  
 aaactctcag ctgatccact tcctccgctc cctctcaatg gggtttccat taaacttttt 180  
 tcgagatcct aa 192

<210> 10  
 <211> 192  
 <212> DNA  
 <213> *Taxus cuspidata*

&lt;400&gt; 10

```
ccattcggag gaggcctgcg catctgtcca ggccgggaat ttgcgaagat ggagatatta 60
gtgtttatgc atcattttgt taaagctttc agcagcttca ttccagttga ccctaacgaa 120
aaaatttcaa cagatccgct tccttccatc cctgtcaatg gattttccat aaaccttgtt 180
cccagatcct aa 192
```

&lt;210&gt; 11

&lt;211&gt; 192

&lt;212&gt; DNA

<213> *Taxus cuspidata*

&lt;400&gt; 11

```
ccatttggag gaggcctgcg catctgtgca ggctgggaat ttgcaaagat ggagatatta 60
ctgtttatgc atcattttgt taaaactttc agtcacttca ttccagttga cccaacgaa 120
aagatttcga gagatccact gcctcccac cctgtcaaag gattttccat aaagcctttt 180
cctagatcat aa 192
```

&lt;210&gt; 12

&lt;211&gt; 192

&lt;212&gt; DNA

<213> *Taxus cuspidata*

&lt;400&gt; 12

```
cccttcggtg gaggccaacg gtcattgtgt ggatgggaat tttcaaagat ggagatatta 60
ctattcggtc atcattttgt caaaaactttt agcagctaca cccagttga tcccgacgaa 120
aaaatatcag gggatccact ccctcctctt ccttccaagg gattttccat taaactgttt 180
ccgagaccat ag 192
```

&lt;210&gt; 13

&lt;211&gt; 192

&lt;212&gt; DNA

<213> *Taxus cuspidata*

&lt;400&gt; 13

```
ccatttggag gaggcctgcg cacatgtcca ggatgggaat tttcaaagat tgaaatatta 60
ctgtttgtcc atcatttctg taaaaatttc agcagctaca ttccagttga tcccaatgaa 120
aaagttttat cagatccact acctcctctc cctgccaatg gattttccat aaaacttttt 180
ccgagatcct aa 192
```

&lt;210&gt; 14

&lt;211&gt; 192

&lt;212&gt; DNA

<213> *Taxus cuspidata*

&lt;400&gt; 14

```
cccttcggag gaggggagcg cacctgtcca ggatatgaat tttcaaagac tcatatatta 60
ctgttcatcc accaatttct taaaactttc actggttaca tcccgcttga tccaaacgaa 120
agcatttcgg cgaatccgct cccccctcta cctgccaatg gatttcctgt aaaacttttt 180
ctcaggtcct aa 192
```

&lt;210&gt; 15

&lt;211&gt; 192

&lt;212&gt; DNA

<213> *Taxus cuspidata*

&lt;400&gt; 15

```
cccttcggcc agggtaatcg gatgtgcccc ggaaatgaat tcgcaagggt ggaaatggaa 60
ttatttctat atcatttgggt ttgagatat gattgggaat taatggaggc ggatgaacgc 120
accaacatgt acttcatttc tcaccctgtg cacagtttgc ctttactact taaacacggt 180
cctcctacat ga 192
```



<210> 16  
<211> 154  
<212> DNA  
<213> *Taxus cuspidata*

<400> 16  
ccatttgga agatttgaaa ttgctctctt tcttcacaac ttgtgacta aattcagatg 60  
ggagcagctg gaaattgatc gtgcgactta ctttctctt ccttccacag aaaatgggtt 120  
tccaatccgt ctctattctc gactacacga atga 154

<210> 17  
<211> 210  
<212> DNA  
<213> *Taxus cuspidata*

<400> 17  
ccgtttgggt cagggagaag aatgtgtccg ggcattgagc tggcattgag tgttggttacg 60  
tatacgtctg ggaggctgct gcagagcttc gagggtgctg ttccagaagg tgtgataatc 120  
gacatgacgg aggggttggg actaacaatg cccaaagcag ttccgttga gaccattatc 180  
aaacctcgcc ttcccttcca tctctactga 210

<210> 18  
<211> 202  
<212> DNA  
<213> *Taxus cuspidata*

<400> 18  
cccttcgggt gtatccggcg gggcctctgt tagttcctga tgaatcgaca gaggactgca 60  
gtgtcggagg gtatcatgtc ccagcagctg cgttcctgctg ggtacaacaa ttgacatgag 120  
agaggggttt ggactcacia tgcccaaagc gattccgttg gaagccaata taaaacctcg 180  
cctgcccttt catctctact ag 202

<210> 19  
<211> 228  
<212> DNA  
<213> *Taxus cuspidata*

<400> 19  
ccctttgggt gaggccagcg ttcatgtcca ggatgggaat tttcaaagat ggagatttta 60  
ctgtcgggtg atcattttgt taaaacattc agcaccttca cccagttga cccagcagaa 120  
ataattgcaa gagattccct ctgccctctc ccttccaatg gggtttctgt aaaacttttt 180  
cctagatcct attcacttca cacaggcaac caggtaaga aaatataa 228

<210> 20  
<211> 219  
<212> DNA  
<213> *Taxus cuspidata*

<400> 20  
cccttcggag caggcgtgct cacctgcccga ggatgggaat tttcaaaaac ccagatatta 60  
ctgttcttac attattttgt taaaactttc agtggtctaca tccactcga ccctgacgaa 120  
aaagtgttag ggaatccagt cctcctctc cctgccaatg gatttgctat aaaacttttc 180  
cccaggccct cattogatca aggatcacc atggaataa 219

<210> 21  
<211> 201  
<212> DNA  
<213> *Taxus cuspidata*

<400> 21  
ccttttgggt cggaaggag aggatgcccga ggggcaagca tggccgttgt gacgatggaa 60

cttgcggttg cacaactcat gcactgcttc cagtggcgca ttgaaggaga gttggatatg 120  
 agtgaacgct tcgcagcctc cttgcaaaga aaagtcgatac tttgtgttct tcctcaatgg 180  
 aggctaacta gtagcccttg a 201

<210> 22  
 <211> 63  
 <212> PRT  
 <213> *Taxus cuspidata*

<400> 22  
 Pro Phe Gly Gly Gly Arg Arg Thr Cys Pro Gly Trp Glu Tyr Ala Lys  
 1 5 10 15  
 Val Glu Ile Leu Leu Phe Leu His His Phe Val Lys Ala Phe Ser Gly  
 20 25 30  
 Tyr Thr Pro Thr Asp Pro His Glu Arg Ile Cys Gly Tyr Pro Val Pro  
 35 40 45  
 Leu Val Pro Val Lys Gly Phe Pro Ile Lys Leu Ile Ala Arg Ser  
 50 55 60

<210> 23  
 <211> 63  
 <212> PRT  
 <213> *Taxus cuspidata*

<400> 23  
 Pro Phe Gly Gly Gly Met Arg Val Cys Pro Gly Trp Glu Phe Ala Lys  
 1 5 10 15  
 Met Glu Thr Leu Leu Phe Leu His His Phe Val Lys Ala Phe Ser Gly  
 20 25 30  
 Leu Lys Ala Ile Asp Pro Asn Glu Lys Leu Ser Gly Lys Pro Leu Pro  
 35 40 45  
 Pro Leu Pro Val Asn Gly Leu Pro Ile Lys Leu Tyr Ser Arg Ser  
 50 55 60

<210> 24  
 <211> 63  
 <212> PRT  
 <213> *Taxus cuspidata*

<400> 24  
 Pro Phe Gly Ala Gly Val Arg Ile Cys Ala Gly Trp Glu Phe Ala Lys  
 1 5 10 15  
 Thr Glu Leu Leu Leu Phe Val His His Phe Val Lys Asn Phe Arg Gly  
 20 25 30  
 Cys Ile Val Ile Asp Pro Asn Glu Lys Ile Ser Gly Asp Pro Phe Pro  
 35 40 45  
 Pro Leu Pro Thr Ser Gly Gln Leu Met Lys Leu Ile Pro Arg Ser  
 50 55 60

<210> 25  
 <211> 63  
 <212> PRT  
 <213> *Taxus cuspidata*

<400> 25  
 Pro Phe Gly Ala Gly Val Arg Ile Cys Ala Gly Trp Glu Phe Ala Lys  
     1                    5                    10                    15  
 Thr Glu Leu Leu Leu Phe Val His His Phe Val Lys Asn Phe Ser Gly  
                     20                    25                    30  
 Cys Ile Val Ile Asp Pro Ser Glu Lys Ile Ser Gly Asp Pro Phe Pro  
                     35                    40                    45  
 Pro Leu Pro Thr Ser Gly Gln Arg Met Lys Leu Ile Pro Arg Ser  
     50                    55                    60

<210> 26  
 <211> 63  
 <212> PRT  
 <213> *Taxus cuspidata*

<400> 26  
 Leu Ser Gly Ala Gly Lys Arg Ile Cys Pro Gly Trp Glu Phe Ala Lys  
     1                    5                    10                    15  
 Leu Glu Met Leu Leu Phe Ile His His Phe Val Lys Asn Phe Ser Gly  
                     20                    25                    30  
 Tyr Leu Pro Leu Asp Thr Lys Glu Lys Ile Ser Gly Asp Pro Phe Pro  
                     35                    40                    45  
 Pro Leu Pro Lys Asn Gly Phe Pro Ile Lys Leu Phe Pro Arg Thr  
     50                    55                    60

<210> 27  
 <211> 66  
 <212> PRT  
 <213> *Taxus cuspidata*

<400> 27  
 Pro Phe Gly Gly Gly Ala Arg Thr Cys Pro Gly Trp Glu Phe Ser Lys  
     1                    5                    10                    15  
 Thr Glu Ile Leu Leu Phe Ile His His Phe Val Arg Thr Phe Ser Ser  
                     20                    25                    30  
 Tyr Leu Pro Val Asp Ser Asn Glu Lys Ile Ser Ala Asp Pro Phe Pro  
                     35                    40                    45  
 Pro Leu Pro Ala Asn Gly Phe Ser Ile Lys Leu Phe Pro Arg Ser Gln  
     50                    55                    60

Ser Asn  
 65

<210> 28

<211> 63  
 <212> PRT  
 <213> *Taxus cuspidata*

<400> 28

Pro Phe Gly Gly Gly Leu Arg Thr Cys Pro Gly Trp Glu Phe Ser Lys  
 1 5 10 15

Thr Glu Ile Leu Leu Phe Ile His His Phe Val Lys Thr Phe Gly Ser  
 20 25 30

Tyr Leu Pro Val Asp Pro Asn Glu Lys Ile Ser Ala Asp Pro Phe Pro  
 35 40 45

Pro Leu Pro Ala Asn Gly Phe Ser Ile Lys Leu Phe Pro Arg Ser  
 50 55 60

<210> 29  
 <211> 63  
 <212> PRT  
 <213> *Taxus cuspidata*

<400> 29

Pro Phe Gly Gly Gly Leu Arg Ile Cys Pro Gly Trp Glu Phe Ala Lys  
 1 5 10 15

Thr Glu Met Leu Leu Phe Ile His Tyr Phe Val Lys Thr Phe Ser Ser  
 20 25 30

Tyr Val Pro Val Asp Pro Asn Glu Lys Ile Ser Ala Asp Pro Leu Ala  
 35 40 45

Ser Phe Pro Val Asn Gly Phe Ser Val Lys Leu Phe Pro Arg Ser  
 50 55 60

<210> 30  
 <211> 63  
 <212> PRT  
 <213> *Taxus cuspidata*

<400> 30

Pro Phe Gly Ala Gly Leu Arg Val Cys Pro Gly Trp Glu Leu Ala Lys  
 1 5 10 15

Thr Glu Ile Leu Leu Phe Val His His Phe Val Lys Thr Phe Ser Ser  
 20 25 30

Tyr Ile Pro Val Asp Pro Lys Glu Lys Leu Ser Ala Asp Pro Leu Pro  
 35 40 45

Pro Leu Pro Leu Asn Gly Phe Ser Ile Lys Leu Phe Ser Arg Ser  
 50 55 60

<210> 31  
 <211> 63  
 <212> PRT  
 <213> *Taxus cuspidata*

&lt;400&gt; 31

Pro Phe Gly Gly Gly Leu Arg Ile Cys Pro Gly Arg Glu Phe Ala Lys  
1 5 10 15

Met Glu Ile Leu Val Phe Met His His Phe Val Lys Ala Phe Ser Ser  
20 25 30

Phe Ile Pro Val Asp Pro Asn Glu Lys Ile Ser Thr Asp Pro Leu Pro  
35 40 45

Ser Ile Pro Val Asn Gly Phe Ser Ile Asn Leu Val Pro Arg Ser  
50 55 60

&lt;210&gt; 32

&lt;211&gt; 63

&lt;212&gt; PRT

<213> *Taxus cuspidata*

&lt;400&gt; 32

Pro Phe Gly Gly Gly Leu Arg Ile Cys Ala Gly Trp Glu Phe Ala Lys  
1 5 10 15

Met Glu Ile Leu Leu Phe Met His His Phe Val Lys Thr Phe Ser His  
20 25 30

Phe Ile Pro Val Asp Pro Asn Glu Lys Ile Ser Arg Asp Pro Leu Pro  
35 40 45

Pro Ile Pro Val Lys Gly Phe Ser Ile Lys Pro Phe Pro Arg Ser  
50 55 60

&lt;210&gt; 33

&lt;211&gt; 63

&lt;212&gt; PRT

<213> *Taxus cuspidata*

&lt;400&gt; 33

Pro Phe Gly Gly Gly Gln Arg Ser Cys Val Gly Trp Glu Phe Ser Lys  
1 5 10 15

Met Glu Ile Leu Leu Phe Val His His Phe Val Lys Thr Phe Ser Ser  
20 25 30

Tyr Thr Pro Val Asp Pro Asp Glu Lys Ile Ser Gly Asp Pro Leu Pro  
35 40 45

Pro Leu Pro Ser Lys Gly Phe Ser Ile Lys Leu Phe Pro Arg Pro  
50 55 60

&lt;210&gt; 34

&lt;211&gt; 63

&lt;212&gt; PRT

<213> *Taxus cuspidata*

&lt;400&gt; 34

Pro Phe Gly Gly Gly Leu Arg Thr Cys Pro Gly Trp Glu Phe Ser Lys  
1 5 10 15

Ile Glu Ile Leu Leu Phe Val His His Phe Val Lys Asn Phe Ser Ser  
                   20                                  25                                  30

Tyr Ile Pro Val Asp Pro Asn Glu Lys Val Leu Ser Asp Pro Leu Pro  
                   35                                  40                                  45

Pro Leu Pro Ala Asn Gly Phe Ser Ile Lys Leu Phe Pro Arg Ser  
                   50                                  55                                  60

<210> 35

<211> 63

<212> PRT

<213> *Taxus cuspidata*

<400> 35

Pro Phe Gly Gly Gly Glu Arg Thr Cys Pro Gly Tyr Glu Phe Ser Lys  
                   1                                  5                                  10                                  15

Thr His Ile Leu Leu Phe Ile His Gln Phe Val Lys Thr Phe Thr Gly  
                   20                                  25                                  30

Tyr Ile Pro Leu Asp Pro Asn Glu Ser Ile Ser Ala Asn Pro Leu Pro  
                   35                                  40                                  45

Pro Leu Pro Ala Asn Gly Phe Pro Val Lys Leu Phe Leu Arg Ser  
                   50                                  55                                  60

<210> 36

<211> 63

<212> PRT

<213> *Taxus cuspidata*

<400> 36

Pro Phe Gly Gln Gly Asn Arg Met Cys Pro Gly Asn Glu Phe Ala Arg  
                   1                                  5                                  10                                  15

Leu Glu Met Glu Leu Phe Leu Tyr His Leu Val Leu Arg Tyr Asp Trp  
                   20                                  25                                  30

Glu Leu Met Glu Ala Asp Glu Arg Thr Asn Met Tyr Phe Ile Pro His  
                   35                                  40                                  45

Pro Val His Ser Leu Pro Leu Leu Leu Lys His Val Pro Pro Thr  
                   50                                  55                                  60

<210> 37

<211> 50

<212> PRT

<213> *Taxus cuspidata*

<400> 37

His Leu Ala Arg Phe Glu Ile Ala Leu Phe Leu His Asn Phe Val Thr  
                   1                                  5                                  10                                  15

Lys Phe Arg Trp Glu Gln Leu Glu Ile Asp Arg Ala Thr Tyr Phe Pro  
                   20                                  25                                  30

Leu Pro Ser Thr Glu Asn Gly Phe Pro Ile Arg Leu Tyr Ser Arg Val

35

40

45

His Glu  
50

&lt;210&gt; 38

&lt;211&gt; 69

&lt;212&gt; PRT

<213> *Taxus cuspidata*

&lt;400&gt; 38

Pro Phe Gly Ser Gly Arg Arg Met Cys Pro Gly Met Ser Leu Ala Leu  
1 5 10 15

Ser Val Val Thr Tyr Thr Leu Gly Arg Leu Leu Gln Ser Phe Glu Trp  
20 25 30

Ser Val Pro Glu Gly Val Ile Ile Asp Met Thr Glu Gly Leu Gly Leu  
35 40 45

Thr Met Pro Lys Ala Val Pro Leu Glu Thr Ile Ile Lys Pro Arg Leu  
50 55 60

Pro Phe His Leu Tyr  
65

&lt;210&gt; 39

&lt;211&gt; 66

&lt;212&gt; PRT

<213> *Taxus cuspidata*

&lt;400&gt; 39

Leu Arg Leu Tyr Pro Ala Gly Pro Leu Leu Val Pro Asp Glu Ser Thr  
1 5 10 15

Glu Asp Cys Ser Val Gly Gly Tyr His Val Pro Xaa Xaa Xaa Val Pro  
20 25 30

Ala Gly Thr Thr Ile Asp Met Arg Glu Gly Phe Gly Leu Thr Met Pro  
35 40 45

Lys Ala Ile Pro Leu Glu Ala Asn Ile Lys Pro Arg Leu Pro Phe His  
50 55 60

Leu Tyr  
65

&lt;210&gt; 40

&lt;211&gt; 75

&lt;212&gt; PRT

<213> *Taxus cuspidata*

&lt;400&gt; 40

Pro Phe Gly Gly Gly Gln Arg Ser Cys Pro Gly Trp Glu Phe Ser Lys  
1 5 10 15

Met Glu Ile Leu Leu Ser Val His His Phe Val Lys Thr Phe Ser Thr  
20 25 30

Phe Thr Pro Val Asp Pro Ala Glu Ile Ile Ala Arg Asp Ser Leu Cys  
 35 40 45

Pro Leu Pro Ser Asn Gly Phe Ser Val Lys Leu Phe Pro Arg Ser Tyr  
 50 55 60

Ser Leu His Thr Gly Asn Gln Val Lys Lys Ile  
 65 70 75

<210> 41

<211> 72

<212> PRT

<213> *Taxus cuspidata*

<400> 41

Pro Phe Gly Ala Gly Val Arg Thr Cys Pro Gly Trp Glu Phe Ser Lys  
 1 5 10 15

Thr Gln Ile Leu Leu Phe Leu His Tyr Phe Val Lys Thr Phe Ser Gly  
 20 25 30

Tyr Ile Pro Leu Asp Pro Asp Glu Lys Val Leu Gly Asn Pro Val Pro  
 35 40 45

Pro Leu Pro Ala Asn Gly Phe Ala Ile Lys Leu Phe Pro Arg Pro Ser  
 50 55 60

Phe Asp Gln Gly Ser Pro Met Glu  
 65 70

<210> 42

<211> 66

<212> PRT

<213> *Taxus cuspidata*

<400> 42

Pro Phe Gly Ala Gly Arg Arg Gly Cys Pro Gly Ala Ser Met Ala Val  
 1 5 10 15

Val Thr Met Glu Leu Ala Leu Ala Gln Leu Met His Cys Phe Gln Trp  
 20 25 30

Arg Ile Glu Gly Glu Leu Asp Met Ser Glu Arg Phe Ala Ala Ser Leu  
 35 40 45

Gln Arg Lys Val Asp Leu Cys Val Leu Pro Gln Trp Arg Leu Thr Ser  
 50 55 60

Ser Pro  
 65

<210> 43

<211> 1455

<212> DNA

<213> *Taxus cuspidata*

<400> 43



```

atggatacct tcattcagca cgagtcttcc ccacttcttc tttctcttac tctcgtgtt 60
attcttggca caattcttct tttgatatta agtggtaaac agtacagatc ttctcgtaaa 120
cttccccctg gaaacatggg cttccctctc attggggaga ctatagcact tatatcagat 180
acacctcgga agtttatcga cgacagagtg aagaaattcg gcctggtttt caagacttcg 240
ctaattggtc atcccgcagt tgtaatatgc ggctcctccg caaacggttt cctcctctcc 300
aacgaggaaa agctggtgcg gatgtctttg cccaacgcag tactgaaact ctgggggcag 360
gattgcgtta tggggaaaac cggagtggag catgggattg tacgtaccgc actagcccgc 420
gccttgggcc cccaggcggt gcagaattat gtggccaaaa tgagttcaga gatcgaacac 480
catatcaacc aaaaatggaa ggggaaagat gaggtgaagg tgcttcctct gataagaagc 540
ctcgtcttct ccatttcaac cagcttggtt ttcggtataa acgatgagca ccaacagaag 600
cgacttcac atcttttggg aactgtagct atgggacttg tgagtattcc cctagacttt 660
ccaggaaactc gttttcgtaa agcactttac gcgcggtcga agctcgatga aattatgtct 720
tctgtaatag aaaggagaag aagcgatctt cgttcaggag cagcttcaag cgaccaagat 780
ctactgtcgg tgttggtcac cttcaaagat gaaagaggga attcattcgc agacaaggag 840
atactggata acttctcttt tctacttcac gccttatacg acaccacaat ttcaccactc 900
accttgatat ttaagctgct ctctctagt cctgaatgct atgagaatat agctcaagag 960
cagctggaaa tacttggcaa taaaaaggat agagaggaaa tcagctggaa ggatctgaag 1020
gatatgaaat atacatggca agcagttcag gaaactttga ggatgttccc tccagtttat 1080
ggatatattc gcgaggcttt gacagatatt gactatgatg gctatacaat accaaaagga 1140
tggaagaatat tatgttcacc tcatactacg catagtaaag aggagtattt cgatgagccg 1200
gaagaattca gaccttcaag attcgaggat caagggaaggc atgtggctcc ttacacattc 1260
ataccatttg gaggaggcct gcgcactctgt gcaggctggg aatttgcaaa gatggagata 1320
ttactgttta tgcattcatt tgttaaaact ttcagtcact tcattccagt tgaccccaac 1380
gaaaagattt cgagagatcc actgcctccc atccctgtca aaggattttc cataaagcct 1440
tttctagat cataa 1455

```

&lt;210&gt; 44

&lt;211&gt; 1455

&lt;212&gt; DNA

<213> *Taxus cuspidata*

&lt;400&gt; 44

```

atgcttatcg aaatggatac cttcgttcag ctcgagtctt cccctgttct tctttccctt 60
accctcacac ttattcttct ttttatattc tgtagtaaac aatacagatc ctctcttaaa 120
cttccccctg gaaacatggg cttccctctc attggggaga cgatagcact ggcacacag 180
acacctgata aatttttcgg cgatagaatg aagaaattcg gcaaggtttt caagacttcg 240
ttaattgggc atcccacaat tgtgctctgc ggttcctccg gaaaccgttt tctcctctcc 300
aacgaggaaa aactggtgcg gatgtttccg cccaactcat ccagcaaaact cctggggcag 360
gattctgttc tggggaaaat aggagaggag catcggattg tacgtaccgc actagcccgc 420
tgtttgggcc cccaagcgct gcagaattac gtgtccaaa tgagttcaga gatccaacgt 480
catatcaacc aaaaatggaa gggaaaagggt gaagtgaaga tgcttcctct gataagaagc 540
cttgtcttct ccatcgcaac cagcttattt tttggtatta ccgatgagca acaacaagaa 600
cgacttcac atcttctgga aacagttggt acgggacttt tgtgtattcc gctcgacttt 660
ccaggaaacta catttcgtaa agcacttcac gcgcggtcga agctcgatga gattatgtct 720
tctgtaatag aaaggagaag aaacgatctg cgtttaggcg cagcttcaag cgaccaagat 780
ctattgtcgg tgttgtcac cttcaaagat gaaagaggga atccattcgc tgacaaggag 840
atcctggata acttctcttt tctacttcac gccttatacg acaccacaat ttcaccactc 900
acgttgggtat ttaagctggt gtctccaat cctgaatgct acgaaaatat agctcaagag 960
caattggaaa ttcttcgcaa taaaaaggat ggagaagata tcagctgggc ggatctgaag 1020
gatatgaaat atacgtggca agcagttcag gaaaccttga ggatgtgtcc tccagtttat 1080
ggaaattttc gcaaggcttt gacagatatt cattatgatg gctatacaat cccaaaagga 1140
tgaggattt tatgttcacc ttatactaca catagtaaag aggagtattt tgacgacccg 1200
gagaaattca gaccttcaag attcgaagag caagggaagg atgtggctcc ttacacattc 1260
ataccattcg gaggaggcct gcgcactctgt ccaggccggg aatttgcaaa gatggagata 1320
ttagtgttta tgcattcatt tgttaaagct ttcagcagct tcattccagt tgaccctaac 1380
gaaaaaattt caacagatcc gcttccttcc atccctgtca atggattttc cataaacctt 1440
gttccagat cctaa 1455

```

&lt;210&gt; 45

&lt;211&gt; 1506

&lt;212&gt; DNA

<213> *Taxus cuspidata*

&lt;400&gt; 45

```

atggattcct tcagttttct aaaaagcatg gaagcgaaat tcggccaagt catacaccgg 60
gatcagttct ccagtactgc tcttctgtcc ctgcattca cagctgctgt tgccattttt 120
cttgtgttgc tctttcgatt taaaagccgg ccctctacta atttccctcc aggaaatttt 180
ggcttccctt tcattggaga gacgatacag ttcttgccgg cacttcgacg agaatcgct 240
catatgtttt ttgatgagag attgaagaaa ttggggcgtg tattcaagac gtcattaact 300
gggcatccca cagctgtgtt ctgcgggcct gcgggaaacc ggtttattta ctcgaaatgag 360
cacaagctgg tgcagtcgtc tgggccaac tccttcgtca aactggttgg gcagcaatcc 420
atcgtgacca aaacaggaga ggagcaccgc atctttcttg gtgtcctgaa cgagttttctg 480
gggcctcatg ctttacagag ttatacgctt aaaatgagtt ccaaaatcca ggagaatata 540
aataagcatt ggaagggtaa agatgaagtg aacatgcttc cttcgataag acagctcgctc 600
ttctccattt caagcagctt gttttttgat attaatgatg aggatcaaca ggaacaactt 660
aaaactcttt tagaaactat tcttgtggga actttgtcgg ttccctctga cattccagga 720
tctaattttt gtaaagctct tcgggcgcgt tccaagctgg atgaaattct gtctcgttta 780
atcgaaagca gaagaaaaga tatgcgttct gggatagctt ctaccagtaa aaatctactg 840
tcggtgctgc tcgccttcaa agatgaaaga gggaatccat tgacggacac ggagatcctc 900
gacaactttt cttttatgct tcacgcctca tacgacacca ccgtttcgcc cacagtttgt 960
atatttaagc tgctctccgc caatccagaa tgctatgaaa aagtagttca agaacaattg 1020
ggaatacttg gcaataaaaa ggacggtgaa gaaatgtgtt ggaacgatct gaaagctatg 1080
aaatatacat ggcaagcagc tcaagaaaca atgaggcttt tccctccagc gtttgatca 1140
tttcgcaagg tcactgcgca tattcatcat gatggctata taattcccaa aggatggaaa 1200
gctatggtga caaattacag tacaagtagg aaagaagagt acttcgatga accagacaat 1260
ttcaagcctt caagatttgg ggatgaaag tatgtggctc cgtaacacatt cttacctttc 1320
ggggcaggca tacgcatatg cccaggatgg gagttcgcta agttggagat gttactgttc 1380
atccatcatt ttgtcaaaaa tttagcggga tacctccac ttgacaccaa ggaaaagatt 1440
tccggagatc cattccctcc tctcccaaaa aatggatttc ccattaaact atttccgaga 1500
acctaa 1506

```

&lt;210&gt; 46

&lt;211&gt; 1503

&lt;212&gt; DNA

<213> *Taxus cuspidata*

&lt;400&gt; 46

```

atggatgccc tttctcttgt aaacagcaca gttgcaaaat ttaatgaggt aacgcagcta 60
caggcttccc ctgctattct gtccactgcc ctactgcta ttgcaggcat tattgtgctc 120
ctcgtcatca cttctaaacg ccgttcctct cttaaaacttc ctccctgaaa actaggcctc 180
cctttcattg gcgagacttt agagttcgtg aaggctcttc gatcagacac acttcgacaa 240
tttgtggagg aaagggaggg gaaatttgga cgtgtgttca agacttcatt gcttgggaag 300
cccactgtaa tactctgcgg ccctgcggga aaccgcttag ttctttccaa cgaggaaaaa 360
ctgttgacag tgctgtggtc cgcccaaat gccagaatcc tgggtctcaa ttctgttgca 420
gtgaaaaggg gagatgatca ccgcgttctg cgtgtcgcac tagcaggttt ttggggtctc 480
gcagggttac agctttacat aggtaaaatg agtgactta tcagaaatca tatcaatgaa 540
aaatggaagg gaaaagatga agtgaatgta ctgagtttgg taagagatct tgtcatggac 600
aattcagcta tcttgttttt caatatatac gataaagagc gaaagcaaca actgcatgaa 660
atattgaaaa tcattcttgc ctcacatttc ggcatacctt taaacattcc cggattttctg 720
tatcgcaaaag cactcaaggg gagcttgaag cggaaaaaaa ttctctccgc tttactggaa 780
aagagaaaaag acgaactgcg ctcaagatta gcgtctagca atcaagatct tctctctgtt 840
ttgctcagct tcagagatga aagagggaaa ccactgagcg acgaggcagt cttagacaac 900
tgttttgcaa tgctgtatgc ctctatgac accaccactt cacaatgac tctgatttta 960
aagatgttgt cttccaatcc agaattgctt gaaaaagtag ttcaagagca attggagata 1020
gcgtcaataa aaaaggaggg agaagaaatc acaatgaagg atatcaaagc catgaaatac 1080
acatggcaag tgctccagga aagtctacgg atgctttctc cagtatttgg aacacttcgt 1140
aagaccatga atgacattaa tcacgatggt tacacaattc caaaaggatg gcaggttgta 1200
tggaacaactt attctacaca tcagaaagac atatatattc agcagccaga taaattcatg 1260
ccttcgagat tcgaagagga agatgggcat ttggatgctt atacattcgt accatttgga 1320
ggaggacggc ggacatgtcc aggatgggaa tacgcaaaag tggaaatatt actgttcttc 1380
catcattttg tgaaagcatt cagtgtttac accccaactg accctcatga aaggatttgt 1440
gggtatccag tccctcttgt ccctgtcaag ggatttccaa taaaacttat cgccagatcc 1500

```

tga

1503

&lt;210&gt; 47

&lt;211&gt; 1476

&lt;212&gt; DNA

<213> *Taxus cuspidata*

&lt;400&gt; 47

```

atggatacca tacgagcaag ttttggcgaa gttattcagc cagagtattc tcctctcacc 60
atttccgncg ctctggcagc ttttcttggg attgttattt tctcgatctt cagttccact 120
cgacgatcct atgtgaatct cccccctgga aatttaggtt tacctttcat tggcgagacg 180
atacagttct tgggggcaact tcagtcagaa aaaccccata catttttcga tgagagagtg 240
aagaaattcg gtaagggtctt caagacttct ctaattgggg atcccacggt ggtactctgc 300
gggcccggcg gaaaccgctt agttctgtcg aacgaagaca agctgggtgca gtccgcaggg 360
cccaagtctt tcctgaaact gtttggggag gattccgttg cggccaaaag agaagagagc 420
catcgatctt tacgttcggc tctgggtcga tttctgggtc cccatgcttt acagaattat 480
attgggaaaa tgaattcaga aatgcaacgn catttcgatg acaaattgaa gggaaaagat 540
gaggtgaagg tgcttccttt ggtagaggc ctcatcttct ccattgctac ctccctgttc 600
ttcaatataa atgatgacag acaacgtgag caactccatg gtctgctgga tacaatactt 660
gtgggaagta tgactattcc tctgaacatt ccaggaactc ttttctgtaa agctgtcaag 720
gcacggggcg agctggacga aattcttttt gctttgatag agaacagaag aagagagctg 780
agatcggggc taaattcttg taatcaagat cttctgtcgt ccttgctcac cttcaaagat 840
gaaaaaggga atccactgac agacaaggag atcctcgaca acttctctgt tatgcttcat 900
gctcgtatg acactatgt ttcaccaacg gtcttgatat tgaagcttct cgcctccaat 960
cctgaatgct atgaaaaagt tggtcaagag cagttgggaa tacttgctag taaaaaggag 1020
ggagaagaag tcaattggaa ggatctgaaa gctatgccat atacatggca agcaattcag 1080
gaacccctaa gnatgccccn ccagcttttg gaatgtttcg aagagcttcc cctgatattc 1140
agttggaagg ctatacaatt ccaaaaggat gggcaattgt gtggccanct tatagtcaat 1200
gggagagaag agttcttcaa tgaaccagac aaattcaagc cttccagatt cgaggaagga 1260
aagcccctgg atccttacac attcatacca ttcggagcag gggtagcat atgtgcagga 1320
tgggaatttg caaaggctga actattactg tttgtccatc cctttgttaa aaacttcagc 1380
ggttgcatta taattgatcc gaatgaaaaa atttcagggg atccattccc tccactccct 1440
accagtggac aactcatgaa acttattccg agatca 1476

```

&lt;210&gt; 48

&lt;211&gt; 1503

&lt;212&gt; DNA

<213> *Taxus cuspidata*

&lt;400&gt; 48

```

atggatagct tcaatttctt gagaggcatt ggagcagatt ttgggggatt cattcagttc 60
cagtcttccc ctgctgttct ttccctttcc ctgatcaca ctattcttgg cgttctactt 120
ctctggttct tccttcataa aaacgggtcc tctgttactc tccccctgg aaatttaggc 180
ttccctttca ttggggagac cataccattc ttgaggcac ttcgatcaga aacacctcag 240
acgttttttg atgagagggt gaagaaattc ggtgtgtat tcaagactcg gatagttggg 300
catcccacag ttgtactctg cgggcctgag ggaaaccgct ttcttctctc caacgaggac 360
aaactggtgc aggcgtcatt gcccaactct tccgagaaac taattgggaa atattccatt 420
ctgtccaaaa gaggggagga gcatcgcata ttacgtgctg cacttgcccg ctttttgca 480
cccaagctt tgcagggtta tgttgctaaa atgagttcag aaatccaaca tcatatcaag 540
caaaaatgga agggaaatga tgaagtgaag gtgcttctc tgataagaac cctgatcttc 600
aacattgcaa gcagcctgtt tttcggcata aatgatgaac accaacagga acagcttcat 660
catcttttgg aagccattgt tctgggaagt ctgtctgttc cgctcgactt tccaggaact 720
cgttttctga aagctcttga tgcgcggtct aagctggatg agattcttcc tcttttaag 780
gagagcagaa gaagggtatc gcgtttgggc acggttctg agaatcaaga tcttcttct 840
gtgttgctca ctttcaaaga tgaagagggt aatccactca cagacaagga aatcttcgac 900
aatttttcat ttatgcttca tgcctcgtat gataccactg tttaccaac gggtttgatg 960
cttaagcttc tcttctctag tcttgattgc tatgaaaaac tagttcaaga acaattggga 1020
atagttggca ataaaaagga gggagaagaa atcagctgga acgatctgaa agctatgaaa 1080
tatacatgca aggttggtgca ggaaagtatg aggatgctcc ctccagttt tggatcgat 1140
cgcaaggcta ncacctatat ccattatgat gggatataca ttccaaaagg atggaatata 1200
ttctggtcac cttatactac acacgggaaa gaagaatact tcaatgaagc ggacaagttc 1260

```

```

atgccttcga gattcgagga aggcacaaatat gttgctcctt acacattcctt gccattcgga 1320
gcaggtctgc gcgtatgtcc aggatgggaa tttgcaaaga ccgagatatt actgttcgtc 1380
catcatttta ttacaacttt cagcagctac atcccaattg accccaaaga taaaatttca 1440
ggggatccat ttctcctctt gcctaccaat ggattttcca tgaaactttt taccagatct 1500
taa 1503

```

&lt;210&gt; 49

&lt;211&gt; 1452

&lt;212&gt; DNA

<213> *Taxus cuspidata*

&lt;400&gt; 49

```

atggatacct taattcagat ccagtcttcc cctgatttcc tttcctttac tctcacagcg 60
tttctgggcg ttgttgtgct tttgatattc cggtataaac accgatccgc tctcaaactt 120
ccacctggaa atttaggctt gcccttcatt ggggagacaa taacatttgc atctcaacct 180
cctcagaagt ttttaaacga gagggggaag aaatttgggc ctgttttcaa gacgtcgcta 240
attgggcac cccacagtgt tctctgcgcg tcctcgggaa accgttttct cctctccaac 300
gaggaaaagc tgggtcggat gtctttgccc aactcataca tgaaactcct ggggcaggat 360
tcccttctgg ggaaaacggg acaggaacat cggattgtgc gtaccgcact aggacgtttt 420
ttgggcccc aagagttgca gaatcatgtg gccaaagatga gtccagacat tcagcatcac 480
atcaacccaa aatggaaggg gaatgatgaa gtgaagggtc ttctctctgat aaggaacctt 540
gtcttctcca ttgcaaccag cttgtttttc ggtataaacg atgagcacca acaggagcga 600
cttcatcttc ttttggaac tattgtaatg ggagctgtgt gtattccgct cgcctttcca 660
ggatctgggt ttcgtaaagc gcttcaggca cggtcggagc tcgatggaat tctcatttct 720
ttaatgaaaa tcagaagaag cgatctgcgt tcaggcgag cttcaagcaa ccaagatcta 780
ctgtcgggtg tgcacacctt caaagatgaa agaggaaatc cattgacaga caaggagatc 840
ctcgacaact tctctgttct acttcatggc ttatatgaca ccacaatttc accactcacc 900
ttgattttta agctcatgtc ctccaatact gaatgctacg agaatgtagt ccaagagcaa 960
ttagaaatac tttcccatag agagaaggga gaggagatcg gttggaagga tctgaaatct 1020
atgaaatata cttggcaagc cattcaggaa accttgagaa tgttccctcc ggtttacgga 1080
aattttcgca aggccttgac tgatattcat tacgatggct atacaatccc aaaagggtgg 1140
agggttttat gttcgccctt taccacgcac agcaatgaag aatattttta tgagccagat 1200
gaattcagac cttcaagatt cgaggggcaa ggaaagaatg tgccttctta cacattcata 1260
ccgttcggag gcggcctgcg catatgtcca ggatgggaat ttgcaaagac agagatgtta 1320
ctgtttatac attattttgt taaaactttc agcagctacg tcccagttga ccccaacgaa 1380
aagatttcag cagatccgct cgcttcttcc cctgttaatg gattctccgt aaaacttttt 1440
ccaaggtcct aa 1452

```

&lt;210&gt; 50

&lt;211&gt; 1512

&lt;212&gt; DNA

<213> *Taxus cuspidata*

&lt;400&gt; 50

```

atggacgctt ttaatatattt aaagggccct gctgcaaaac ttaatggagt cgtgcagctc 60
ggctcttaca ccgatcgat tctttccatt acagtcgttg ccttcattac tattctcctg 120
ttgctcatgc tccgttgga aagccagctt tctgtgaagc ttccccggg gaactttggc 180
ttccctttga tcggcgaaac attacaattg ttgaggcat ttcgatctaa cagactcaa 240
cagttttttg atgagaggca aaaaaaattt ggttgtgtt tcaagacatc actagtcgga 300
gaacgcacgg tagtactctg cggtcctgtt ggaaaccgtt tagtgctcgc caaccagaac 360
aagggtggtg agtcatcgtg gccgagcgct tcatcaaac tcatcgga ggattccatt 420
gccaacacaa acggagagaa gcacgggac ttacgcgcg cactgcttag atatcttggt 480
cccggtcgt tacagaatta tgtggggaat atgaggtcag aaatcgaa tcatatcaat 540
gagaaatgga agggaaaaga tgaagtgaag gtgctcgatt tggtaagaaa gaatgtcttc 600
tccgttgcaa ccgccttggt ttcggtgtn aatgacgagg aaagaaaaag gatccgacct 660
ccatcaatct tgcggaaact gcactttgcg ggcagttttt ctattccgct ggactttcca 720
ggaactagtt atcggagagc tctggaggca cggttgaagc tggataaaat cctctcttct 780
ctgatagaaa ggagaagaag cgatctgcgc tcgggcttg catctggtta tgaggatctg 840
gtctccgtgt tgctcacctt caaagacgaa ggaggaaatc ctctgacaga caaggagatc 900
ctcgataatt tctccgggt acttcacgca tcgtatgaca ccacaacttc agcactcacc 960
ttgacattca agctcatgtc ctctctgct gaatgctatg acaaagtagt tcaagagcaa 1020

```

```

ctgagaatag tttccaataa aaaggaggga gaagaaatca gcttgaaaga tctgaaagac 1080
atgaaatata catggcaagt ggtgcaggaa actctgagga tgttccctcc gcttttcgga 1140
tcatttcgga agaccatcgc cgacattcag tacgatggct atacaattcc aaaaggatgg 1200
aaagttttat gggcaactta taccacacat gggagagatg agtatttcag tgagcccaa 1260
aaattcaggc cttcgagatt cgaagaggga ggaaagcatg tggctcctta cacattcttg 1320
cccttcgaag gaggggagcg cacctgtcca ggatatgaat tttcaaagac tcatatatta 1380
ctgttcaccc accaatttgt taaaactttc actggttaca tcccgttga tccaaacgaa 1440
agcatttcgg cgaatccgct cccccctcta cctgccaatg gatttcctgt aaaacttttt 1500
caaaggtcct aa 1512

```

&lt;210&gt; 51

&lt;211&gt; 1494

&lt;212&gt; DNA

<213> *Taxus cuspidata*

&lt;400&gt; 51

```

atggatagct tcatttttct gagaagcata ggaacaaaat ttgggcagct ggagtcttcc 60
cctgctattc tttcccttac cctcgcacct attctcgcca ttattcttct cttgctcttc 120
cgttacaatc accgatcctc tgttaaaactt ccccttgga agttaggttt tcctctcacc 180
ggggagacca tacaattatt gcggacactc cgatcagaaa cacctcaaaa gttttttgat 240
gatagattga agaaattcgg tcctgtttac atgacttccc taattgggca tcccacagtt 300
gtactctgcg ggctgcggg aaacaaatta gttctttcga acgaggacaa gctggtagag 360
atggaagggc ccaagtcttt catgaaactg attggggaag attccattgt tgctaaaaga 420
ggcgagatc atcgcatctt acgcactgca cttgctcggg ttttgggcgc tcaagcttta 480
caaaattatc tgggtagaat gagttcagaa ataggacacc atttcaatga aaaatggaag 540
ggtaaagatg aagtgaaggt gcttcctttg gtaagagggc ttatcttctc cattgcaagc 600
accctgtttt tcgatgtaaa tgatggacac caacagaagc aacttcatca tcttctggaa 660
actattcttg tgggaagttt gtcagtcctg ctggacttcc caggaaactcg ttatcgtaaa 720
gggcttcagg cgcggtgaa gcttgatgaa attctctcct ctctaataaa acgcagaaga 780
agagatctgc gttcaggcat agcttctgat gatcaagatc tactgtcggg gttgctcacc 840
ttcagagatc aaaaaggga ctcactgaca gaccaggga ttctggacaa cttttctgct 900
atgtttcatg cttcatatga caccactgtt gcaccaatgg ccttgatatt taagcttcta 960
tactccaatc ctgaatacca tgaaaaagta tttcaagagc agttggaaat aattggcaat 1020
aaaaaggaag gggaagaaat cagttggaag gatttgaaat ctatgaaata tacatggcaa 1080
gcagttcaag aatcactacg aatgtaccca ccagtttttg gaatatttcg taaggctatc 1140
actgatattc attatgatgg gtatacaatt ccaaaaggat ggagggtttt atgttcacct 1200
tatactacac atctgagaga agagtacttc cctgagcctg aagaattcag gccttcaaga 1260
tttgaggatg aaggcaggca tgtgactcct tacacatatg taccatttgg aggaggcctg 1320
cgcacatgtc caggatggga attttcaaag attgaaatat tactgtttgt ccatcatttc 1380
gttaaaaatt tcagcagcta cattccagtt gatcccaatg aaaaagtttt atcagatcca 1440
ctacctctc tccttgccaa tggattttcc ataaaacttt ttccgagatc ctaa 1494

```

&lt;210&gt; 52

&lt;211&gt; 1524

&lt;212&gt; DNA

<213> *Taxus cuspidata*

&lt;400&gt; 52

```

atggaaacta aatttgggca acttatgcag ctngagtttc ttccctttat cctcacacct 60
attctcggcg ccctgtttct tctccatctc ttccgtcata gaaaccgac ctctgttaaa 120
cttccacctg gaaagttagg tttcccgcgc attggggaga cgatacagtt cctgagggca 180
cttcgatcac aaacacctca aaagtttttc gatgatagag tgcagaaatt tgggtggtgt 240
ttcaagactt cactaatttg aaatccccta gtggtcatgt gcgggcctgc gggaaaccgg 300
ttagttctgt ccaacgagga caagcttgtg cagttggaag cgcccaatc cttgatgaaa 360
ctgatggggc aggactccct cctggccaaa agacaagagg accaccgcac cttacgtgct 420
gcactagccc ggttttttag ccccaagct ctacanaatt atatgactaa aatcagttca 480
agaaccgaac atcatatgaa tgaaaaatg aagggaaaag atgaagtgag gacgcttct 540
ttgataagag agctcatctt ctccaatgca agcagcttgt ttttcgatat caatgatgag 600
caccaacagg agcgacttca tcatcttttg gaagctgttg ttgttggaag tatgtctatt 660
ccgctggact ttccaggaac tcgcttacgt aaagcccttc aggcgcgatc taagctggat 720
gaaattctct cctctttaat aaaaagcaga agaaaagatc ttgtttcagg gatagcttct 780

```

```

gatgatcaag atctactgtc ggtgttgctc accttcaaag acgagagagg aaatccactg 840
accgacaaag agatcctcga caacttttct cttctgcttc atgcctcgtg tgacaccact 900
gtttcccca tgggttttgac attgaagctc ctctcctcca atccagaatg ctatgaaaaa 960
gtagttcaag agcaattggg aatagttgcc aataaaagg taggagaaga aatcagctgg 1020
aaggatttga aagccatgaa atacacatgg caagtagttc aggaaacact gagaatgttc 1080
cctccacttt ttggatcatt tcgcaaggct atggttgata ttgattatga tggctacaca 1140
attccgaaag gatggatgat tttatggaca acctacggta cacacctgag agaagagtac 1200
ttcaatgaac cggtgaaatt taggccttca agatttgaag aagacgggag tgtgactcct 1260
tacacattca taccattcgg agggagcgcg cgcacatgcc caggatggga attttcaaag 1320
acggagatat tactgttcat ccatcatttt gttagaactt tcagcagcta cctcccagtt 1380
gactccaacg aaaaaatttc agcagatcca ttccctcccc tccctgcca tgggttctcc 1440
ataaaacttt cagcagatcc attccctccc ctccctgcca atgggttctc cataaaactt 1500
tttcccagat ctcaatccaa ttga 1524

```

&lt;210&gt; 53

&lt;211&gt; 1539

&lt;212&gt; DNA

<213> *Taxus cuspidata*

&lt;400&gt; 53

```

atggcttata cggagttgct cgaaaattta tcgggagacc gagctcaatc tccagcaata 60
gccgcggtgc ttacaatttt attcttgttg gggattttct acatactgcg cgggctgaga 120
aacaatggaa gaagattgcc ccccgcccca attccatggc cgatcgtggg aaatctccac 180
cagttgggaa agcttcccaa ccgtaatctg gaagagctcg caaagaaaca cggacccatc 240
atgctcatga aattgggttc cgttcctgcc gttatcgttt cttcctctgc catggcaaaa 300
gaagttctga aaactcatga tctggttttc gccagccgac ccgaaagcgc cgcaggaaaa 360
tacatagcgt ataattacaa ggatatagtt ttctctccct acggacctta ctggagacag 420
atgaagaaaa tatgcgtggt ggaattgttg aatgccagaa gaatcgagtc gttgagatcc 480
gtaagagagg aagaggtgtc tgttataatt cgttcggtgt gggagaagag caagcagggg 540
gcggtcgccg tcaatctgag caagacgctg tcatccctta cacagggact catgttgag 600
atcttttcca gtaacgatga cggcggaat agcagcgtca ccgccattaa agaaatgatg 660
tcggaggtgt ctgagacggc gggagctttt aacattggag attattttcc atggatggac 720
tggtatgatt tgcagggtat acagcggcgc atgacgaagg cacacgatta tttcgaccag 780
gtcattacga aaattataga gcaacaccag aggacgagag cgatggagga cactcaacaa 840
ccaaaagaca taattgacgc cctgttgacg atggagaaca ccgatggcgt caccatcaca 900
atggaaaata tcaaagccgt cgttttgggt atttttctgg gcggagcgga gacgacgtcc 960
actacgttgg aatgggcgat gagcgcgatg cttgaaaacc ctgaggtggc caagaaagtg 1020
caagaagaga tcgaatccgt tgtgggaaga aagaggttgg tgaaagaaat gatctgggaa 1080
agtatggaat acctgcaatg tgtggtgaaa aagacgatga gattatatcc ggcggtgcct 1140
ttgcttatcc cgcacgaatc gacccaagat tgcactgtca atggatactt cattcctgaa 1200
agaaccagaa ttctcgttaa cgcgtgggag ataggaaaag atccaaacgt gtgggatgat 1260
gcgctggcat tcaaaccaaa aagatttttg ggcanaaatg tggacttgca aaaaggaaaa 1320
gagtttttgc atatggttcc ctttgggtgc ggaaggaaaag gatgccaggg ggcaagcatg 1380
gccgttgtga cgatggaaca tgcgttggca caactcatgc actgcttcca gtggcgcatt 1440
gaaggagagt tggatatgag tgaacgcttg gcagcctccg tgcaaaaaaa agtcgatctt 1500
tgtgttcttc cccaatggag gctaactagt agcccctga 1539

```

&lt;210&gt; 54

&lt;211&gt; 1530

&lt;212&gt; DNA

<213> *Taxus cuspidata*

&lt;400&gt; 54

```

atggatgtct tttatccgtt aaaaagtaca gtagcaaaat ttaacgaatg tttccctgct 60
attcttttca ttgtcctcag tgctgttgct ggcattgttc tgcccctgct gctgttccta 120
cgttcttaaa gccgttcttc tgttggaact cccccaggga aattaggtta ccttttcatt 180
ggcgagtcgt tactgttctt gaaggctctt cgatcaaaaca cagttgaaca atttttgag 240
gagagagtga agaatttcgg gaatgtcttc aagacgtcat taattgggca tccgacagta 300
gttctctgag gccctgcagg aaaccggcta atcctggcga acgaggagaa gctggtgcag 360
atgtcgtggc ccaaatcctc tatgaaactc atgggggaga agtctattac tgccaaaagg 420
ggcgaaggcc atatgatcat ccgctccgca ctgcaaggct ttttcagccc tgggtgctctg 480

```

```

cagaaataca taggccaat gagtaaaaca atagaaaatc atattaatga gaaatggaag 540
ggaacgacc aagtgaagt agttgctttg gtaggagatc tcgtcttcga tatttcggcc 600
tgtttgttct tcaatataaa tgagaagcat gaacgggaac gactgtttga gcttttgag 660
attatagctg tcggagtttt ggctgttccg gtggatcttc ccgggtttgc ttaccatcgg 720
gcacttcaag cacggtcgaa gcttaatgca attctctccg gtttgataga aaagagaaaa 780
atggatctga gctcaggatt agcgactagc aatcaggatc ttctttctgt gtttctcacc 840
ttcaaagatg acagaggaaa tccatgcagc gatgaggaaa tcctcgacaa cttttccggg 900
ctgcttcatg gatcctatga caccactgtt tcagcaatgg cctgcgtttt taagcttttg 960
tcttccaatc ccgaatgcta tgaaaaagta gttcaagagc aattggggat actttcgaat 1020
aaattggaag gagacgaaat cacatggaaa gatgtgaaat ccatgaaata tacatggcaa 1080
gtcgttcagg aaacgttacg attgtatccg tcaatttttg gatcatttcg ccaggccatc 1140
actgacattc attataatgg ttacataatt ccaaaagggg ggaagctttt gtggacacca 1200
tacacaacac atcccaagga aatgtatttc agtgagccgg agaaattcct gccttcgag 1260
ttcgatcagg aagggaaact tgtagctcct tacacatttt taccctttgg tggaggccag 1320
cgttcatgct caggatggga attttcaaag atggagattt tactgtcggg gcatcatttt 1380
gttaaaacat tcagcacctt caccacagtt gaccagcag aaataattgc aagagattcc 1440
ctctgccctc tcccttccaa tgggttttct gtaaaacttt ttcttagatc ctattcactt 1500
cacacaggca accaggtcaa gaaaataaa 1530

```

&lt;210&gt; 55

&lt;211&gt; 1545

&lt;212&gt; DNA

<213> *Taxus cuspidata*

&lt;400&gt; 55

```

atggcattcg aagcagctac tgttattctt ttcactctgg ctgccctgtt gctagtcgtc 60
atacagcgcc gtagaattag aaggcacaaa ttgcaggga aggtgaaggc accacaacct 120
ccttcatggc ccgttattgg gaatcttcat ctgcttaac agaaagtgcc tattcaccga 180
attctatctt cgctttcgga gagctatgga ccaatcatgc atcttcaact cgggtctccga 240
ccagctttgg ttattgcctc ttcagatctg gcgaaagaat gcttcacaac aaatgacaaa 300
gccttcgctt ctgcgccacg tctgtctgca ggaaagcatg taggatatga ctacaaaatc 360
ttcagtatgg ctcttacgg ttcctactgg cgaaaccttc ggaaaatgtg cacgatccag 420
atcctctctg caaccagaat tgactccttc agacacatcc gcgtagagga agtttctgct 480
ctcattegtt cgttgtttga cagttgccag cgaggagaca ctccagtcaa catgaaagcg 540
aggctctctg atttcacgtt tagtatcatc ctccgtatgg ttgccaacaa gaaattatca 600
ggacctgttt attccgagga atacgaagaa gcggatcatt ttaaccagat gataaaacag 660
tctgtgttct tacttgagc atttgagggt ggagatttcc tgccgtttct caagtggctt 720
gatcttcagg gtttcatagc tgctatgaaa aaactgcagc agaaaagaga tgtctttatg 780
cagaaattgg tgattgatca ccgtgagaag agaggagag tcgatgcaa tgcacaagac 840
ttaattgatg ttctcatctc tgcaacagac aaccatgaaa ttcagtccga tagtaacgac 900
gatgttgatg aagccaccgc ccttacaatg ctgaacgcag gtacagatac atcctcgggtg 960
accatcgaat gggcattggc ggctctgatg cagcacctc atattttgag caaagccag 1020
caggagctcg acacgcatac cggacgcagc cgattactag aggaagcaga tctgcacgag 1080
ctgaaatatt tgcaggcaat tgtgaaagaa acgttgaggc tatatccagc cgcacctctc 1140
ttagttcctc acgaagccat tgaggattgc actgttgagg ggtaccatgt ctccgcagga 1200
acgcgactga ttgtgaatgc ttgggcaatt cacagagacc cggcagtgtg ggaacggccg 1260
accgtgttcg atcctgaacg gtttttgaag agcggaaaag aggttgacgt aaaagggcgg 1320
gagtttgaat tgattccgtt tggttcaggg agaagaatgt gtccgggcat gagtctggca 1380
ttgagtgttg ttacgtatac gctggggagg ctgctgcaga gcttcgagtg gtctgttcca 1440
gaaggtatga taattgacat gacggaaggt ttgggactca caatgcccaa agcagttccg 1500
ttggagacca ttatcaaacc tcgccttccc ttccatctct actga 1545

```

&lt;210&gt; 56

&lt;211&gt; 484

&lt;212&gt; PRT

<213> *Taxus cuspidata*

&lt;400&gt; 56

Met Asp Thr Phe Ile Gln His Glu Ser Ser Pro Leu Leu Leu Ser Leu

1

5

10

15

Thr Leu Ala Val Ile Leu Gly Thr Ile Leu Leu Leu Ile Leu Ser Gly  
 20 25 30  
 Lys Gln Tyr Arg Ser Ser Arg Lys Leu Pro Pro Gly Asn Met Gly Phe  
 35 40 45  
 Pro Leu Ile Gly Glu Thr Ile Ala Leu Ile Ser Asp Thr Pro Arg Lys  
 50 55 60  
 Phe Ile Asp Asp Arg Val Lys Lys Phe Gly Leu Val Phe Lys Thr Ser  
 65 70 75 80  
 Leu Ile Gly His Pro Ala Val Val Ile Cys Gly Ser Ser Ala Asn Arg  
 85 90 95  
 Phe Leu Leu Ser Asn Glu Glu Lys Leu Val Arg Met Ser Leu Pro Asn  
 100 105 110  
 Ala Val Leu Lys Leu Leu Gly Gln Asp Cys Val Met Gly Lys Thr Gly  
 115 120 125  
 Val Glu His Gly Ile Val Arg Thr Ala Leu Ala Arg Ala Leu Gly Pro  
 130 135 140  
 Gln Ala Leu Gln Asn Tyr Val Ala Lys Met Ser Ser Glu Ile Glu His  
 145 150 155 160  
 His Ile Asn Gln Lys Trp Lys Gly Lys Asp Glu Val Lys Val Leu Pro  
 165 170 175  
 Leu Ile Arg Ser Leu Val Phe Ser Ile Ser Thr Ser Leu Phe Phe Gly  
 180 185 190  
 Ile Asn Asp Glu His Gln Gln Lys Arg Leu His His Leu Leu Glu Thr  
 195 200 205  
 Val Ala Met Gly Leu Val Ser Ile Pro Leu Asp Phe Pro Gly Thr Arg  
 210 215 220  
 Phe Arg Lys Ala Leu Tyr Ala Arg Ser Lys Leu Asp Glu Ile Met Ser  
 225 230 235 240  
 Ser Val Ile Glu Arg Arg Arg Ser Asp Leu Arg Ser Gly Ala Ala Ser  
 245 250 255  
 Ser Asp Gln Asp Leu Leu Ser Val Leu Val Thr Phe Lys Asp Glu Arg  
 260 265 270  
 Gly Asn Ser Phe Ala Asp Lys Glu Ile Leu Asp Asn Phe Ser Phe Leu  
 275 280 285  
 Leu His Ala Leu Tyr Asp Thr Thr Ile Ser Pro Leu Thr Leu Ile Phe  
 290 295 300  
 Lys Leu Leu Ser Ser Ser Pro Glu Cys Tyr Glu Asn Ile Ala Gln Glu  
 305 310 315 320  
 Gln Leu Glu Ile Leu Gly Asn Lys Lys Asp Arg Glu Glu Ile Ser Trp  
 325 330 335  
 Lys Asp Leu Lys Asp Met Lys Tyr Thr Trp Gln Ala Val Gln Glu Thr



340 345 350  
 Leu Arg Met Phe Pro Pro Val Tyr Gly Tyr Ile Arg Glu Ala Leu Thr  
 355 360 365  
 Asp Ile Asp Tyr Asp Gly Tyr Thr Ile Pro Lys Gly Trp Arg Ile Leu  
 370 375 380  
 Cys Ser Pro His Thr Thr His Ser Lys Glu Glu Tyr Phe Asp Glu Pro  
 385 390 395 400  
 Glu Glu Phe Arg Pro Ser Arg Phe Glu Asp Gln Gly Arg His Val Ala  
 405 410 415  
 Pro Tyr Thr Phe Ile Pro Phe Gly Gly Gly Leu Arg Ile Cys Ala Gly  
 420 425 430  
 Trp Glu Phe Ala Lys Met Glu Ile Leu Leu Phe Met His His Phe Val  
 435 440 445  
 Lys Thr Phe Ser His Phe Ile Pro Val Asp Pro Asn Glu Lys Ile Ser  
 450 455 460  
 Arg Asp Pro Leu Pro Pro Ile Pro Val Lys Gly Phe Ser Ile Lys Pro  
 465 470 475 480  
 Phe Pro Arg Ser

<210> 57  
 <211> 484  
 <212> PRT  
 <213> *Taxus cuspidata*

<400> 57  
 Met Leu Ile Glu Met Asp Thr Phe Val Gln Leu Glu Ser Ser Pro Val  
 1 5 10 15  
 Leu Leu Ser Leu Thr Leu Thr Leu Ile Leu Leu Phe Ile Phe Cys Ser  
 20 25 30  
 Lys Gln Tyr Arg Ser Ser Leu Lys Leu Pro Pro Gly Asn Met Gly Phe  
 35 40 45  
 Pro Leu Ile Gly Glu Thr Ile Ala Leu Ala Ser Gln Thr Pro Asp Lys  
 50 55 60  
 Phe Phe Gly Asp Arg Met Lys Lys Phe Gly Lys Val Phe Lys Thr Ser  
 65 70 75 80  
 Leu Ile Gly His Pro Thr Ile Val Leu Cys Gly Ser Ser Gly Asn Arg  
 85 90 95  
 Phe Leu Leu Ser Asn Glu Glu Lys Leu Val Arg Met Phe Pro Pro Asn  
 100 105 110  
 Ser Ser Ser Lys Leu Leu Gly Gln Asp Ser Val Leu Gly Lys Ile Gly  
 115 120 125  
 Glu Glu His Arg Ile Val Arg Thr Ala Leu Ala Arg Cys Leu Gly Pro

130										135										140									
Gln	Ala	Leu	Gln	Asn	Tyr	Val	Ser	Lys	Met	Ser	Ser	Glu	Ile	Gln	Arg														
145					150					155					160														
His	Ile	Asn	Gln	Lys	Trp	Lys	Gly	Lys	Gly	Glu	Val	Lys	Met	Leu	Pro														
				165					170					175															
Leu	Ile	Arg	Ser	Leu	Val	Phe	Ser	Ile	Ala	Thr	Ser	Leu	Phe	Phe	Gly														
			180					185					190																
Ile	Thr	Asp	Glu	Gln	Gln	Gln	Glu	Arg	Leu	His	His	Leu	Leu	Glu	Thr														
		195					200					205																	
Val	Val	Thr	Gly	Leu	Leu	Cys	Ile	Pro	Leu	Asp	Phe	Pro	Gly	Thr	Thr														
		210				215					220																		
Phe	Arg	Lys	Ala	Leu	His	Ala	Arg	Ser	Lys	Leu	Asp	Glu	Ile	Met	Ser														
225					230					235				240															
Ser	Val	Ile	Glu	Arg	Arg	Arg	Asn	Asp	Leu	Arg	Leu	Gly	Ala	Ala	Ser														
				245					250					255															
Ser	Asp	Gln	Asp	Leu	Leu	Ser	Val	Leu	Leu	Thr	Phe	Lys	Asp	Glu	Arg														
			260					265					270																
Gly	Asn	Pro	Phe	Ala	Asp	Lys	Glu	Ile	Leu	Asp	Asn	Phe	Ser	Phe	Leu														
		275					280				285																		
Leu	His	Ala	Leu	Tyr	Asp	Thr	Thr	Ile	Ser	Pro	Leu	Thr	Leu	Val	Phe														
		290				295					300																		
Lys	Leu	Val	Ser	Ser	Asn	Pro	Glu	Cys	Tyr	Glu	Asn	Ile	Ala	Gln	Glu														
305					310					315				320															
Gln	Leu	Glu	Ile	Leu	Arg	Asn	Lys	Lys	Asp	Gly	Glu	Asp	Ile	Ser	Trp														
				325					330					335															
Ala	Asp	Leu	Lys	Asp	Met	Lys	Tyr	Thr	Trp	Gln	Ala	Val	Gln	Glu	Thr														
			340					345					350																
Leu	Arg	Met	Cys	Pro	Pro	Val	Tyr	Gly	Asn	Phe	Arg	Lys	Ala	Leu	Thr														
		355					360					365																	
Asp	Ile	His	Tyr	Asp	Gly	Tyr	Thr	Ile	Pro	Lys	Gly	Trp	Arg	Ile	Leu														
		370				375					380																		
Cys	Ser	Pro	Tyr	Thr	Thr	His	Ser	Lys	Glu	Glu	Tyr	Phe	Asp	Asp	Pro														
385					390					395				400															
Glu	Lys	Phe	Arg	Pro	Ser	Arg	Phe	Glu	Glu	Gln	Gly	Arg	Asp	Val	Ala														
				405				410						415															
Pro	Tyr	Thr	Phe	Ile	Pro	Phe	Gly	Gly	Gly	Leu	Arg	Ile	Cys	Pro	Gly														
			420					425					430																
Arg	Glu	Phe	Ala	Lys	Met	Glu	Ile	Leu	Val	Phe	Met	His	His	Phe	Val														
		435					440					445																	
Lys	Ala	Phe	Ser	Ser	Phe	Ile	Pro	Val	Asp	Pro	Asn	Glu	Lys	Ile	Ser														
		450				455					460																		

Thr Asp Pro Leu Pro Ser Ile Pro Val Asn Gly Phe Ser Ile Asn Leu  
 465 470 475 480

Val Pro Arg Ser

<210> 58

<211> 501

<212> PRT

<213> Taxus cuspidata

<400> 58

Met Asp Ser Phe Ser Phe Leu Lys Ser Met Glu Ala Lys Phe Gly Gln  
 1 5 10 15

Val Ile His Arg Asp Gln Ser Ser Ser Thr Ala Leu Leu Ser Leu Ala  
 20 25 30

Phe Thr Ala Ala Val Ala Ile Phe Leu Val Leu Leu Phe Arg Phe Lys  
 35 40 45

Ser Arg Pro Ser Thr Asn Phe Pro Pro Gly Asn Phe Gly Phe Pro Phe  
 50 55 60

Ile Gly Glu Thr Ile Gln Phe Leu Arg Ala Leu Arg Ser Glu Ser Pro  
 65 70 75 80

His Met Phe Phe Asp Glu Arg Leu Lys Lys Phe Gly Arg Val Phe Lys  
 85 90 95

Thr Ser Leu Thr Gly His Pro Thr Ala Val Phe Cys Gly Pro Ala Gly  
 100 105 110

Asn Arg Phe Ile Tyr Ser Asn Glu His Lys Leu Val Gln Ser Ser Gly  
 115 120 125

Pro Asn Ser Phe Val Lys Leu Val Gly Gln Gln Ser Ile Val Thr Lys  
 130 135 140

Thr Gly Glu Glu His Arg Ile Phe Leu Gly Val Leu Asn Glu Phe Leu  
 145 150 155 160

Gly Pro His Ala Leu Gln Ser Tyr Thr Pro Lys Met Ser Ser Lys Ile  
 165 170 175

Gln Glu Asn Ile Asn Lys His Trp Lys Gly Lys Asp Glu Val Asn Met  
 180 185 190

Leu Pro Ser Ile Arg Gln Leu Val Phe Ser Ile Ser Ser Ser Leu Phe  
 195 200 205

Phe Asp Ile Asn Asp Glu Asp Gln Gln Glu Gln Leu Lys Thr Leu Leu  
 210 215 220

Glu Thr Ile Leu Val Gly Thr Leu Ser Val Pro Leu Asp Ile Pro Gly  
 225 230 235 240

Ser Asn Phe Arg Lys Ala Leu Arg Ala Arg Ser Lys Leu Asp Glu Ile  
 245 250 255

Leu Ser Arg Leu Ile Glu Ser Arg Arg Lys Asp Met Arg Ser Gly Ile  
 260 265 270  
 Ala Ser Thr Ser Lys Asn Leu Leu Ser Val Leu Leu Ala Phe Lys Asp  
 275 280 285  
 Glu Arg Gly Asn Pro Leu Thr Asp Thr Glu Ile Leu Asp Asn Phe Ser  
 290 295 300  
 Phe Met Leu His Ala Ser Tyr Asp Thr Thr Val Ser Pro Thr Val Cys  
 305 310 315 320  
 Ile Phe Lys Leu Leu Ser Ala Asn Pro Glu Cys Tyr Glu Lys Val Val  
 325 330 335  
 Gln Glu Gln Leu Gly Ile Leu Gly Asn Lys Lys Asp Gly Glu Glu Met  
 340 345 350  
 Cys Trp Asn Asp Leu Lys Ala Met Lys Tyr Thr Trp Gln Ala Ala Gln  
 355 360 365  
 Glu Thr Met Arg Leu Phe Pro Pro Ala Phe Gly Ser Phe Arg Lys Val  
 370 375 380  
 Ile Ala Asp Ile His His Asp Gly Tyr Ile Ile Pro Lys Gly Trp Lys  
 385 390 395 400  
 Ala Met Val Thr Asn Tyr Ser Thr Ser Arg Lys Glu Glu Tyr Phe Asp  
 405 410 415  
 Glu Pro Asp Asn Phe Lys Pro Ser Arg Phe Gly Asp Gly Lys Tyr Val  
 420 425 430  
 Ala Pro Tyr Thr Phe Leu Pro Phe Gly Ala Gly Ile Arg Ile Cys Pro  
 435 440 445  
 Gly Trp Glu Phe Ala Lys Leu Glu Met Leu Leu Phe Ile His His Phe  
 450 455 460  
 Val Lys Asn Phe Ser Gly Tyr Leu Pro Leu Asp Thr Lys Glu Lys Ile  
 465 470 475 480  
 Ser Gly Asp Pro Phe Pro Pro Leu Pro Lys Asn Gly Phe Pro Ile Lys  
 485 490 495  
 Leu Phe Pro Arg Thr  
 500

&lt;210&gt; 59

&lt;211&gt; 500

&lt;212&gt; PRT

&lt;213&gt; Taxus cuspidata

&lt;400&gt; 59

Met Asp Ala Leu Ser Leu Val Asn Ser Thr Val Ala Lys Phe Asn Glu  
 1 5 10 15

Val Thr Gln Leu Gln Ala Ser Pro Ala Ile Leu Ser Thr Ala Leu Thr  
 20 25 30

Ala Ile Ala Gly Ile Ile Val Leu Leu Val Ile Thr Ser Lys Arg Arg  
 35 40 45  
 Ser Ser Leu Lys Leu Pro Pro Gly Lys Leu Gly Leu Pro Phe Ile Gly  
 50 55 60  
 Glu Thr Leu Glu Phe Val Lys Ala Leu Arg Ser Asp Thr Leu Arg Gln  
 65 70 75 80  
 Phe Val Glu Glu Arg Glu Gly Lys Phe Gly Arg Val Phe Lys Thr Ser  
 85 90 95  
 Leu Leu Gly Lys Pro Thr Val Ile Leu Cys Gly Pro Ala Gly Asn Arg  
 100 105 110  
 Leu Val Leu Ser Asn Glu Glu Lys Leu Leu His Val Ser Trp Ser Ala  
 115 120 125  
 Gln Ile Ala Arg Ile Leu Gly Leu Asn Ser Val Ala Val Lys Arg Gly  
 130 135 140  
 Asp Asp His Arg Val Leu Arg Val Ala Leu Ala Gly Phe Leu Gly Ser  
 145 150 155 160  
 Ala Gly Leu Gln Leu Tyr Ile Gly Lys Met Ser Ala Leu Ile Arg Asn  
 165 170 175  
 His Ile Asn Glu Lys Trp Lys Gly Lys Asp Glu Val Asn Val Leu Ser  
 180 185 190  
 Leu Val Arg Asp Leu Val Met Asp Asn Ser Ala Ile Leu Phe Phe Asn  
 195 200 205  
 Ile Tyr Asp Lys Glu Arg Lys Gln Gln Leu His Glu Ile Leu Lys Ile  
 210 215 220  
 Ile Leu Ala Ser His Phe Gly Ile Pro Leu Asn Ile Pro Gly Phe Leu  
 225 230 235 240  
 Tyr Arg Lys Ala Leu Lys Gly Ser Leu Lys Arg Lys Lys Ile Leu Ser  
 245 250 255  
 Ala Leu Leu Glu Lys Arg Lys Asp Glu Leu Arg Ser Arg Leu Ala Ser  
 260 265 270  
 Ser Asn Gln Asp Leu Leu Ser Val Leu Leu Ser Phe Arg Asp Glu Arg  
 275 280 285  
 Gly Lys Pro Leu Ser Asp Glu Ala Val Leu Asp Asn Cys Phe Ala Met  
 290 295 300  
 Leu Asp Ala Ser Tyr Asp Thr Thr Thr Ser Gln Met Thr Leu Ile Leu  
 305 310 315 320  
 Lys Met Leu Ser Ser Asn Pro Glu Cys Phe Glu Lys Val Val Gln Glu  
 325 330 335  
 Gln Leu Glu Ile Ala Ser Asn Lys Lys Glu Gly Glu Glu Ile Thr Met  
 340 345 350

Lys Asp Ile Lys Ala Met Lys Tyr Thr Trp Gln Val Leu Gln Glu Ser  
 355 360 365  
 Leu Arg Met Leu Ser Pro Val Phe Gly Thr Leu Arg Lys Thr Met Asn  
 370 375 380  
 Asp Ile Asn His Asp Gly Tyr Thr Ile Pro Lys Gly Trp Gln Val Val  
 385 390 395 400  
 Trp Thr Thr Tyr Ser Thr His Gln Lys Asp Ile Tyr Phe Lys Gln Pro  
 405 410 415  
 Asp Lys Phe Met Pro Ser Arg Phe Glu Glu Glu Asp Gly His Leu Asp  
 420 425 430  
 Ala Tyr Thr Phe Val Pro Phe Gly Gly Gly Arg Arg Thr Cys Pro Gly  
 435 440 445  
 Trp Glu Tyr Ala Lys Val Glu Ile Leu Leu Phe Leu His His Phe Val  
 450 455 460  
 Lys Ala Phe Ser Gly Tyr Thr Pro Thr Asp Pro His Glu Arg Ile Cys  
 465 470 475 480  
 Gly Tyr Pro Val Pro Leu Val Pro Val Lys Gly Phe Pro Ile Lys Leu  
 485 490 495  
 Ile Ala Arg Ser  
 500

&lt;210&gt; 60

&lt;211&gt; 492

&lt;212&gt; PRT

&lt;213&gt; Taxus cuspidata

&lt;400&gt; 60

Met Asp Thr Ile Arg Ala Ser Phe Gly Glu Val Ile Gln Pro Glu Tyr  
 1 5 10 15  
 Ser Pro Leu Ile Ile Ser Xaa Ala Leu Ala Ala Phe Leu Gly Ile Val  
 20 25 30  
 Ile Phe Ser Ile Phe Ser Ser Thr Arg Arg Ser Tyr Val Asn Leu Pro  
 35 40 45  
 Pro Gly Asn Leu Gly Leu Pro Phe Ile Gly Glu Thr Ile Gln Phe Leu  
 50 55 60  
 Gly Ala Leu Gln Ser Glu Lys Pro His Thr Phe Phe Asp Glu Arg Val  
 65 70 75 80  
 Lys Lys Phe Gly Lys Val Phe Lys Thr Ser Leu Ile Gly Asp Pro Thr  
 85 90 95  
 Val Val Leu Cys Gly Pro Ala Gly Asn Arg Leu Val Leu Ser Asn Glu  
 100 105 110  
 Asp Lys Leu Val Gln Ser Ala Gly Pro Lys Ser Phe Leu Lys Leu Phe  
 115 120 125

Gly Glu Asp Ser Val Ala Ala Lys Arg Glu Glu Ser His Arg Ile Leu  
 130 135 140  
 Arg Ser Ala Leu Gly Arg Phe Leu Gly Pro His Ala Leu Gln Asn Tyr  
 145 150 155 160  
 Ile Gly Lys Met Asn Ser Glu Met Gln Arg His Phe Asp Asp Lys Trp  
 165 170 175  
 Lys Gly Lys Asp Glu Val Lys Val Leu Pro Leu Val Arg Gly Leu Ile  
 180 185 190  
 Phe Ser Ile Ala Thr Ser Leu Phe Phe Asn Ile Asn Asp Asp Arg Gln  
 195 200 205  
 Arg Glu Gln Leu His Gly Leu Leu Asp Thr Ile Leu Val Gly Ser Met  
 210 215 220  
 Thr Ile Pro Leu Asn Ile Pro Gly Thr Leu Phe Arg Lys Ala Val Lys  
 225 230 235 240  
 Ala Arg Ala Lys Leu Asp Glu Ile Leu Phe Ala Leu Ile Glu Asn Arg  
 245 250 255  
 Arg Arg Glu Leu Arg Ser Gly Leu Asn Ser Gly Asn Gln Asp Leu Leu  
 260 265 270  
 Ser Ser Leu Leu Thr Phe Lys Asp Glu Lys Gly Asn Pro Leu Thr Asp  
 275 280 285  
 Lys Glu Ile Leu Asp Asn Phe Ser Val Met Leu His Ala Ser Tyr Asp  
 290 295 300  
 Thr Thr Val Ser Pro Thr Val Leu Ile Leu Lys Leu Leu Ala Ser Asn  
 305 310 315 320  
 Pro Glu Cys Tyr Glu Lys Val Val Gln Glu Gln Leu Gly Ile Leu Ala  
 325 330 335  
 Ser Lys Lys Glu Gly Glu Glu Val Asn Trp Lys Asp Leu Lys Ala Met  
 340 345 350  
 Pro Tyr Thr Trp Gln Ala Ile Gln Glu Pro Leu Xaa Met Pro Xaa Gln  
 355 360 365  
 Leu Leu Glu Cys Phe Glu Glu Leu Ser Leu Ile Phe Ser Trp Lys Ala  
 370 375 380  
 Ile Gln Phe Gln Lys Asp Gly Gln Leu Cys Gly Xaa Leu Ile Val Asn  
 385 390 395 400  
 Gly Arg Glu Glu Phe Phe Asn Glu Pro Asp Lys Phe Lys Pro Ser Arg  
 405 410 415  
 Phe Glu Glu Gly Lys Pro Leu Asp Pro Tyr Thr Phe Ile Pro Phe Gly  
 420 425 430  
 Ala Gly Val Arg Ile Cys Ala Gly Trp Glu Phe Ala Lys Ala Glu Leu  
 435 440 445  
 Leu Leu Phe Val His Pro Phe Val Lys Asn Phe Ser Gly Cys Ile Ile

450                      455                      460  
 Ile Asp Pro Asn Glu Lys Ile Ser Gly Asp Pro Phe Pro Pro Leu Pro  
 465                      470                      475                      480  
 Thr Ser Gly Gln Leu Met Lys Leu Ile Pro Arg Ser  
                     485                      490  
  
 <210> 61  
 <211> 500  
 <212> PRT  
 <213> Taxus cuspidata  
  
 <400> 61  
 Met Asp Ser Phe Asn Phe Leu Arg Gly Ile Gly Ala Asp Phe Gly Gly  
   1                      5                      10                      15  
 Phe Ile Gln Phe Gln Ser Ser Pro Ala Val Leu Ser Leu Ser Leu Ile  
                     20                      25                      30  
 Thr Thr Ile Leu Gly Val Leu Leu Leu Trp Phe Phe Leu His Lys Asn  
                     35                      40                      45  
 Gly Ser Ser Val Thr Leu Pro Pro Gly Asn Leu Gly Phe Pro Phe Ile  
                     50                      55                      60  
 Gly Glu Thr Ile Pro Phe Leu Arg Ala Leu Arg Ser Glu Thr Pro Gln  
   65                      70                      75                      80  
 Thr Phe Phe Asp Glu Arg Val Lys Lys Phe Gly Val Val Phe Lys Thr  
                     85                      90                      95  
 Arg Ile Val Gly His Pro Thr Val Val Leu Cys Gly Pro Glu Gly Asn  
                     100                      105                      110  
 Arg Phe Leu Leu Ser Asn Glu Asp Lys Leu Val Gln Ala Ser Leu Pro  
                     115                      120                      125  
 Asn Ser Ser Glu Lys Leu Ile Gly Lys Tyr Ser Ile Leu Ser Lys Arg  
   130                      135                      140  
 Gly Glu Glu His Arg Ile Leu Arg Ala Ala Leu Ala Arg Phe Leu Arg  
   145                      150                      155                      160  
 Pro Gln Ala Leu Gln Gly Tyr Val Ala Lys Met Ser Ser Glu Ile Gln  
                     165                      170                      175  
 His His Ile Lys Gln Lys Trp Lys Gly Asn Asp Glu Val Lys Val Leu  
                     180                      185                      190  
 Pro Leu Ile Arg Thr Leu Ile Phe Asn Ile Ala Ser Ser Leu Phe Phe  
                     195                      200                      205  
 Gly Ile Asn Asp Glu His Gln Gln Glu Gln Leu His His Leu Leu Glu  
   210                      215                      220  
 Ala Ile Val Leu Gly Ser Leu Ser Val Pro Leu Asp Phe Pro Gly Thr  
   225                      230                      235                      240  
 Arg Phe Arg Lys Ala Leu Asp Ala Arg Ser Lys Leu Asp Glu Ile Leu



245	250	255
Ser Ser Leu Met Glu Ser Arg Arg Arg Asp Leu Arg Leu Gly Thr Ala 260 265 270		
Ser Glu Asn Gln Asp Leu Leu Ser Val Leu Leu Thr Phe Lys Asp Glu 275 280 285		
Arg Gly Asn Pro Leu Thr Asp Lys Glu Ile Phe Asp Asn Phe Ser Phe 290 295 300		
Met Leu His Ala Ser Tyr Asp Thr Thr Val Ser Pro Thr Gly Leu Met 305 310 315 320		
Leu Lys Leu Leu Phe Ser Ser Pro Asp Cys Tyr Glu Lys Leu Val Gln 325 330 335		
Glu Gln Leu Gly Ile Val Gly Asn Lys Lys Glu Gly Glu Glu Ile Ser 340 345 350		
Trp Asn Asp Leu Lys Ala Met Lys Tyr Thr Cys Lys Val Val Gln Glu 355 360 365		
Ser Met Arg Met Leu Pro Pro Val Phe Gly Ser Tyr Arg Lys Ala Xaa 370 375 380		
Thr Tyr Ile His Tyr Asp Gly Tyr Thr Ile Pro Lys Gly Trp Asn Ile 385 390 395 400		
Phe Trp Ser Pro Tyr Thr Thr His Gly Lys Glu Glu Tyr Phe Asn Glu 405 410 415		
Ala Asp Lys Phe Met Pro Ser Arg Phe Glu Glu Gly Lys Tyr Val Ala 420 425 430		
Pro Tyr Thr Phe Leu Pro Phe Gly Ala Gly Leu Arg Val Cys Pro Gly 435 440 445		
Trp Glu Phe Ala Lys Thr Glu Ile Leu Leu Phe Val His His Phe Ile 450 455 460		
Thr Thr Phe Ser Ser Tyr Ile Pro Ile Asp Pro Lys Asp Lys Ile Ser 465 470 475 480		
Gly Asp Pro Phe Pro Pro Leu Pro Thr Asn Gly Phe Ser Met Lys Leu 485 490 495		
Phe Thr Arg Ser 500		

&lt;210&gt; 62

&lt;211&gt; 483

&lt;212&gt; PRT

&lt;213&gt; Taxus cuspidata

&lt;400&gt; 62

Met	Asp	Thr	Leu	Ile	Gln	Ile	Gln	Ser	Ser	Pro	Asp	Phe	Leu	Ser	Phe
1				5				10					15		

Thr Leu Thr Ala Phe Leu Gly Val Val Val Leu Leu Ile Phe Arg Tyr

20										25					30															
Lys	His	Arg	Ser	Ala	Leu	Lys	Leu	Pro	Pro	Gly	Asn	Leu	Gly	Leu	Pro															
		35					40					45																		
Phe	Ile	Gly	Glu	Thr	Ile	Thr	Phe	Ala	Ser	Gln	Pro	Pro	Gln	Lys	Phe															
	50					55					60																			
Leu	Asn	Glu	Arg	Gly	Lys	Lys	Phe	Gly	Pro	Val	Phe	Lys	Thr	Ser	Leu															
65					70					75					80															
Ile	Gly	His	Pro	Thr	Val	Val	Leu	Cys	Gly	Ser	Ser	Gly	Asn	Arg	Phe															
				85				90					95																	
Leu	Leu	Ser	Asn	Glu	Glu	Lys	Leu	Val	Arg	Met	Ser	Leu	Pro	Asn	Ser															
		100					105					110																		
Tyr	Met	Lys	Leu	Leu	Gly	Gln	Asp	Ser	Leu	Leu	Gly	Lys	Thr	Gly	Gln															
	115					120					125																			
Glu	His	Arg	Ile	Val	Arg	Thr	Ala	Leu	Gly	Arg	Phe	Leu	Gly	Pro	Gln															
	130				135					140																				
Glu	Leu	Gln	Asn	His	Val	Ala	Lys	Met	Ser	Ser	Asp	Ile	Gln	His	His															
145				150				155					160																	
Ile	Asn	Gln	Lys	Trp	Lys	Gly	Asn	Asp	Glu	Val	Lys	Val	Leu	Pro	Leu															
		165				170							175																	
Ile	Arg	Asn	Leu	Val	Phe	Ser	Ile	Ala	Thr	Ser	Leu	Phe	Phe	Gly	Ile															
	180				185							190																		
Asn	Asp	Glu	His	Gln	Gln	Glu	Arg	Leu	His	Leu	Leu	Leu	Glu	Thr	Ile															
	195				200						205																			
Val	Met	Gly	Ala	Val	Cys	Ile	Pro	Leu	Ala	Phe	Pro	Gly	Ser	Gly	Phe															
	210				215					220																				
Arg	Lys	Ala	Leu	Gln	Ala	Arg	Ser	Glu	Leu	Asp	Gly	Ile	Leu	Ile	Ser															
225				230				235					240																	
Leu	Met	Lys	Ile	Arg	Arg	Ser	Asp	Leu	Arg	Ser	Gly	Ala	Ala	Ser	Ser															
		245				250							255																	
Asn	Gln	Asp	Leu	Leu	Ser	Val	Leu	Leu	Thr	Phe	Lys	Asp	Glu	Arg	Gly															
	260				265							270																		
Asn	Pro	Leu	Thr	Asp	Lys	Glu	Ile	Leu	Asp	Asn	Phe	Ser	Val	Leu	Leu															
	275				280						285																			
His	Gly	Leu	Tyr	Asp	Thr	Thr	Ile	Ser	Pro	Leu	Thr	Leu	Ile	Phe	Lys															
	290				295					300																				
Leu	Met	Ser	Ser	Asn	Thr	Glu	Cys	Tyr	Glu	Asn	Val	Val	Gln	Glu	Gln															
305				310				315					320																	
Leu	Glu	Ile	Leu	Ser	His	Arg	Glu	Lys	Gly	Glu	Glu	Ile	Gly	Trp	Lys															
		325				330							335																	
Asp	Leu	Lys	Ser	Met	Lys	Tyr	Thr	Trp	Gln	Ala	Ile	Gln	Glu	Thr	Leu															
	340					345						350																		

Arg Met Phe Pro Pro Val Tyr Gly Asn Phe Arg Lys Ala Leu Thr Asp  
 355 360 365  
 Ile His Tyr Asp Gly Tyr Thr Ile Pro Lys Gly Trp Arg Val Leu Cys  
 370 375 380  
 Ser Pro Phe Thr Thr His Ser Asn Glu Glu Tyr Phe Asn Glu Pro Asp  
 385 390 395 400  
 Glu Phe Arg Pro Ser Arg Phe Glu Gly Gln Gly Lys Asn Val Pro Ser  
 405 410 415  
 Tyr Thr Phe Ile Pro Phe Gly Gly Gly Leu Arg Ile Cys Pro Gly Trp  
 420 425 430  
 Glu Phe Ala Lys Thr Glu Met Leu Leu Phe Ile His Tyr Phe Val Lys  
 435 440 445  
 Thr Phe Ser Ser Tyr Val Pro Val Asp Pro Asn Glu Lys Ile Ser Ala  
 450 455 460  
 Asp Pro Leu Ala Ser Phe Pro Val Asn Gly Phe Ser Val Lys Leu Phe  
 465 470 475 480  
 Pro Arg Ser

<210> 63  
 <211> 503  
 <212> PRT  
 <213> Taxus cuspidata

<400> 63  
 Met Asp Ala Phe Asn Ile Leu Lys Gly Pro Ala Ala Lys Leu Asn Gly  
 1 5 10 15  
 Val Val Gln Leu Gly Ser Tyr Thr Asp Arg Ile Leu Ser Ile Thr Val  
 20 25 30  
 Val Ala Phe Ile Thr Ile Leu Leu Leu Met Leu Arg Trp Lys Ser  
 35 40 45  
 Gln Ser Ser Val Lys Leu Pro Pro Gly Asn Phe Gly Phe Pro Leu Ile  
 50 55 60  
 Gly Glu Thr Leu Gln Leu Leu Arg Ala Phe Arg Ser Asn Thr Thr Gln  
 65 70 75 80  
 Gln Phe Phe Asp Glu Arg Gln Lys Lys Phe Gly Cys Val Phe Lys Thr  
 85 90 95  
 Ser Leu Val Gly Glu Arg Thr Val Val Leu Cys Gly Pro Ser Gly Asn  
 100 105 110  
 Arg Leu Val Leu Ala Asn Gln Asn Lys Val Val Glu Ser Ser Trp Pro  
 115 120 125  
 Ser Ala Phe Ile Lys Leu Ile Gly Glu Asp Ser Ile Ala Asn Thr Asn  
 130 135 140

Gly Glu Lys His Arg Ile Leu Arg Ala Ala Leu Leu Arg Tyr Leu Gly  
 145 150 155 160  
 Pro Gly Ser Leu Gln Asn Tyr Val Gly Lys Met Arg Ser Glu Ile Glu  
 165 170 175  
 His His Ile Asn Glu Lys Trp Lys Gly Lys Asp Glu Val Lys Val Leu  
 180 185 190  
 Asp Leu Val Arg Lys Asn Val Phe Ser Val Ala Thr Ala Leu Phe Phe  
 195 200 205  
 Gly Val Asn Asp Glu Glu Arg Lys Arg Ile Arg Pro Pro Ser Ile Leu  
 210 215 220  
 Arg Lys Leu His Phe Ala Gly Ser Phe Ser Ile Pro Leu Asp Phe Pro  
 225 230 235 240  
 Gly Thr Ser Tyr Arg Arg Ala Leu Glu Ala Arg Leu Lys Leu Asp Lys  
 245 250 255  
 Ile Leu Ser Ser Leu Ile Glu Arg Arg Arg Ser Asp Leu Arg Ser Gly  
 260 265 270  
 Leu Ala Ser Gly Asn Glu Asp Leu Val Ser Val Leu Leu Thr Phe Lys  
 275 280 285  
 Asp Glu Gly Gly Asn Pro Leu Thr Asp Lys Glu Ile Leu Asp Asn Phe  
 290 295 300  
 Ser Gly Leu Leu His Ala Ser Tyr Asp Thr Thr Thr Ser Ala Leu Thr  
 305 310 315 320  
 Leu Thr Phe Lys Leu Met Ser Ser Ser Ala Glu Cys Tyr Asp Lys Val  
 325 330 335  
 Val Gln Glu Gln Leu Arg Ile Val Ser Asn Lys Lys Glu Gly Glu Glu  
 340 345 350  
 Ile Ser Leu Lys Asp Leu Lys Asp Met Lys Tyr Thr Trp Gln Val Val  
 355 360 365  
 Gln Glu Thr Leu Arg Met Phe Pro Pro Leu Phe Gly Ser Phe Arg Lys  
 370 375 380  
 Thr Ile Ala Asp Ile Gln Tyr Asp Gly Tyr Thr Ile Pro Lys Gly Trp  
 385 390 395 400  
 Lys Val Leu Trp Ala Thr Tyr Thr Thr His Gly Arg Asp Glu Tyr Phe  
 405 410 415  
 Ser Glu Pro Gln Lys Phe Arg Pro Ser Arg Phe Glu Glu Gly Gly Lys  
 420 425 430  
 His Val Ala Pro Tyr Thr Phe Leu Pro Phe Glu Gly Gly Glu Arg Thr  
 435 440 445  
 Cys Pro Gly Tyr Glu Phe Ser Lys Thr His Ile Leu Leu Phe Ile His  
 450 455 460

Gln Phe Val Lys Thr Phe Thr Gly Tyr Ile Pro Leu Asp Pro Asn Glu  
 465 470 475 480

Ser Ile Ser Ala Asn Pro Leu Pro Pro Leu Pro Ala Asn Gly Phe Pro  
 485 490 495

Val Lys Leu Phe Gln Arg Ser  
 500

<210> 64

<211> 497

<212> PRT

<213> Taxus cuspidata

<400> 64

Met Asp Ser Phe Ile Phe Leu Arg Ser Ile Gly Thr Lys Phe Gly Gln  
 1 5 10 15

Leu Glu Ser Ser Pro Ala Ile Leu Ser Leu Thr Leu Ala Pro Ile Leu  
 20 25 30

Ala Ile Ile Leu Leu Leu Leu Phe Arg Tyr Asn His Arg Ser Ser Val  
 35 40 45

Lys Leu Pro Pro Gly Lys Leu Gly Phe Pro Leu Ile Gly Glu Thr Ile  
 50 55 60

Gln Leu Leu Arg Thr Leu Arg Ser Glu Thr Pro Gln Lys Phe Phe Asp  
 65 70 75 80

Asp Arg Leu Lys Lys Phe Gly Pro Val Tyr Met Thr Ser Leu Ile Gly  
 85 90 95

His Pro Thr Val Val Leu Cys Gly Pro Ala Gly Asn Lys Leu Val Leu  
 100 105 110

Ser Asn Glu Asp Lys Leu Val Glu Met Glu Gly Pro Lys Ser Phe Met  
 115 120 125

Lys Leu Ile Gly Glu Asp Ser Ile Val Ala Lys Arg Gly Glu Asp His  
 130 135 140

Arg Ile Leu Arg Thr Ala Leu Ala Arg Phe Leu Gly Ala Gln Ala Leu  
 145 150 155 160

Gln Asn Tyr Leu Gly Arg Met Ser Ser Glu Ile Gly His His Phe Asn  
 165 170 175

Glu Lys Trp Lys Gly Lys Asp Glu Val Lys Val Leu Pro Leu Val Arg  
 180 185 190

Gly Leu Ile Phe Ser Ile Ala Ser Thr Leu Phe Phe Asp Val Asn Asp  
 195 200 205

Gly His Gln Gln Lys Gln Leu His His Leu Leu Glu Thr Ile Leu Val  
 210 215 220

Gly Ser Leu Ser Val Pro Leu Asp Phe Pro Gly Thr Arg Tyr Arg Lys  
 225 230 235 240

Gly Leu Gln Ala Arg Leu Lys Leu Asp Glu Ile Leu Ser Ser Leu Ile  
 245 250 255  
 Lys Arg Arg Arg Arg Asp Leu Arg Ser Gly Ile Ala Ser Asp Asp Gln  
 260 265 270  
 Asp Leu Leu Ser Val Leu Leu Thr Phe Arg Asp Glu Lys Gly Asn Ser  
 275 280 285  
 Leu Thr Asp Gln Gly Ile Leu Asp Asn Phe Ser Ala Met Phe His Ala  
 290 295 300  
 Ser Tyr Asp Thr Thr Val Ala Pro Met Ala Leu Ile Phe Lys Leu Leu  
 305 310 315 320  
 Tyr Ser Asn Pro Glu Tyr His Glu Lys Val Phe Gln Glu Gln Leu Glu  
 325 330 335  
 Ile Ile Gly Asn Lys Lys Glu Gly Glu Glu Ile Ser Trp Lys Asp Leu  
 340 345 350  
 Lys Ser Met Lys Tyr Thr Trp Gln Ala Val Gln Glu Ser Leu Arg Met  
 355 360 365  
 Tyr Pro Pro Val Phe Gly Ile Phe Arg Lys Ala Ile Thr Asp Ile His  
 370 375 380  
 Tyr Asp Gly Tyr Thr Ile Pro Lys Gly Trp Arg Val Leu Cys Ser Pro  
 385 390 395 400  
 Tyr Thr Thr His Leu Arg Glu Glu Tyr Phe Pro Glu Pro Glu Glu Phe  
 405 410 415  
 Arg Pro Ser Arg Phe Glu Asp Glu Gly Arg His Val Thr Pro Tyr Thr  
 420 425 430  
 Tyr Val Pro Phe Gly Gly Gly Leu Arg Thr Cys Pro Gly Trp Glu Phe  
 435 440 445  
 Ser Lys Ile Glu Ile Leu Leu Phe Val His His Phe Val Lys Asn Phe  
 450 455 460  
 Ser Ser Tyr Ile Pro Val Asp Pro Asn Glu Lys Val Leu Ser Asp Pro  
 465 470 475 480  
 Leu Pro Pro Leu Pro Ala Asn Gly Phe Ser Ile Lys Leu Phe Pro Arg  
 485 490 495  
 Ser

&lt;210&gt; 65

&lt;211&gt; 507

&lt;212&gt; PRT

&lt;213&gt; Taxus cuspidata

&lt;400&gt; 65

Met Glu Thr Lys Phe Gly Gln Leu Met Gln Leu Glu Phe Leu Pro Phe  
 1 5 10 15

Ile Leu Thr Pro Ile Leu Gly Ala Leu Val Leu Leu His Leu Phe Arg  
 20 25 30  
 His Arg Asn Arg Ser Ser Val Lys Leu Pro Pro Gly Lys Leu Gly Phe  
 35 40 45  
 Pro Val Ile Gly Glu Thr Ile Gln Phe Leu Arg Ala Leu Arg Ser Gln  
 50 55 60  
 Thr Pro Gln Lys Phe Phe Asp Asp Arg Val Gln Lys Phe Gly Gly Val  
 65 70 75 80  
 Phe Lys Thr Ser Leu Ile Gly Asn Pro Leu Val Val Met Cys Gly Pro  
 85 90 95  
 Ala Gly Asn Arg Leu Val Leu Ser Asn Glu Asp Lys Leu Val Gln Leu  
 100 105 110  
 Glu Ala Pro Asn Ser Leu Met Lys Leu Met Gly Gln Asp Ser Leu Leu  
 115 120 125  
 Ala Lys Arg Gln Glu Asp His Arg Thr Leu Arg Ala Ala Leu Ala Arg  
 130 135 140  
 Phe Leu Gly Pro Gln Ala Leu Xaa Asn Tyr Met Thr Lys Ile Ser Ser  
 145 150 155 160  
 Arg Thr Glu His His Met Asn Glu Lys Trp Lys Gly Lys Asp Glu Val  
 165 170 175  
 Arg Thr Leu Pro Leu Ile Arg Glu Leu Ile Phe Ser Asn Ala Ser Ser  
 180 185 190  
 Leu Phe Phe Asp Ile Asn Asp Glu His Gln Gln Glu Arg Leu His His  
 195 200 205  
 Leu Leu Glu Ala Val Val Val Gly Ser Met Ser Ile Pro Leu Asp Phe  
 210 215 220  
 Pro Gly Thr Arg Leu Arg Lys Ala Leu Gln Ala Arg Ser Lys Leu Asp  
 225 230 235 240  
 Glu Ile Leu Ser Ser Leu Ile Lys Ser Arg Arg Lys Asp Leu Val Ser  
 245 250 255  
 Gly Ile Ala Ser Asp Asp Gln Asp Leu Leu Ser Val Leu Leu Thr Phe  
 260 265 270  
 Lys Asp Glu Arg Gly Asn Pro Leu Thr Asp Lys Glu Ile Leu Asp Asn  
 275 280 285  
 Phe Ser Leu Leu Leu His Ala Ser Tyr Asp Thr Thr Val Ser Pro Met  
 290 295 300  
 Val Leu Thr Leu Lys Leu Leu Ser Ser Asn Pro Glu Cys Tyr Glu Lys  
 305 310 315 320  
 Val Val Gln Glu Gln Leu Gly Ile Val Ala Asn Lys Arg Ile Gly Glu  
 325 330 335  
 Glu Ile Ser Trp Lys Asp Leu Lys Ala Met Lys Tyr Thr Trp Gln Val

340 345 350  
 Val Gln Glu Thr Leu Arg Met Phe Pro Pro Leu Phe Gly Ser Phe Arg  
 355 360 365  
 Lys Ala Met Val Asp Ile Asp Tyr Asp Gly Tyr Thr Ile Pro Lys Gly  
 370 375 380  
 Trp Met Ile Leu Trp Thr Thr Tyr Gly Thr His Leu Arg Glu Glu Tyr  
 385 390 395 400  
 Phe Asn Glu Pro Leu Lys Phe Arg Pro Ser Arg Phe Glu Glu Asp Gly  
 405 410 415  
 Arg Val Thr Pro Tyr Thr Phe Ile Pro Phe Gly Gly Gly Ala Arg Thr  
 420 425 430  
 Cys Pro Gly Trp Glu Phe Ser Lys Thr Glu Ile Leu Leu Phe Ile His  
 435 440 445  
 His Phe Val Arg Thr Phe Ser Ser Tyr Leu Pro Val Asp Ser Asn Glu  
 450 455 460  
 Lys Ile Ser Ala Asp Pro Phe Pro Pro Leu Pro Ala Asn Gly Phe Ser  
 465 470 475 480  
 Ile Lys Leu Ser Ala Asp Pro Phe Pro Pro Leu Pro Ala Asn Gly Phe  
 485 490 495  
 Ser Ile Lys Leu Phe Pro Arg Ser Gln Ser Asn  
 500 505

&lt;210&gt; 66

&lt;211&gt; 512

&lt;212&gt; PRT

<213> *Taxus cuspidata*

&lt;400&gt; 66

Met Ala Tyr Pro Glu Leu Leu Glu Asn Leu Ser Gly Asp Arg Ala Gln  
 1 5 10 15  
 Ser Pro Ala Ile Ala Ala Val Leu Thr Ile Leu Phe Leu Leu Gly Ile  
 20 25 30  
 Phe Tyr Ile Leu Arg Gly Leu Arg Asn Asn Gly Arg Arg Leu Pro Pro  
 35 40 45  
 Gly Pro Ile Pro Trp Pro Ile Val Gly Asn Leu His Gln Leu Gly Lys  
 50 55 60  
 Leu Pro Asn Arg Asn Leu Glu Glu Leu Ala Lys Lys His Gly Pro Ile  
 65 70 75 80  
 Met Leu Met Lys Leu Gly Ser Val Pro Ala Val Ile Val Ser Ser Ser  
 85 90 95  
 Ala Met Ala Lys Glu Val Leu Lys Thr His Asp Leu Val Phe Ala Ser  
 100 105 110  
 Arg Pro Glu Ser Ala Ala Gly Lys Tyr Ile Ala Tyr Asn Tyr Lys Asp



115	120	125
Ile Val Phe Ser Pro Tyr 130	Gly Pro Tyr Trp Arg 135	Gln Met Lys Lys Ile 140
Cys Val Val Glu Leu Leu 145	Asn Ala Arg Arg 150	Ile Glu Ser Leu Arg Ser 155
Val Arg Glu Glu Glu Val 165	Ser Val Ile Ile Arg 170	Ser Val Trp Glu Lys 175
Ser Lys Gln Gly Ala Val 180	Ala Val Asn Leu Ser 185	Lys Thr Leu Ser Ser 190
Leu Thr Gln Gly Leu Met 195	Leu Gln Ile Phe Ser 200	Ser Ser Asn Asp Asp Gly 205
Gly Asn Ser Ser Val Thr 210	Ala Ile Lys Glu Met 215	Met Ser Glu Val Ser 220
Glu Thr Ala Gly Ala Phe 225	Asn Ile Gly Asp Tyr 230	Phe Pro Trp Met Asp 235
Trp Met Asp Leu Gln Gly 245	Ile Gln Arg Arg Met 250	Thr Lys Ala His Asp 255
Tyr Phe Asp Gln Val Ile 260	Thr Lys Ile Ile Glu 265	Gln His Gln Arg Thr 270
Arg Ala Met Glu Asp Thr 275	Gln Gln Pro Lys Asp 280	Ile Ile Asp Ala Leu 285
Leu Gln Met Glu Asn Thr 290	Asp Gly Val Thr Ile 295	Thr Met Glu Asn Ile 300
Lys Ala Val Val Leu Gly 305	Ile Phe Leu Gly Gly 310	Ala Glu Thr Thr Ser 315
Thr Thr Leu Glu Trp Ala 325	Met Ser Ala Met Leu 330	Glu Asn Pro Glu Val 335
Ala Lys Lys Val Gln Glu 340	Glu Ile Glu Ser Val 345	Val Gly Arg Lys Arg 350
Val Val Lys Glu Met Ile 355	Trp Glu Ser Met Glu 360	Tyr Leu Gln Cys Val 365
Val Lys Lys Thr Met Arg 370	Leu Tyr Pro Ala Val 375	Pro Leu Leu Ile Pro 380
His Glu Ser Thr Gln Asp 385	Cys Thr Val Asn Gly 390	Tyr Phe Ile Pro Glu 395
Arg Thr Arg Ile Leu Val 405	Asn Ala Trp Ala Ile 410	Gly Lys Asp Pro Asn 415
Val Trp Asp Asp Ala Leu 420	Ala Phe Lys Pro Lys 425	Arg Phe Leu Gly Xaa 430
Asn Val Asp Leu Gln Lys 435	Gly Lys Glu Phe Phe 440	Asp Met Val Pro Phe 445

Gly Ala Gly Arg Lys Gly Cys Pro Gly Ala Ser Met Ala Val Val Thr  
 450 455 460  
 Met Glu His Ala Leu Ala Gln Leu Met His Cys Phe Gln Trp Arg Ile  
 465 470 475 480  
 Glu Gly Glu Leu Asp Met Ser Glu Arg Leu Ala Ala Ser Val Gln Lys  
 485 490 495  
 Lys Val Asp Leu Cys Val Leu Pro Gln Trp Arg Leu Thr Ser Ser Pro  
 500 505 510

<210> 67  
 <211> 509  
 <212> PRT  
 <213> *Taxus cuspidata*

<400> 67  
 Met Asp Val Phe Tyr Pro Leu Lys Ser Thr Val Ala Lys Phe Asn Glu  
 1 5 10 15  
 Cys Phe Pro Ala Ile Leu Phe Ile Val Leu Ser Ala Val Ala Gly Ile  
 20 25 30  
 Val Leu Pro Leu Leu Leu Phe Leu Arg Ser Lys Arg Arg Ser Ser Val  
 35 40 45  
 Gly Leu Pro Pro Gly Lys Leu Gly Tyr Pro Phe Ile Gly Glu Ser Leu  
 50 55 60  
 Leu Phe Leu Lys Ala Leu Arg Ser Asn Thr Val Glu Gln Phe Leu Asp  
 65 70 75 80  
 Glu Arg Val Lys Asn Phe Gly Asn Val Phe Lys Thr Ser Leu Ile Gly  
 85 90 95  
 His Pro Thr Val Val Leu Cys Gly Pro Ala Gly Asn Arg Leu Ile Leu  
 100 105 110  
 Ala Asn Glu Glu Lys Leu Val Gln Met Ser Trp Pro Lys Ser Ser Met  
 115 120 125  
 Lys Leu Met Gly Glu Lys Ser Ile Thr Ala Lys Arg Gly Glu Gly His  
 130 135 140  
 Met Ile Ile Arg Ser Ala Leu Gln Gly Phe Phe Ser Pro Gly Ala Leu  
 145 150 155 160  
 Gln Lys Tyr Ile Gly Gln Met Ser Lys Thr Ile Glu Asn His Ile Asn  
 165 170 175  
 Glu Lys Trp Lys Gly Asn Asp Gln Val Ser Val Val Ala Leu Val Gly  
 180 185 190  
 Asp Leu Val Phe Asp Ile Ser Ala Cys Leu Phe Phe Asn Ile Asn Glu  
 195 200 205

Lys His Glu Arg Glu Arg Leu Phe Glu Leu Leu Glu Ile Ile Ala Val  
 210 215 220  
 Gly Val Leu Ala Val Pro Val Asp Leu Pro Gly Phe Ala Tyr His Arg  
 225 230 235 240  
 Ala Leu Gln Ala Arg Ser Lys Leu Asn Ala Ile Leu Ser Gly Leu Ile  
 245 250 255  
 Glu Lys Arg Lys Met Asp Leu Ser Ser Gly Leu Ala Thr Ser Asn Gln  
 260 265 270  
 Asp Leu Leu Ser Val Phe Leu Thr Phe Lys Asp Asp Arg Gly Asn Pro  
 275 280 285  
 Cys Ser Asp Glu Glu Ile Leu Asp Asn Phe Ser Gly Leu Leu His Gly  
 290 295 300  
 Ser Tyr Asp Thr Thr Val Ser Ala Met Ala Cys Val Phe Lys Leu Leu  
 305 310 315 320  
 Ser Ser Asn Pro Glu Cys Tyr Glu Lys Val Val Gln Glu Gln Leu Gly  
 325 330 335  
 Ile Leu Ser Asn Lys Leu Glu Gly Asp Glu Ile Thr Trp Lys Asp Val  
 340 345 350  
 Lys Ser Met Lys Tyr Thr Trp Gln Val Val Gln Glu Thr Leu Arg Leu  
 355 360 365  
 Tyr Pro Ser Ile Phe Gly Ser Phe Arg Gln Ala Ile Thr Asp Ile His  
 370 375 380  
 Tyr Asn Gly Tyr Ile Ile Pro Lys Gly Trp Lys Leu Leu Trp Thr Pro  
 385 390 395 400  
 Tyr Thr Thr His Pro Lys Glu Met Tyr Phe Ser Glu Pro Glu Lys Phe  
 405 410 415  
 Leu Pro Ser Arg Phe Asp Gln Glu Gly Lys Leu Val Ala Pro Tyr Thr  
 420 425 430  
 Phe Leu Pro Phe Gly Gly Gly Gln Arg Ser Cys Pro Gly Trp Glu Phe  
 435 440 445  
 Ser Lys Met Glu Ile Leu Leu Ser Val His His Phe Val Lys Thr Phe  
 450 455 460  
 Ser Thr Phe Thr Pro Val Asp Pro Ala Glu Ile Ile Ala Arg Asp Ser  
 465 470 475 480  
 Leu Cys Pro Leu Pro Ser Asn Gly Phe Ser Val Lys Leu Phe Pro Arg  
 485 490 495  
 Ser Tyr Ser Leu His Thr Gly Asn Gln Val Lys Lys Ile  
 500 505

&lt;210&gt; 68

&lt;211&gt; 514

&lt;212&gt; PRT

&lt;213&gt; Taxus cuspidata

&lt;400&gt; 68

Met Ala Phe Glu Ala Ala Thr Val Ile Leu Phe Thr Leu Ala Ala Leu  
 1 5 10 15

Leu Leu Val Val Ile Gln Arg Arg Arg Ile Arg Arg His Lys Leu Gln  
 20 25 30

Gly Lys Val Lys Ala Pro Gln Pro Pro Ser Trp Pro Val Ile Gly Asn  
 35 40 45

Leu His Leu Leu Thr Gln Lys Val Pro Ile His Arg Ile Leu Ser Ser  
 50 55 60

Leu Ser Glu Ser Tyr Gly Pro Ile Met His Leu Gln Leu Gly Leu Arg  
 65 70 75 80

Pro Ala Leu Val Ile Ala Ser Ser Asp Leu Ala Lys Glu Cys Phe Thr  
 85 90 95

Thr Asn Asp Lys Ala Phe Ala Ser Arg Pro Arg Leu Ser Ala Gly Lys  
 100 105 110

His Val Gly Tyr Asp Tyr Lys Ile Phe Ser Met Ala Pro Tyr Gly Ser  
 115 120 125

Tyr Trp Arg Asn Leu Arg Lys Met Cys Thr Ile Gln Ile Leu Ser Ala  
 130 135 140

Thr Arg Ile Asp Ser Phe Arg His Ile Arg Val Glu Glu Val Ser Ala  
 145 150 155 160

Leu Ile Arg Ser Leu Phe Asp Ser Cys Gln Arg Glu Asp Thr Pro Val  
 165 170 175

Asn Met Lys Ala Arg Leu Ser Asp Leu Thr Phe Ser Ile Ile Leu Arg  
 180 185 190

Met Val Ala Asn Lys Lys Leu Ser Gly Pro Val Tyr Ser Glu Glu Tyr  
 195 200 205

Glu Glu Ala Asp His Phe Asn Gln Met Ile Lys Gln Ser Val Phe Leu  
 210 215 220

Leu Gly Ala Phe Glu Val Gly Asp Phe Leu Pro Phe Leu Lys Trp Leu  
 225 230 235 240

Asp Leu Gln Gly Phe Ile Ala Ala Met Lys Lys Leu Gln Gln Lys Arg  
 245 250 255

Asp Val Phe Met Gln Lys Leu Val Ile Asp His Arg Glu Lys Arg Gly  
 260 265 270

Arg Val Asp Ala Asn Ala Gln Asp Leu Ile Asp Val Leu Ile Ser Ala  
 275 280 285

Thr Asp Asn His Glu Ile Gln Ser Asp Ser Asn Asp Asp Val Val Lys  
 290 295 300

Ala Thr Ala Leu Thr Met Leu Asn Ala Gly Thr Asp Thr Ser Ser Val  
 305 310 315 320

Thr Ile Glu Trp Ala Leu Ala Ala Leu Met Gln His Pro His Ile Leu  
 325 330 335

Ser Lys Ala Gln Gln Glu Leu Asp Thr His Ile Gly Arg Ser Arg Leu  
 340 345 350

Leu Glu Glu Ala Asp Leu His Glu Leu Lys Tyr Leu Gln Ala Ile Val  
 355 360 365

Lys Glu Thr Leu Arg Leu Tyr Pro Ala Ala Pro Leu Leu Val Pro His  
 370 375 380

Glu Ala Ile Glu Asp Cys Thr Val Gly Gly Tyr His Val Ser Ala Gly  
 385 390 395 400

Thr Arg Leu Ile Val Asn Ala Trp Ala Ile His Arg Asp Pro Ala Val  
 405 410 415

Trp Glu Arg Pro Thr Val Phe Asp Pro Glu Arg Phe Leu Lys Ser Gly  
 420 425 430

Lys Glu Val Asp Val Lys Gly Arg Glu Phe Glu Leu Ile Pro Phe Gly  
 435 440 445

Ser Gly Arg Arg Met Cys Pro Gly Met Ser Leu Ala Leu Ser Val Val  
 450 455 460

Thr Tyr Thr Leu Gly Arg Leu Leu Gln Ser Phe Glu Trp Ser Val Pro  
 465 470 475 480

Glu Gly Met Ile Ile Asp Met Thr Glu Gly Leu Gly Leu Thr Met Pro  
 485 490 495

Lys Ala Val Pro Leu Glu Thr Ile Ile Lys Pro Arg Leu Pro Phe His  
 500 505 510

Leu Tyr

<210> 69

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Primer

<400> 69

tcggtgattg taacggaaga gc

22

<210> 70

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Primer

<400> 70  
ctggcttttc caacggagca tgag

24

<210> 71  
<211> 25  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: PCR Primer

<400> 71  
attgtttctc agcccgcgca gtag

25

<210> 72  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: PCR Primer

<400> 72  
tcggtttcta tgacggaagc gatg

24

<210> 73  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: PCR Primer

<400> 73  
attaaccctc actaaacctt ttgg

24

<210> 74  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: PCR Primer

<400> 74  
attaaccctc actaaacctt tcgg

24

<210> 75  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: PCR Primer

<400> 75

attaaccctc actaaaccat ttgg

24

<210> 76

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Primer

<400> 76

attaaccctc actaaaccat tcgg

24

<210> 77

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Primer

<400> 77

attaaccctc actaaaccgt ttgg

24

<210> 78

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Primer

<400> 78

attaaccctc actaaaccgt tcgg

24

<210> 79

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Primer

<400> 79

attaaccctc actaaaccct ttgg

24

<210> 80

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Primer

<400> 80

attaaccctc actaaaccct tcgg

24

<210> 81  
 <211> 1539  
 <212> DNA  
 <213> *Taxus cuspidata*

<400> 81  
 atggacgctt ttaatgtttt aatggggcct ctagcaaaat ttgataattt catgcagctc 60  
 ggcctcttact ctgaaaatct ttccgttaca attaccgtca cagcgattgc cgtcattact 120  
 cttctcctgg tgttgatccg ttccaaaccc caatcttgtg taaaccttcc tccgggaaaag 180  
 cttggctacc ctttcatcgg cgaacatta caattgttgc aggcatttcg atcgaacagg 240  
 ccgcaacagt tctttgatga gaggcagaag aaatttgggt ctgttttcaa gacttcacta 300  
 attggggacc gcacagtggg gctgtgcggg ccctcaggaa accgtttgct gctctccaac 360  
 gaaaacaagc tgggtggagg atcctggccg agttcttcca ttaaattgat cggagaggat 420  
 tccattgctg ggaaaaacgg agagaagcat cggatcttac gcgccgcggg aaaccgttac 480  
 ctgggacccg gagcattaca gaattatatg gcgaagatga ggtcagaaat cgaacatcat 540  
 atgaatgaga aatggaaggg gaaagagcaa gtgaaggtgc ttcctttggt aaaagagaat 600  
 gtcttctcca tcgcaaccag cttgtttttc ggtgtcaatg atgacggaga acgggaacgg 660  
 cttcatgacc ttttgaaac cgcacttgcg ggtgtttttt ctattccact ggattttcca 720  
 ggaacaaatt attcggaaag ccttgaaagc cggttaaaac tggataaagt cctttcttct 780  
 ctgatatgaa ggagaagaag cgtctgcga tcaggcgtgg catctggtta tgaggatctg 840  
 ctctctgtgt ggctcacttt caaagacgaa gaagggaatc ctctgacaga caaggagatc 900  
 ctcgacaact tctccacctt gcttcatgca tcatatgaca ccacaacctc agcactcacc 960  
 ttgacattaa agctcatgtc ctcccttact gaatgctatc acaaagtagt tcaagagcaa 1020  
 ctgagaatag tttccaacaa aaaggaggga gaagaaatca gcttgaaaga tctgaaagac 1080  
 atgaaatata catggcaagt tgtgcaggaa actctgagga tgttccctcc gctttttgga 1140  
 tcatttcgta aggccatcac tgacattcat tatgatggtt atacaatccc aaaaggatgg 1200  
 aaagttttat ggcaacttta tagtacacat gggagagaag agtatttcaa tgaaccagag 1260  
 aaattcatgc cttcaagatt cgaagaggaa ggaaggcatg ttgctcctta cacattttta 1320  
 cccttcggag caggcgtgcg cacctgcccc ggatgggaat tttcaaaaac ccagatatta 1380  
 ctgttcttac attattttgt taaaactttc agtggctaca tcccactcga ccctgacgaa 1440  
 aaagtgttag ggaatccagt ccctcctctc cctgccaatg gatttgctat aaaacttttc 1500  
 cccaggcctt cattcgatca aggatcccc atggaataa 1539

<210> 82  
 <211> 1458  
 <212> DNA  
 <213> *Taxus cuspidata*

<400> 82  
 atggatgccc ttaagcaatt ggaagtttcc ccttccattc ttttcgttac cctcgagta 60  
 atggcaggca ttatcctctt cttccgctct aaacgccatt cctctgtaaa actccccct 120  
 ggaaatctag gcttccctct ggttggggag aactgcagt tcgtgaggtc acttggtcg 180  
 agcactccac agcagtttat tgaagagaga atgagcaaat ttggggatgt gttcaagact 240  
 tccataatcg ggcatccac agtagtctg tgtggacctg ccggaaccg gttggttctg 300  
 tcgaacgaga acaagctggg gcagatgtca tggccgagct ccatgatgaa actcatcggc 360  
 gaagattgtc tcggcggcaa aacgggagag cagcatcgga tcgtacgcgc tgcactaact 420  
 cggtttttgg gtcctcaagc attgcagaat catttcgcta aaatgagctc gggaatccaa 480  
 cgccacatca atgaaaaatg gaagggaag gatgaggcca ctgtacttcc tttggtaaaa 540  
 gacctcgtct tctccgtcgc aagccgcttg ttttttggt taactgagga gcacctgcag 600  
 gagcaacttc ataatctgtt ggaagtatt cttgtgggat ctttttctgt tccactcaac 660  
 attcccggat tcagttacca taaagcgatt caggcaaggg ccaccctcgc tgacatcatg 720  
 acccatttga tagaaaagag gagaatgag ctgcgtgcag gcaactgcac tgagaatcaa 780  
 gatttgctct ctgttttctg cactttcact gacgaaagg ggaattcact ggcggacaag 840  
 gagatccctc acaacttttc tatgttact catggatcat atgactccac caattcccca 900  
 cttaccatgt tgattaaagt cttggcctcc catccagaaa gctatgaaaa agtggctcaa 960  
 gagcaatttg gaatactctc caccaaaatg gagggagaag aaattgcttg gaaagacctg 1020  
 aaggagatga aatattcatg gcaagtgtt caggaaacat tgcgcatgta tctccatt 1080  
 tttggaacat ttcgcaaagc catcactgac attcattaca atgtttatc aattccaaaa 1140



```

ggatggaaac ttttatggac aacttacagt actcaaacca aggaagagta tttcaaggac 1200
gccgatcaat tcaagccatc aagatttgag gaggaaggga agcatgtaac cccttacaca 1260
tacttacctt tcgaggagg catgctgtgt tgtccagggt gggaattcgc caagatggag 1320
acattactgt ttctccatca ttttggttaa gccttctctg ggttgaaggc aattgatcca 1380
aatgaaaaac tttcagggaa accacttctt cctctccctg tcaatgggct tcccattaaa 1440
ctctattcca gatcttaa                                     1458

```

&lt;210&gt; 83

&lt;211&gt; 1482

&lt;212&gt; DNA

<213> *Taxus cuspidata*

&lt;400&gt; 83

```

atggacagct tcacttttgt aaccatcaaa atgggaaaaa tttggcaagt cattcaggtg 60
gagtacattc tatcccttac cctcacagct attcttctct tcttcttccg ttacagaaac 120
aaatcctctc ataaacttcc ccttgaaac ttgggcttcc cttttatttg ggagaccata 180
caattcttgc gtacacttgc atcacaacaa cctgaatttt tttttgacga gaggtgaaag 240
aaattcggtc ctgttttcaa gacctcgcta attggggctc ccacagtgt attctgcggg 300
gcggcagggg gccgattagt tctgtctaac gaggacaagc tgggtcagat ggaatcgcca 360
agctctttaa agaagctaag gggggagaat tccattctgt ataaaagaga agaggaaacac 420
cgcatcttgc gttctgcatt atcccgttt ttgggtcccc aagctttgca aacttacatt 480
gctaaaatga gtacagaaat cgagcgtcat atcaacgaaa aatggaaggg aaaagaagaa 540
gtgaagacgc ttcttttgat aagagggctc gtcttctcca ttgcaagcag tctgtttttc 600
gatataaatg atgagcccca acaggagcga cttcatcatc atttggaag tcttgttgca 660
ggaagtatgg ctgttcgcct cgactttcca ggaactcgct ttcgtaaagc cgttgaggcg 720
cgttcgaagc tggatgaagc tctccattct ttaataaaaa gcagacgaag cgatctgctt 780
tctggcaaaag cttcaagtaa tcaagatctt ctttcgggtg tgctcagctt caaagatgaa 840
agaggaaatc cactgagaga cgaggagatc ctgcacaatt tttctcttat acttcatgcc 900
tcgtatgata ccactatttc accaatggtt ttgacattga agctgctgtc ctccaatcca 960
gaatgctatg acaaagtagt tcaagagcaa tttggaatac ttgccaataa aaaagaggga 1020
gaggaaatca gttggaagga tctgaaagct atgaaatata catggcaagt agtgcaggaa 1080
acactgagga tgttccctcc acttttttga tcatccgcga aggctatggt tgatattaat 1140
tatgacgggt acacaattcc aaaaggatgg atcgttttat ggacaactta cagtacacat 1200
gtgaagaag agtacttcaa tgaacctggc aaattcaggc ctcaagatt cgagcatgat 1260
ggaaggcatg tggctcctta cacattctta ccattcggag gaggcctgcg cacatgtcca 1320
ggatgggaat tctcaaagac ggagatatta ctgtttatcc atcattttgt taaaactttc 1380
ggcagctacc tcccagttga cccaacgaa aaaatttcag cagatccatt ccctcctctc 1440
cctgccaatg gcttttctat aaaacttttt cccagatctt aa                                     1482

```

&lt;210&gt; 84

&lt;211&gt; 1491

&lt;212&gt; DNA

<213> *Taxus cuspidata*

&lt;400&gt; 84

```

atggaactgt ggaatatgtt tctgccatgg atctccattg caacagcaac atcccttaca 60
gtgggcatgg catccgcatt cgctataatt tatgctcctc ttttgcgtgc attcctgaga 120
ttgaagacgg ccagaagaaa tatgcctccg attcctccag gaagcatggg aatgccattc 180
tgaggagaaat ctctgggcta tctcggtcca tgggaataacc agagcaaccc tgacgtgtgg 240
tacgacacac ggaaggccaa acacggcaaa attttcacaa cccacattct gggcagcccc 300
actgtgtgtca tgttgggtcc ggatgccaac aggttcatcc tcattaacga aaacaagctt 360
tttctcaaca gttggcccaa atctctcaac gctctcatcg gaaagcacgc cctcatcact 420
tcgcagggcg cagaacacaa aaggatgcgg cgaattatac attccgtgct cggcccaaga 480
aaccctgaaa ctagcgtggg aagattcgaa ggactgggtg tgcatcatct cgattccgac 540
tggaatggcg gccaaatcat ccaagcctac gcceaagtta aggacatggc gctctgtttg 600
gctgccgatt ttttcatggg gttaaagccc ggaaaagaat tggagacttt caggcggcat 660
ttcagtgatt tcagcgcggg gcttttatct caccctctcg atcttccctg gactgtgttt 720
gggaaggcga aacgagcgcg cgccgccatg gtcactcaga ttttttcaca aattcggctg 780
cataggactt ccatgcacaa aagtggagag gaggggggaa atttcttgga catggtgttg 840

```

```

ggttcgcagg agaagggagg cgatttgagg ctgagtgagg aggagattgc agacaatctt 900
atgggtcttt taactggcgg acaggacacg acagcctcgg cattagccac cattctgaag 960
cacctctctc tctccccaca tctattacaa aggcttcgca aagagtgtga aaaacttaga 1020
gataacaagg aggcaggggg gcctcttaca tggagtgaag taaaaagtgt gggctattta 1080
cacaatgtaa tctcagaagg actacggatg gtagccccc aaaaatggagg atttaagaaa 1140
gcaaaagtag acgttggtata tggaggttat actattccca aaggtatgaa ggttcattac 1200
tccgtgagac agacaaacaa caaagaagag tattttccta gtccagagag atttgatcca 1260
gatcgcttca atgagagaca tgagcctttt tctttcatcc ccttcggcca gggtaatcgg 1320
atgtgccccg gaaatgaatt cgcaagggtg gaaatggaat tatttctata tcatttggtt 1380
ttgagatatg attgggaatt aatggaggcg gatgaacgca ccaacatgta cttcattcct 1440
cacctgtgac acagtttgcc tttactactt aaacacgttc ctctacatg a 1491

```

&lt;210&gt; 85

&lt;211&gt; 1497

&lt;212&gt; DNA

<213> *Taxus cuspidata*

&lt;400&gt; 85

```

atggagcggc tgtataagag cacagttgca aaatttaatg aggtcacaca gctggactgt 60
tccactgaat ctttttccat tgccctctca gctattgctg gtattctctt gcttctctctg 120
ctcttccggt cttaacgcca ctctccctt aaacttcctc ctgggaaatt aggcacccct 180
ttcattggcg agtcgtttat ctctctgagg gctcttcgat cgaactcgct ggagcaattt 240
tttgacgaga gagtgaagaa attcggcctc gtgttcaaga cctccttgat tgggcatccc 300
acagtagtac tctgcggccc tgcgggaaac cggcttattc tgtccaacga ggagaagctg 360
gtgcagatgt cgtggcccg ctaatttatg aagctcatgg gggagaattc cgttgccacc 420
aggaggggtg aagaccatat agttatgcgc tctgctcttg caggtttttt cggccctggt 480
gcgctgcaga gttacattgg taaaatgaat acagagatcc agagtcatat caacgaaaaa 540
tggaggggaa aagatgaggt gaatgtactt cctttggtta gagagctcgt cttcaacatt 600
tcggccatct tgtttttcaa catatatgat aagcaggaac aggatcgtct gcataagctt 660
ttggaaacta ttctggctcg aagttttgct ctctcgattg acttgcccgg atttggtttc 720
catagagcac tccagggacg ggccaagctc aacaaaatta tgctgtcttt aattaaaaag 780
agaaaagaag attgcagttc ggatcggcaa cagccacgca ggatctgctc tttgttttgc 840
tcactttcag agatgacaaa gggactccct caccacatgg atgagatact cgacaacttt 900
tcttctctgc tccatgcctc ctatgacacc accacttcgc caatggcttt gattttcaag 960
ctcttgctct ccaatccaga atgctatcaa aaagtgttc aagagcaatt ggagatcctt 1020
tccaacaaag aggagggcga agaaatcaca tggaaaggat tcaaagccat gaaatacaca 1080
tggcaagtag ctcaggaaac gctgcggatg tttcctccag ttttcggaac atttcgcaag 1140
gccatcactg acattcagta tgatggtacc aattccaaaa gggggaagct gttgtggaca 1200
acttacagta cacatcccaa ggacttgat ttcaatgaac cagagaaatt catgccttca 1260
agattcgatc aggaaggaaa gcatgtagct ccttacacat ttttgccctt cgggtggaggc 1320
caacggtcac gtgtgggatg ggaattttca aagatggaga tattactatt cggtcatcat 1380
ttgtcaaaaa cttttagcag ctacacccca gttgatcccg acgaaaaaat atcaggggat 1440
ccactccctc ctcttccttc caagggattt tccattaaac tgtttccgag accatag 1497

```

&lt;210&gt; 86

&lt;211&gt; 1461

&lt;212&gt; DNA

<213> *Taxus cuspidata*

&lt;400&gt; 86

```

atggagcagc taatctatag tattgtctat tccaattggt atttatgggt tttgggactg 60
tttatctgtg taattttact gttattaaaga cggagtaatg acagacaagg gaatggatcc 120
gccataaac ccaaacttcc acctggatca gctggattgc catttatttg agagactatc 180
cgttttctta gagacgctaa atcgctgga cggcgaaagt tctttgatga acatgagctc 240
aggtaatggc cgattttcag atgtagtttg tttggaagaa cacgtgcagt tgtgtcgggt 300
gatccccgat tcaataagta cgtcttgcaa aatgagggaa ggctgttcga atccaacgca 360
ctcgcgccct tcagaaatct tatcgcaaaa tatggattgt cggcgggtaca gggggaactt 420
caaaggaagc tccatgcaac tgctgtcaat ttgttgaagc atgagacgct cagctctgac 480
ttcatggaag atatacaaga catctttcag gctggaatga gaaaatggga ggaggaggga 540

```

```

gacatcccta ttcaacacaa gtgcaatcag attgttctga acttgatggc gaagagattg 600
ctggacttac ctccatcaga agaaatggga catatttata aagctttcga cgatttcgtg 660
ggagctgtcc tctctttccc cctcaatata cctggaacca cttatgagag aggaattcgg 720
gccaggggaa tctgttaaaa aagaattcac aagtgtataa aggagaggag agaacatcca 780
gaggtgctcc gcaatgactt gttgaccaa cttgtgaggg agggcacatt ttcggacgaa 840
attattgcag atacaataat cttttttgtg tttgctggtg tcgaaacttc agcaatggcc 900
atgacgtttg ctgtaaagta cctcgtgag aatccacgag cactggagga gttgagggt 960
gagcatgacg ctcttttgaa ggccaaaggg aaaggcaatg aaaagctgac gtggaatgac 1020
taccaatcaa tgaaattcgt tcattgtgta ataaatgaaa cacttcgtct ggggtgtgca 1080
accgtggttc ttttcaggga agccaaacaa gatattaaag tgaaagattt tgttattccc 1140
aaaggatgga ccgtttctgt tttcttgagc gccacacatg ttgatggaaa ataccattat 1200
gaagctgaca aattcctccc ttggcgctgg caaaatgagg gtcaagaaac gttggaggag 1260
ccatgttata tgccatttgg aagaggtggc aggcctctgtc caggactcca tttggcaaga 1320
tttgaattg ctctctttct tcacaacttt gtcactaaat tcagatggga gcagctggaa 1380
attgatcgtg cgacttactt tcctcttctt tccacagaaa atggttttcc aatccgtctc 1440
tattctcgag tacacgaatg a 1461

```

&lt;210&gt; 87

&lt;211&gt; 512

&lt;212&gt; PRT

<213> *Taxus cuspidata*

&lt;400&gt; 87

```

Met Asp Ala Phe Asn Val Leu Met Gly Pro Leu Ala Lys Phe Asp Asn
 1             5             10             15

```

```

Phe Met Gln Leu Gly Ser Tyr Ser Glu Asn Leu Ser Val Thr Ile Thr
          20             25             30

```

```

Val Thr Ala Ile Ala Val Ile Thr Leu Leu Leu Val Leu Ile Arg Ser
      35             40             45

```

```

Lys Pro Gln Ser Cys Val Asn Leu Pro Pro Gly Lys Leu Gly Tyr Pro
      50             55             60

```

```

Phe Ile Gly Glu Thr Leu Gln Leu Leu Gln Ala Phe Arg Ser Asn Arg
      65             70             75             80

```

```

Pro Gln Gln Phe Phe Asp Glu Arg Gln Lys Lys Phe Gly Ser Val Phe
          85             90             95

```

```

Lys Thr Ser Leu Ile Gly Asp Arg Thr Val Val Leu Cys Gly Pro Ser
      100             105             110

```

```

Gly Asn Arg Leu Leu Leu Ser Asn Glu Asn Lys Leu Val Glu Ala Ser
      115             120             125

```

```

Trp Pro Ser Ser Ser Ile Lys Leu Ile Gly Glu Asp Ser Ile Ala Gly
      130             135             140

```

```

Lys Asn Gly Glu Lys His Arg Ile Leu Arg Ala Ala Val Asn Arg Tyr
      145             150             155             160

```

```

Leu Gly Pro Gly Ala Leu Gln Asn Tyr Met Ala Lys Met Arg Ser Glu
          165             170             175

```

```

Ile Glu His His Met Asn Glu Lys Trp Lys Gly Lys Glu Gln Val Lys
      180             185             190

```

```

Val Leu Pro Leu Val Lys Glu Asn Val Phe Ser Ile Ala Thr Ser Leu

```

195					200					205					
Phe	Phe	Gly	Val	Asn	Asp	Asp	Gly	Glu	Arg	Glu	Arg	Leu	His	Asp	Leu
210					215					220					
Leu	Glu	Thr	Ala	Leu	Ala	Gly	Val	Phe	Ser	Ile	Pro	Leu	Asp	Phe	Pro
225					230					235					240
Gly	Thr	Asn	Tyr	Arg	Lys	Ala	Leu	Glu	Ala	Arg	Leu	Lys	Leu	Asp	Lys
				245					250					255	
Val	Leu	Ser	Ser	Leu	Ile	Glu	Arg	Arg	Arg	Ser	Asp	Leu	Arg	Ser	Gly
			260					265					270		
Val	Ala	Ser	Gly	Asn	Glu	Asp	Leu	Leu	Ser	Val	Trp	Leu	Thr	Phe	Lys
	275						280					285			
Asp	Glu	Glu	Gly	Asn	Pro	Leu	Thr	Asp	Lys	Glu	Ile	Leu	Asp	Asn	Phe
	290					295					300				
Ser	Thr	Leu	Leu	His	Ala	Ser	Tyr	Asp	Thr	Thr	Thr	Ser	Ala	Leu	Thr
	305				310					315					320
Leu	Thr	Leu	Lys	Leu	Met	Ser	Ser	Ser	Thr	Glu	Cys	Tyr	His	Lys	Val
			325						330					335	
Val	Gln	Glu	Gln	Leu	Arg	Ile	Val	Ser	Asn	Lys	Lys	Glu	Gly	Glu	Glu
			340					345					350		
Ile	Ser	Leu	Lys	Asp	Leu	Lys	Asp	Met	Lys	Tyr	Thr	Trp	Gln	Val	Val
	355						360					365			
Gln	Glu	Thr	Leu	Arg	Met	Phe	Pro	Pro	Leu	Phe	Gly	Ser	Phe	Arg	Lys
	370					375					380				
Ala	Ile	Thr	Asp	Ile	His	Tyr	Asp	Gly	Tyr	Thr	Ile	Pro	Lys	Gly	Trp
	385				390					395					400
Lys	Val	Leu	Trp	Thr	Thr	Tyr	Ser	Thr	His	Gly	Arg	Glu	Glu	Tyr	Phe
			405						410					415	
Asn	Glu	Pro	Glu	Lys	Phe	Met	Pro	Ser	Arg	Phe	Glu	Glu	Glu	Gly	Arg
			420					425					430		
His	Val	Ala	Pro	Tyr	Thr	Phe	Leu	Pro	Phe	Gly	Ala	Gly	Val	Arg	Thr
	435						440					445			
Cys	Pro	Gly	Trp	Glu	Phe	Ser	Lys	Thr	Gln	Ile	Leu	Leu	Phe	Leu	His
	450					455					460				
Tyr	Phe	Val	Lys	Thr	Phe	Ser	Gly	Tyr	Ile	Pro	Leu	Asp	Pro	Asp	Glu
	465					470					475				480
Lys	Val	Leu	Gly	Asn	Pro	Val	Pro	Pro	Leu	Pro	Ala	Asn	Gly	Phe	Ala
			485						490					495	
Ile	Lys	Leu	Phe	Pro	Arg	Pro	Ser	Phe	Asp	Gln	Gly	Ser	Pro	Met	Glu
			500					505					510		

&lt;210&gt; 88

&lt;211&gt; 485

&lt;212&gt; PRT

<213> *Taxus cuspidata*

&lt;400&gt; 88

Met Asp Ala Leu Lys Gln Leu Glu Val Ser Pro Ser Ile Leu Phe Val  
 1 5 10 15

Thr Leu Ala Val Met Ala Gly Ile Ile Leu Phe Phe Arg Ser Lys Arg  
 20 25 30

His Ser Ser Val Lys Leu Pro Pro Gly Asn Leu Gly Phe Pro Leu Val  
 35 40 45

Gly Glu Thr Leu Gln Phe Val Arg Ser Leu Gly Ser Ser Thr Pro Gln  
 50 55 60

Gln Phe Ile Glu Glu Arg Met Ser Lys Phe Gly Asp Val Phe Lys Thr  
 65 70 75 80

Ser Ile Ile Gly His Pro Thr Val Val Leu Cys Gly Pro Ala Gly Asn  
 85 90 95

Arg Leu Val Leu Ser Asn Glu Asn Lys Leu Val Gln Met Ser Trp Pro  
 100 105 110

Ser Ser Met Met Lys Leu Ile Gly Glu Asp Cys Leu Gly Gly Lys Thr  
 115 120 125

Gly Glu Gln His Arg Ile Val Arg Ala Ala Leu Thr Arg Phe Leu Gly  
 130 135 140

Pro Gln Ala Leu Gln Asn His Phe Ala Lys Met Ser Ser Gly Ile Gln  
 145 150 155 160

Arg His Ile Asn Glu Lys Trp Lys Gly Lys Asp Glu Ala Thr Val Leu  
 165 170 175

Pro Leu Val Lys Asp Leu Val Phe Ser Val Ala Ser Arg Leu Phe Phe  
 180 185 190

Gly Ile Thr Glu Glu His Leu Gln Glu Gln Leu His Asn Leu Leu Glu  
 195 200 205

Val Ile Leu Val Gly Ser Phe Ser Val Pro Leu Asn Ile Pro Gly Phe  
 210 215 220

Ser Tyr His Lys Ala Ile Gln Ala Arg Ala Thr Leu Ala Asp Ile Met  
 225 230 235 240

Thr His Leu Ile Glu Lys Arg Arg Asn Glu Leu Arg Ala Gly Thr Ala  
 245 250 255

Ser Glu Asn Gln Asp Leu Leu Ser Val Leu Leu Thr Phe Thr Asp Glu  
 260 265 270

Arg Gly Asn Ser Leu Ala Asp Lys Glu Ile Leu Asp Asn Phe Ser Met  
 275 280 285

Leu Leu His Gly Ser Tyr Asp Ser Thr Asn Ser Pro Leu Thr Met Leu  
 290 295 300  
 Ile Lys Val Leu Ala Ser His Pro Glu Ser Tyr Glu Lys Val Ala Gln  
 305 310 315 320  
 Glu Gln Phe Gly Ile Leu Ser Thr Lys Met Glu Gly Glu Glu Ile Ala  
 325 330 335  
 Trp Lys Asp Leu Lys Glu Met Lys Tyr Ser Trp Gln Val Val Gln Glu  
 340 345 350  
 Thr Leu Arg Met Tyr Pro Pro Ile Phe Gly Thr Phe Arg Lys Ala Ile  
 355 360 365  
 Thr Asp Ile His Tyr Asn Gly Tyr Thr Ile Pro Lys Gly Trp Lys Leu  
 370 375 380  
 Leu Trp Thr Thr Tyr Ser Thr Gln Thr Lys Glu Glu Tyr Phe Lys Asp  
 385 390 395 400  
 Ala Asp Gln Phe Lys Pro Ser Arg Phe Glu Glu Glu Gly Lys His Val  
 405 410 415  
 Thr Pro Tyr Thr Tyr Leu Pro Phe Gly Gly Gly Met Arg Val Cys Pro  
 420 425 430  
 Gly Trp Glu Phe Ala Lys Met Glu Thr Leu Leu Phe Leu His His Phe  
 435 440 445  
 Val Lys Ala Phe Ser Gly Leu Lys Ala Ile Asp Pro Asn Glu Lys Leu  
 450 455 460  
 Ser Gly Lys Pro Leu Pro Pro Leu Pro Val Asn Gly Leu Pro Ile Lys  
 465 470 475 480  
 Leu Tyr Ser Arg Ser  
 485

<210> 89  
 <211> 493  
 <212> PRT  
 <213> Taxus cuspidata

<400> 89  
 Met Asp Ser Phe Thr Phe Val Thr Ile Lys Met Gly Lys Ile Trp Gln  
 1 5 10 15  
 Val Ile Gln Val Glu Tyr Ile Leu Ser Leu Thr Leu Thr Ala Ile Leu  
 20 25 30  
 Leu Phe Phe Phe Arg Tyr Arg Asn Lys Ser Ser His Lys Leu Pro Pro  
 35 40 45  
 Gly Asn Leu Gly Phe Pro Phe Ile Gly Glu Thr Ile Gln Phe Leu Arg  
 50 55 60  
 Ser Leu Arg Ser Gln Thr Pro Glu Phe Phe Phe Asp Glu Arg Val Lys  
 65 70 75 80

Lys Phe Gly Pro Val Phe Lys Thr Ser Leu Ile Gly Ala Pro Thr Val  
 85 90 95  
 Ile Phe Cys Gly Ala Ala Gly Ser Arg Leu Val Leu Ser Asn Glu Asp  
 100 105 110  
 Lys Leu Val Gln Met Glu Ser Pro Ser Ser Leu Lys Lys Leu Met Gly  
 115 120 125  
 Glu Asn Ser Ile Leu Tyr Lys Arg Glu Glu Glu His Arg Ile Leu Arg  
 130 135 140  
 Ser Ala Leu Ser Arg Phe Leu Gly Pro Gln Ala Leu Gln Thr Tyr Ile  
 145 150 155 160  
 Ala Lys Met Ser Thr Glu Ile Glu Arg His Ile Asn Glu Lys Trp Lys  
 165 170 175  
 Gly Lys Glu Glu Val Lys Thr Leu Pro Leu Ile Arg Gly Leu Val Phe  
 180 185 190  
 Ser Ile Ala Ser Ser Leu Phe Phe Asp Ile Asn Asp Glu Pro Gln Gln  
 195 200 205  
 Glu Arg Leu His His His Leu Glu Ser Leu Val Ala Gly Ser Met Ala  
 210 215 220  
 Val Arg Leu Asp Phe Pro Gly Thr Arg Phe Arg Lys Ala Val Glu Ala  
 225 230 235 240  
 Arg Ser Lys Leu Asp Glu Ala Leu His Ser Leu Ile Lys Ser Arg Arg  
 245 250 255  
 Ser Asp Leu Leu Ser Gly Lys Ala Ser Ser Asn Gln Asp Leu Leu Ser  
 260 265 270  
 Val Leu Leu Ser Phe Lys Asp Glu Arg Gly Asn Pro Leu Arg Asp Glu  
 275 280 285  
 Glu Ile Leu Asp Asn Phe Ser Leu Ile Leu His Ala Ser Tyr Asp Thr  
 290 295 300  
 Thr Ile Ser Pro Met Val Leu Thr Leu Lys Leu Leu Ser Ser Asn Pro  
 305 310 315 320  
 Glu Cys Tyr Asp Lys Val Val Gln Glu Gln Phe Gly Ile Leu Ala Asn  
 325 330 335  
 Lys Lys Glu Gly Glu Glu Ile Ser Trp Lys Asp Leu Lys Ala Met Lys  
 340 345 350  
 Tyr Thr Trp Gln Val Val Gln Glu Thr Leu Arg Met Phe Pro Pro Leu  
 355 360 365  
 Phe Gly Ser Phe Arg Lys Ala Met Val Asp Ile Asn Tyr Asp Gly Tyr  
 370 375 380  
 Thr Ile Pro Lys Gly Trp Ile Val Leu Trp Thr Thr Tyr Ser Thr His  
 385 390 395 400

Val Lys Glu Glu Tyr Phe Asn Glu Pro Gly Lys Phe Arg Pro Ser Arg  
 405 410 415

Phe Glu His Asp Gly Arg His Val Ala Pro Tyr Thr Phe Leu Pro Phe  
 420 425 430

Gly Gly Gly Leu Arg Thr Cys Pro Gly Trp Glu Phe Ser Lys Thr Glu  
 435 440 445

Ile Leu Leu Phe Ile His His Phe Val Lys Thr Phe Gly Ser Tyr Leu  
 450 455 460

Pro Val Asp Pro Asn Glu Lys Ile Ser Ala Asp Pro Phe Pro Pro Leu  
 465 470 475 480

Pro Ala Asn Gly Phe Ser Ile Lys Leu Phe Pro Arg Ser  
 485 490

<210> 90  
 <211> 496  
 <212> PRT  
 <213> Taxus cuspidata

<400> 90  
 Met Glu Leu Trp Asn Met Phe Leu Pro Trp Ile Ser Ile Ala Thr Ala  
 1 5 10 15

Thr Ser Leu Thr Val Gly Met Ala Ser Ala Phe Ala Ile Ile Tyr Ala  
 20 25 30

Pro Leu Leu Leu Ser Phe Leu Arg Leu Lys Thr Ala Arg Arg Asn Met  
 35 40 45

Pro Pro Ile Pro Pro Gly Ser Met Gly Met Pro Phe Trp Gly Glu Ser  
 50 55 60

Leu Gly Tyr Leu Gly Ser Trp Asn Asn Gln Ser Asn Pro Asp Val Trp  
 65 70 75 80

Tyr Asp Thr Arg Lys Ala Lys His Gly Lys Ile Phe Thr Thr His Ile  
 85 90 95

Leu Gly Ser Pro Thr Val Val Met Leu Gly Pro Asp Ala Asn Arg Phe  
 100 105 110

Ile Leu Ile Asn Glu Asn Lys Leu Phe Leu Asn Ser Trp Pro Lys Ser  
 115 120 125

Leu Asn Ala Leu Ile Gly Lys His Ala Leu Ile Thr Ser Gln Gly Ala  
 130 135 140

Glu His Lys Arg Met Arg Arg Ile Ile His Ser Val Leu Gly Pro Arg  
 145 150 155 160

Asn Pro Glu Thr Ser Val Gly Arg Phe Glu Gly Leu Val Leu His His  
 165 170 175

Leu Asp Ser Asp Trp His Gly Gly Gln Ile Ile Gln Ala Tyr Arg Gln  
 180 185 190



Val Lys Asp Met Ala Leu Cys Leu Ala Ala Asp Phe Phe Met Gly Leu  
 195 200 205  
 Lys Pro Gly Lys Glu Leu Glu Thr Phe Arg Arg His Phe Ser Asp Phe  
 210 215 220  
 Ser Ala Gly Leu Leu Ser His Pro Leu Asp Leu Pro Trp Thr Val Phe  
 225 230 235 240  
 Gly Lys Ala Lys Arg Ala Arg Ala Ala Met Val Thr Gln Ile Phe Ser  
 245 250 255  
 Gln Ile Arg Leu His Arg Thr Ser Met His Lys Ser Gly Glu Glu Gly  
 260 265 270  
 Gly Asn Phe Leu Asp Met Val Leu Gly Ser Gln Glu Lys Gly Gly Asp  
 275 280 285  
 Leu Arg Leu Ser Glu Glu Glu Ile Ala Asp Asn Leu Met Gly Leu Leu  
 290 295 300  
 Thr Gly Gly Gln Asp Thr Thr Ala Ser Ala Leu Ala Thr Ile Leu Lys  
 305 310 315 320  
 His Leu Ser Leu Ser Pro His Leu Leu Gln Arg Leu Arg Lys Glu Cys  
 325 330 335  
 Glu Lys Leu Arg Asp Asn Lys Glu Ala Gly Gly Pro Leu Thr Trp Ser  
 340 345 350  
 Glu Ile Lys Ser Val Gly Tyr Leu His Asn Val Ile Ser Glu Gly Leu  
 355 360 365  
 Arg Met Val Ala Pro Ile Asn Gly Gly Phe Lys Lys Ala Lys Val Asp  
 370 375 380  
 Val Val Tyr Gly Gly Tyr Thr Ile Pro Lys Gly Trp Lys Val His Tyr  
 385 390 395 400  
 Ser Val Arg Gln Thr Asn Asn Lys Glu Glu Tyr Phe Pro Ser Pro Glu  
 405 410 415  
 Arg Phe Asp Pro Asp Arg Phe Asn Glu Arg His Glu Pro Phe Ser Phe  
 420 425 430  
 Ile Pro Phe Gly Gln Gly Asn Arg Met Cys Pro Gly Asn Glu Phe Ala  
 435 440 445  
 Arg Leu Glu Met Glu Leu Phe Leu Tyr His Leu Val Leu Arg Tyr Asp  
 450 455 460  
 Trp Glu Leu Met Glu Ala Asp Glu Arg Thr Asn Met Tyr Phe Ile Pro  
 465 470 475 480  
 His Pro Val His Ser Leu Pro Leu Leu Leu Lys His Val Pro Pro Thr  
 485 490 495

<210> 91  
 <211> 498  
 <212> PRT  
 <213> *Taxus cuspidata*

<400> 91

```

Met Asp Ala Leu Tyr Lys Ser Thr Val Ala Lys Phe Asn Glu Val Thr
 1           5           10           15

Gln Leu Asp Cys Ser Thr Glu Ser Phe Ser Ile Ala Leu Ser Ala Ile
          20           25           30

Ala Gly Ile Leu Leu Leu Leu Leu Phe Arg Ser Lys Arg His Ser
          35           40           45

Ser Leu Lys Leu Pro Pro Gly Lys Leu Gly Ile Pro Phe Ile Gly Glu
          50           55           60

Ser Phe Ile Phe Leu Arg Ala Leu Arg Ser Asn Ser Leu Glu Gln Phe
          65           70           75           80

Phe Asp Glu Arg Val Lys Lys Phe Gly Leu Val Phe Lys Thr Ser Leu
          85           90           95

Ile Gly His Pro Thr Val Val Leu Cys Gly Pro Ala Gly Asn Arg Leu
          100           105           110

Ile Leu Ser Asn Glu Glu Lys Leu Val Gln Met Ser Trp Pro Ala Gln
          115           120           125

Phe Met Lys Leu Met Gly Glu Asn Ser Val Ala Thr Arg Arg Gly Glu
          130           135           140

Asp His Ile Val Met Arg Ser Ala Leu Ala Gly Phe Phe Gly Pro Gly
          145           150           155           160

Ala Leu Gln Ser Tyr Ile Gly Lys Met Asn Thr Glu Ile Gln Ser His
          165           170           175

Ile Asn Glu Lys Trp Lys Gly Lys Asp Glu Val Asn Val Leu Pro Leu
          180           185           190

Val Arg Glu Leu Val Phe Asn Ile Ser Ala Ile Leu Phe Phe Asn Ile
          195           200           205

Tyr Asp Lys Gln Glu Gln Asp Arg Leu His Lys Leu Leu Glu Thr Ile
          210           215           220

Leu Val Gly Ser Phe Ala Leu Pro Ile Asp Leu Pro Gly Phe Gly Phe
          225           230           235           240

His Arg Ala Leu Gln Gly Arg Ala Lys Leu Asn Lys Ile Met Leu Ser
          245           250           255

Leu Ile Lys Lys Arg Lys Glu Asp Cys Ser Leu Asp Arg Gln Gln Pro
          260           265           270

Arg Arg Ile Cys Ser Leu Phe Cys Ser Leu Ser Glu Met Thr Lys Gly
          275           280           285

Leu Pro His Pro Met Asp Glu Ile Leu Asp Asn Phe Ser Ser Leu Leu

```

290                      295                      300  
 His Ala Ser Tyr Asp Thr Thr Thr Ser Pro Met Ala Leu Ile Phe Lys  
 305                      310                      315                      320  
 Leu Leu Ser Ser Asn Pro Glu Cys Tyr Gln Lys Val Val Gln Glu Gln  
 325                      330                      335  
 Leu Glu Ile Leu Ser Asn Lys Glu Glu Gly Glu Glu Ile Thr Trp Lys  
 340                      345                      350  
 Asp Leu Lys Ala Met Lys Tyr Thr Trp Gln Val Ala Gln Glu Thr Leu  
 355                      360                      365  
 Arg Met Phe Pro Pro Val Phe Gly Thr Phe Arg Lys Ala Ile Thr Asp  
 370                      375                      380  
 Ile Gln Tyr Asp Gly Thr Asn Ser Lys Arg Gly Lys Leu Leu Trp Thr  
 385                      390                      395                      400  
 Thr Tyr Ser Thr His Pro Lys Asp Leu Tyr Phe Asn Glu Pro Glu Lys  
 405                      410                      415  
 Phe Met Pro Ser Arg Phe Asp Gln Glu Gly Lys His Val Ala Pro Tyr  
 420                      425                      430  
 Thr Phe Leu Pro Phe Gly Gly Gly Gln Arg Ser Cys Val Gly Trp Glu  
 435                      440                      445  
 Phe Ser Lys Met Glu Ile Leu Leu Phe Val His His Phe Val Lys Thr  
 450                      455                      460  
 Phe Ser Ser Tyr Thr Pro Val Asp Pro Asp Glu Lys Ile Ser Gly Asp  
 465                      470                      475                      480  
 Pro Leu Pro Pro Leu Pro Ser Lys Gly Phe Ser Ile Lys Leu Phe Pro  
 485                      490                      495

Arg Pro

<210> 92

<211> 486

<212> PRT

<213> *Taxus cuspidata*

<400> 92

Met Glu Gln Leu Ile Tyr Ser Ile Val Tyr Ser Asn Trp Tyr Leu Trp  
 1                      5                      10                      15

Val Leu Gly Leu Phe Ile Cys Val Ile Leu Leu Leu Arg Arg Ser  
 20                      25                      30

Asn Asp Arg Gln Gly Asn Gly Ser Ala Asn Lys Pro Lys Leu Pro Pro  
 35                      40                      45

Gly Ser Ala Gly Leu Pro Phe Ile Gly Glu Thr Ile Arg Phe Leu Arg  
 50                      55                      60

Asp Ala Lys Ser Pro Gly Arg Arg Lys Phe Phe Asp Glu His Glu Leu

65	70	75	80
Arg Tyr Gly Pro Ile Phe Arg Cys Ser Leu Phe Gly Arg Thr Arg Ala	85	90	95
Val Val Ser Val Asp Pro Glu Phe Asn Lys Tyr Val Leu Gln Asn Glu	100	105	110
Gly Arg Leu Phe Glu Ser Asn Ala Leu Ala Pro Phe Arg Asn Leu Ile	115	120	125
Gly Lys Tyr Gly Leu Ser Ala Val Gln Gly Glu Leu Gln Arg Lys Leu	130	135	140
His Ala Thr Ala Val Asn Leu Leu Lys His Glu Thr Leu Ser Ser Asp	145	150	155
Phe Met Glu Asp Ile Gln Asp Ile Phe Gln Ala Gly Met Arg Lys Trp	165	170	175
Glu Glu Glu Gly Asp Ile Pro Ile Gln His Lys Cys Asn Gln Ile Val	180	185	190
Leu Asn Leu Met Ala Lys Arg Leu Leu Asp Leu Pro Pro Ser Glu Glu	195	200	205
Met Gly His Ile Tyr Lys Ala Phe Asp Asp Phe Val Gly Ala Val Leu	210	215	220
Ser Phe Pro Leu Asn Ile Pro Gly Thr Thr Tyr Ala Arg Gly Ile Arg	225	230	235
Ala Arg Gly Ile Leu Leu Lys Arg Ile His Lys Cys Ile Lys Glu Arg	245	250	255
Arg Glu His Pro Glu Val Leu Arg Asn Asp Leu Leu Thr Lys Leu Val	260	265	270
Arg Glu Gly Thr Phe Ser Asp Glu Ile Ile Ala Asp Thr Ile Ile Phe	275	280	285
Phe Val Phe Ala Gly Val Glu Thr Ser Ala Met Ala Met Thr Phe Ala	290	295	300
Val Lys Tyr Leu Ala Glu Asn Pro Arg Ala Leu Glu Glu Leu Arg Ala	305	310	315
Glu His Asp Ala Leu Leu Lys Ala Lys Gly Lys Gly Asn Glu Lys Leu	325	330	335
Thr Trp Asn Asp Tyr Gln Ser Met Lys Phe Val His Cys Val Ile Asn	340	345	350
Glu Thr Leu Arg Leu Gly Gly Ala Thr Val Val Leu Phe Arg Glu Ala	355	360	365
Lys Gln Asp Ile Lys Val Lys Asp Phe Val Ile Pro Lys Gly Trp Thr	370	375	380
Val Ser Val Phe Leu Ser Ala Thr His Val Asp Gly Lys Tyr His Tyr	385	390	395
			400

Glu Ala Asp Lys Phe Leu Pro Trp Arg Trp Gln Asn Glu Gly Gln Glu  
405 410 415

Thr Leu Glu Glu Pro Cys Tyr Met Pro Phe Gly Arg Gly Gly Arg Leu  
420 425 430

Cys Pro Gly Leu His Leu Ala Arg Phe Glu Ile Ala Leu Phe Leu His  
435 440 445

Asn Phe Val Thr Lys Phe Arg Trp Glu Gln Leu Glu Ile Asp Arg Ala  
450 455 460

Thr Tyr Phe Pro Leu Pro Ser Thr Glu Asn Gly Phe Pro Ile Arg Leu  
465 470 475 480

Tyr Ser Arg Val His Glu  
485

<210> 93

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR primer

<400> 93

atggccctta agcaattgga agtttc

26

<210> 94

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Primer

<400> 94

ttaagatctg gaatagagtt taatgg

26